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ABSTRACT 
Profiling medical sites is an important activity in both clinical research and practice.  
Many organizations provide public report cards comparing outcomes across hospitals. An 
analogous   concept applied in multicenter clinical trials, such “report cards” guide 
sponsors to choose sites while designing a study, help identify areas of improvement for 
sites, and motivate sites to perform better. Sponsors include comparative performance of 
sites, a concept to perform risk-based monitoring and central statistical monitoring. In 
clinical research, report cards are powerful tools for relating site performance to treatment 
benefits.   
This study evaluates approaches to estimating the proportion of adverse events at 
the site-level in a multicenter clinical trial setting and also methods in detecting outlying 
sites. We address three topics. First we assess the performance of different models for 
obtaining estimates of adverse events rates utilizing Bayesian beta-binomial and binomial 
logit-normal models with MCMC estimation and fixed effects maximum likelihood 
estimation (MLE) methods.  We - vary sample sizes, number of medical sites, overall 
adverse event rates, and intraclass correlation within sites. Second, we compare the 
performance of these methods in identifying outlier sites, contrasting MLE and Bayesian 
 vi 
approaches. A fixed threshold method detects sites as outliers under a Bayesian approach, 
while in the fixed effects assumption, a 95% interval-based approach is applied. Third, 
we extend this approach in estimating multiple outcomes at the site level and detecting 
outlier sites. A standard bivariate normal MLE method is compared to a Bayesian 
bivariate binomial logit-normal MCMC. These are examined using simulation studies.  
Results show for single outcomes, Bayesian beta-binomial MCMC method perform well 
under certain parametric conditions for estimation and detecting outlier sites. For multiple 
outcomes with higher adverse event rate and larger difference between outliers and non-
outliers, for detecting outlier sites, both methods – Bayesian MCMC and MLE work well, 
irrespective of the correlation between outcomes. 
 
 
  
 vii 
Table of Contents 
Chapter 1 ......................................................................................................................... 1 
Introduction ..................................................................................................................... 1 
1.1 Background ....................................................................................................... 1 
1.2 Outline .............................................................................................................. 5 
Chapter 2 ....................................................................................................................... 10 
Statistical Methods of Estimation on Binomial Counts of Adverse Events in Multicenter 
Clinical Trials for single outcomes setting ..................................................................... 10 
2.1 Background ..................................................................................................... 10 
Motivating Example Dataset ...................................................................................... 13 
2.2 Methods and Models ....................................................................................... 14 
2.3 Data Generation Models .................................................................................. 19 
Distribution of  !".................................................................................................. 19 
2.3.1 Model 1 (Binomial logit-normal): B-LN ................................................... 19 
2.3.2 Model 2 (Beta-binomial): B-B .................................................................. 20 
2.3.3 Fixed Effects Binomial Model .................................................................. 20 
2.4 Methods of Estimation .................................................................................... 23 
Bayesian Methods.................................................................................................. 23 
2.4.1 Method 1 (B-LN Model with MCMC method) ......................................... 23 
2.4.2 Method 2 (B-B Model with MCMC method) ............................................ 24 
Maximum Likelihood Estimation (MLE) Methods................................................. 25 
2.4.3 Method 3 (MLE Approach Using Normal Approximation Method) .......... 25 
 viii 
2.4.4 Method 4 (MLE Approach Using an Exact Method) ................................. 25 
2.5 Determination of Estimates ............................................................................. 26 
Model 1 (Binomial logit-normal): B-LN ................................................................ 27 
Model 2 (Beta-binomial): B-B ............................................................................... 28 
2.6 Estimation and Model Fit ................................................................................ 29 
2.7 Comparison of Methods using Operating Characteristics: non-coverages; 
interval widths; and risk functions. ................................................................................ 30 
2.8 Results ............................................................................................................ 31 
2.9 Sensitivity Analyses with different distribution for Hyperpriors ...................... 51 
2.10 Findings from the Example Dataset ................................................................. 58 
2.11 Summary and Discussion ................................................................................ 60 
2.12 Application...................................................................................................... 61 
Chapter 3 ....................................................................................................................... 64 
Statistical methods for classification of outlier study sites for single adverse events 
outcome in multicenter clinical trials setting .................................................................. 64 
3.1 Background ..................................................................................................... 64 
3.2 Methods and Models ....................................................................................... 69 
3.3 Data Generation Models .................................................................................. 70 
Distribution of  #$ .................................................................................................. 70 
3.3.1 Model 1 (Binomial logit-normal): B-LN ................................................... 70 
3.3.2 Model 2 (Beta-binomial): B-B .................................................................. 71 
3.4 Methods of Estimation .................................................................................... 73 
 ix 
3.5 Determination of Estimates ............................................................................. 73 
3.6 Model Estimation and Fit ................................................................................ 73 
3.7 Outlier Classification ....................................................................................... 73 
3.8 Results Using Simulated Datasets .................................................................... 77 
3.8.1 Beta-Binomial Data .................................................................................. 77 
3.8.2 Binomial Logit-Normal Data .................................................................... 86 
3.8.3 Fixed Effects Data .................................................................................... 92 
3.9 Results Using Example Dataset ..................................................................... 101 
3.10 Discussion ..................................................................................................... 102 
3.11 Application.................................................................................................... 104 
Chapter 4 ..................................................................................................................... 105 
Statistical methods for estimating multiple binary adverse outcomes and identifying 
outlier sites in multicenter clinical trials ....................................................................... 105 
4.1 Background ................................................................................................... 105 
4.2 Methods and Models ..................................................................................... 108 
4.3 Data Generation Models ................................................................................ 108 
4.3.1 Bayesian Model (Multivariate Normal-Binomial): M-LN ....................... 109 
4.3.2 Correlated Binomial Model .................................................................... 110 
4.4 Methods of Estimation .................................................................................. 111 
4.4.1 Bayesian Method (Multivariate Normal Binomial Model with MCMC 
method)  ............................................................................................................... 111 
4.4.2 Maximum Likelihood Method of estimation (MLE) ............................... 112 
 x 
4.5 Estimation and Model Fit .............................................................................. 114 
4.6 Comparison of Methods using Operating Characteristics: non-coverages ...... 115 
4.7 Results .......................................................................................................... 117 
4.8 Sensitivity Analysis on Inverse-Wishart prior ................................................ 119 
4.8.1 Generate Data for Prior .......................................................................... 120 
4.8.2 Methods chosen for Priors ...................................................................... 120 
4.8.3 Results comparing different priors .......................................................... 121 
4.9 Comparison of methods of estimation on detecting outlier sites ..................... 123 
4.9.1 Data Generation ............................................................................................ 123 
4.9.2 Estimation ..................................................................................................... 125 
4.9.3 Identifying sites that are outliers .................................................................... 126 
4.9.4 Results of outlier detection ............................................................................ 129 
4.10 Results Using an Example Dataset................................................................. 132 
4.11 Discussion ..................................................................................................... 133 
4.12 Potential application to the conduct of randomized clinical trials ................... 134 
Chapter 5 ..................................................................................................................... 136 
Conclusions and Future Work...................................................................................... 136 
Appendix A: Derivation of Distribution of %&'$()* ..................................................... 140 
Appendix B: Derivation of parameters using Delta method to represent in terms of 
logit(p)’s ..................................................................................................................... 141 
Appendix 2D: R Code Data Generation for Single Outcome (Chapter 2) ..................... 142 
Appendix 2D.1: Data Generation Using Beta-Binomial Model .................................... 142 
 xi 
Appendix 2D.2: Data Generation Using Binomial Logit-Normal Model .................. 142 
Appendix 2D.3: Data Generation Using Fixed Effects Binomial Model ................... 142 
Appendix 2E: R Code for Estimation of Single Outcome (Chapter 2) .......................... 143 
Appendix 2E.1: MCMC Estimation Using Beta-Binomial Model............................. 143 
Appendix 2E.2: MCMC Estimation Using Binomial Logit-Normal Model ............... 146 
Appendix 2E.3: MLE Estimation Using Common Fixed Effects Model using Normal 
Approximation ......................................................................................................... 149 
Appendix 2E.4: MLE Estimation Using Common Fixed Effects Model using Exact 
Method .................................................................................................................... 150 
Appendix 3D: R Code for Outlier Data Generation for Single Outcome (Chapter 3) .... 151 
Appendix 3D.1: Data Generation using Beta-Binomial Model ................................. 151 
Appendix 3D.2: Data Generation using Binomial Logit-Normal Model ................... 152 
Appendix 3D.3: Data Generation using Beta-Binomial Model with full shrinkage to 
make it close to fixed effects model with varying sample size .................................. 152 
Appendix 3D.4: Data Generation using Beta-Binomial Model with no shrinkage to 
make it close to fixed effects model ......................................................................... 153 
Appendix 3E: R Code for Outlier Estimation for Single Outcome (Chapter 3) ............. 154 
Appendix 3E.1: True Posterior for Beta-Binomial model ......................................... 154 
Appendix 3E.2: True Posterior for Binomial Logit Normal model for varying subjects 
per site (Normal-Normal Conjugate Approach) ........................................................ 155 
Appendix 3E.3: True Posterior for Binomial Logit-Normal model for varying subjects 
per site (BUGS Approximation with Fixed Hyperparameter Approach) ................... 157 
 xii 
Appendix 3E.4: Outlier Estimation Using Beta Binomial Model .............................. 159 
Appendix 3E.5: Outlier Estimation Using Binomial Logit-Normal Model ................ 162 
Appendix 3E.6: Outlier Estimation Using Fixed Effects Model with Exact Method . 164 
Appendix 4D: R Code and Algorithm for Data Generation and Estimation for Multiple 
Outcome (Chapter 4) ................................................................................................... 166 
Appendix 4E: R Code and Algorithm for Outlier Detection for Multiple Outcomes 
(Chapter 4) .................................................................................................................. 175 
Bibliography…………………………………………………………………………… 180 
Curriculum Vitae……………………………………………………………………….. 186 
  
 xiii 
List of Tables 
Table 1: Count of Adverse Events from Motivating Example Dataset ........................... 14 
Table 2: Parametric Conditions used for simulation of p ............................................... 23 
Table 3: True Expected Proportion of AE=0.50, Number of sites =63 (B-B) Data ......... 38 
Table 4: True Expected Proportion of AE=0.50, Number of sites =63 (B-LN Data) ...... 39 
Table 5: True Expected Proportion of AE=0.50, Number of sites =63 (Fixed effects Data)
 ....................................................................................................................... 40 
Table 6: True Proportion of AE=0.17, Number of sites=63 (B-B Data) ......................... 41 
Table 7: True Proportion of AE=0.17, Number of sites=63 (B-LN Data) ....................... 42 
Table 8: True Proportion of AE=0.17, Number of sites=63 (Fixed effects Data) ............ 43 
Table 9: True Proportion of AE=0.05, Number of sites=63 (B-B Data) ......................... 44 
Table 10: True Proportion of AE=0.05, Number of sites=63 (B-LN Data) ..................... 45 
Table 11: True Proportion of AE=0.05, Number of sites=63 (Fixed effects Data) .......... 46 
Table 12: True Proportion of AE=0.50, Varying Sites (B-B Data) .................................. 47 
Table 13: True Proportion of AE=0.50, Varying Sites (B-LN Data) ............................... 48 
Table 14: True Proportion of AE=0.05, Varying Sites (B-B Data) .................................. 49 
Table 15: True Proportion of AE=0.05, Varying Sites (B-LN Data) ............................... 50 
Table 16: True Expected Adverse Event Proportion=0.17, Varying Priors (B-B Data) ... 55 
Table 17: True Expected Adverse Event Proportion=0.17, Varying Priors (B-B Data) ... 56 
Table 18: True Expected Adverse Event Proportion=0.17, Varying Shrinkage (B-B Data)
 ...................................................................................................................... 57 
 
 xiv 
Table 19. Definitions of Sensitivity, Specificity, Positive Predictive Value (PPV), and 
Negative Predictive Value (NPV) ................................................................... 76 
Table 20. B-B and B-LN method of estimation on 1 B-B generated data with expected 
proportion of adverse event rate 0.05 and threshold 0.07 ................................ 79 
Table 21. True Proportion=0.05 Threshold(t)=0.07 (B-B Data) ..................................... 81 
Table 22. True Proportion=0.05, Threshold(t)=0.10 (B-B Data ...................................... 81 
Table 23. Comparison of true to estimated parameters for B-B Data.............................. 82 
Table 24. Percent of times sites declared as outliers of the 300 simulated B-B datasets.. 83 
Table 25. Operating Characteristics of the methods of estimation, Threshold =0.07 (B-B 
Data) ............................................................................................................. 85 
Table 26. Operating Characteristics of the methods of estimation, Threshold=0.10, 0.15                
(B-B Data) ..................................................................................................... 85 
Table 27. Comparison of true to estimated parameters for B-LN dataset........................ 87 
Table 28. True Proportion=0.05, Threshold(t)=0.07....................................................... 88 
Table 29. True Proportion=0.05, Threshold(t)=0.07....................................................... 90 
Table 30. Percent of times Outlier of the 300 simulated B-LN datasets.......................... 90 
Table 31. Operating Characteristics for the methods of estimation, Threshold =0.07 ..... 91 
Table 32. Operating Characteristics for the methods of estimation, Threshold=0.10 ...... 91 
Table 33. Comparison of ML and Bayesian MCMC methods of estimation for outlier 
detection against fixed effects data True Proportion=0.05, Shrinkage=1, 
Threshold=0.07 ............................................................................................. 94 
 
 
 xv 
Table 34. Comparison of ML and Bayesian MCMC methods of estimation for outlier 
detection against fixed effects data, True Proportion=0.05, Shrinkage=0, 
Threshold=0.07 ............................................................................................. 97 
Table 35. Operating Characteristics of methods of estimation ..................................... 100 
Table 36. Operating Characteristics of methods of estimation ..................................... 101 
Table 37. Values of Mean Vector and Covariance Matrix for logit(#+$)s ..................... 110 
Table 38. Values of Mean Vector and Covariance Matrix for #+$ ................................ 110 
Table 39. Non-Coverage for Two Outcomes with expected adverse event proportion at
 .................................................................................................................... 118 
Table 40. Comparison of True Values to The Estimated Values of Parameters ............. 122 
Table 41. Comparison of MLE and Bayesian MCMC methods of estimation on 
Sensitivity and Specificity on Correlated Binomial Data .............................. 131 
Table 42. Comparison of Observed to estimated using Bayesian Multivariate Normal-
Binomial Model on Motivating Example Data set ........................................ 132 
 
 xvi 
List of Figures 
Figure 1: Simulation Studies for Fixed Number of Sites ............................................... 17 
Figure 2: Simulation Studies for Varying Number of Sites ............................................ 18 
Figure 3: Results from Simulation Study (Number of sites fixed at 63) ......................... 36 
Figure 4: Results from Simulation Study by varying the number of sites....................... 37 
Figure 5. Bias of the true posterior p on a random B-B simulated dataset ...................... 77 
Figure 6. Bias of the posterior p on B-LN one random simulated dataset (Normal-
Normal Conjugacy) ....................................................................................... 87 
Figure 7. Bias of posterior p on one random B-LN simulated dataset (BUGS using fixed 
hyperparameters) ........................................................................................... 89 
Figure 8. 95% Confidence or Credible Ellipse ............................................................ 117 
Figure 9. Data Generation Process using Correlated Binomial Model ......................... 126 
 1 
Chapter 1 
 
Introduction 
1.1  Background 
 
Assessing the comparative performance of health care providers is widely practiced and 
is a key feature of health care reform [1]. One of the primary objectives of this 
assessment is to evaluate the quality or value of care provided by individual practitioners, 
a practice referred to as “provider profiling” [2]. Information on the relative performance 
of health care providers may be used by individual patients to select providers, or by 
health care organizations to identify candidates for remedial programs or bonuses [3,4]. 
Moreover, policymakers may use performance data to assess whether core health care 
needs are being met [5].  
Provider profiling is increasingly used to identify providers exceeding performance 
thresholds. It is also equally important to determine if treatment effects and/or other 
outcome differences exist among different participating medical centers in multicenter 
clinical trials that may be contributing to provider performance. Establishing that certain 
centers truly perform better or worse than others may provide insight as to why an 
experimental therapy or intervention was effective in one center but not in another and/or 
whether a trial’s conclusions may have been impacted by these differences. For multi-
center clinical trials, identifying centers performing on the extremes may also explain 
differences in following the study protocol [6]. Quantifying the variability between 
centers provides insight even if it cannot be explained by covariates. Determining 
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whether a specific medical center truly performs better than others can be difficult and/or 
misleading. Each center enrolls a different patient population, has different standard of 
care, the sample size varies between centers and is sometimes small [7]. 
Provider profiling goes back to 1987, since Health Care Financing Administration 
(HCFA) started the annual release of data comparing actual and expected rates of 
Medicare patients at hospitals across the country. Since then, several statistical models 
and analytic methods have been implemented to compare the quality of care of providers 
and test the performance of HCFA’s quality screening approach with respect to various 
parameters. Gills and Hixson (1991) employed Monte Carlo Technique to examine the 
appropriateness of HCFA’s quality screening. Death was considered as the outcome 
dependent on both patient specific and hospital specific characteristics and a logistic 
regression analysis was utilized. Monte Carlo methodology was used to determine how 
altering the characteristics of underlying mortality processes affect the process of HCFA’s 
screening technique results. In 1992, Catalano and Ryan [8] used a latent variable model 
to derive the joint distribution of a continuous and a discrete outcome, and then extended 
the model to allow for clustered data. A quasi-likelihood technique was utilized to model 
the joint distribution as a product of a standard random effects model for the continuous 
response and a correlated probit model for the discrete outcome. In 1993, Fitzmaurice 
and Laird [9] proposed a likelihood based method for analyzing a longitudinal binary 
response based on a multivariate exponential model. This paper, related to a method 
proposed by Zhao & Prentice [10], modeled the association between responses in terms 
of conditional log odds-ratios. In 1995 Silber, Rosenbaum, and Ross [11] examined the 
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hospitals with large standardized difference between observed and expected rates of 
death, adverse events and death following adverse events, for surgical patients. Logit 
regression models were employed to compare the relative importance of two groups of 
outcomes- one depended on patient specific characteristics and the other dependent on 
hospital specific characteristics. To measure the contribution of hospital and patient 
characteristics to the variation in patient and hospital outcomes, the relative variation of 
the factors to the outcomes were considered. 
     In some of the later profiling research studies, Bayesian hierarchical models 
[12,13,14] have been used because of the structural relationship between providers and 
patients whereby a patient-level response is measured for clusters of patients treated by 
the same providers. In the 2003 paper the concept of multidimensional “report cards” 
comparing the quality of services provided by diverse health care organizations was 
brought forward. The primary question of interest was which networks, if any, were 
providing inadequate care. Multilevel multidimensional latent variable models were 
applied to examine the performance of the networks across multidimensional data 
consisting of a mixture of continuous and discrete outcomes, all presumably measuring 
underlying quality. Shwartz et al. 2012 [15] suggest the potential of using shrinkage 
methods when calculating a composite measure that is conceptualized as a formative 
construct. 
Lapses in patient safety are a major concern of the healthcare quality. Thus, there is an 
increasing demand for accountability in all health care systems. Providers face increased 
scrutiny from patients, system managers, and policy makers. As part of this trend, many 
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jurisdictions have released public report cards comparing outcomes across hospitals or 
practice groups [16].In these report cards hospitals observed to have higher- than-
expected adverse events (AE) are flagged as institutions with potential quality problems. 
Clearly, algorithms for identifying aberrant providers need to be linked to the outcome 
under study and to rely on metrics tailored to the needs of the profiling analysis. A similar 
concept may be applied for selecting sites for a randomized controlled clinical trial. 
Selecting the right sites may significantly impact study outcomes. Such “report cards” 
could help sponsors choose the experimental centers while designing a study. Report 
cards can also help sites identify areas of strength and weakness, and motivate them to 
perform better. Sponsors could also use the data in selecting sites for future studies. In the 
case of multicenter trials, sponsors could show sites how their performance compares to 
other sites in the study. Clinical research, designed to advance generalizable knowledge 
about medical treatments, could also advance generalizable knowledge about how to 
conduct clinical research itself. Report cards are powerful tools for accomplishing this 
objective [17]. 
The rate of success and of adverse events among patients, also an aspect of provider 
performance and other factors, primarily the treatment, provide impetus for internal 
review, improvement in clinical performance, and, if necessary, the development of 
regulatory interventions by institutions and government agencies. Investigating and 
reporting of adverse drug events is hence crucial towards the success of a clinical trial 
and improving the quality of care of health care industries. Regular reporting of adverse 
events is done through data collection in case report forms. These adverse events are 
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already known as potential risks when participating in a research study with a specific 
investigational product. Practice in reporting adverse events (AE) varies among 
institutions, especially timeline and what to report: whether it is external or internal, 
serious or not serious, unexpected or expected events. They are generally reported as 
listings with the start and the end date, severity, relationship to the study treatment, action 
taken, outcome of adverse events, whether unexpected and serious or not. In addition, the 
amount of external AE reports is enormous, which is troublesome in terms of required 
human resources and document storage. The current work focuses on this aspect of 
linking the reporting of adverse events as outcomes in determining the performance of 
clinical sites in multi-center clinical trials. 
1.2  Outline 
 
An overview of the chapters is provided. Chapter 2 assesses the performances of four 
analytic methods – the Bayesian beta-binomial model with the Markov Chain Monte 
Carlo (MCMC) estimation method, Bayesian binomial-logit normal model with the 
Markov Chain Monte Carlo (MCMC) estimation method, the common approach with 
maximum likelihood estimation (MLE) method using normal approximation, and the 
common approach with maximum likelihood estimation method using an exact method.  
We examine several operating characteristics - non-coverages, average interval width, 
standardized squared error risks and absolute bias while varying the number of medical 
sites, (at 10, 20, 63 and 100 sites), the sample sizes for each site (equal at 60 or unequal at 
10 to 60 and 150 to 200 observations per site), the expected adverse event proportion (at 
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5%, 17% and 50%) and varying shrinkages on a single outcome. 
The use of Bayesian approaches enables us to obtain a posterior distribution associated 
with the site’s proportion of adverse events and derive several statistics based on it. We 
start with the MLE approach and evaluate how the site estimates obtained from the data 
for maximum likelihood method of estimation and the posterior distribution obtained 
from the Bayesian MCMC method of estimation differ. Unlike MLE methods, Bayesian 
methods assign anything unknown a probability using information from previous 
experiments. In other words, the Bayesian paradigm [18] allows combining previous 
beliefs about underlying parameters, with the observed data to obtain probability 
distributions of the parameters, whereas maximum likelihood (ML) approaches assume 
we have no prior results. The purpose of using shrinkage, the within to total variation 
ratio, obtained under a random-effects (hierarchical or multilevel) model, which assumes 
that there exist hospital-specific ‘random effects’ drawn from some common 
distributions, is to estimate the performance of the sites as the weighted average of the 
site's observed performance and the performance of all sites on the same indicator. In 
other words, the site's performance is pulled or shrunken towards the overall performance 
of the set of sites, which in turn depends on the reliability of the site's performance, 
which is a function of sample size and the distance between the site's performance and 
the overall performance.  
The application of beta-binomial and binomial logit-normal random effects models to the 
generated data aims to assess the relative shrinkage of individual site adverse event rate 
towards the overall rate and compare the models empirically. Shrinkage estimators are 
 7 
more informative when the sample sizes are small and they differ between sites. The 
range of denominator sizes across the sites warrant the use of shrinkage estimators in this 
case. Shrinkage estimators are also informative with regard to variation between the sites 
and whether use of hierarchical models should be warranted.  
In Chapter 3, both the Bayesian beta-binomial and binomial-logit normal models are 
utilized to choose the sites providing poor quality of care, if any. To answer that a 
summary measure based on the performance indices of the providers is constructed which 
compares the posterior probability of adverse event for each provider to be greater than a 
critical threshold. We recommend improvements that are based on the use of better 
statistical models and propose a performance measure based on statistical standards. With 
the Bayesian methods, we adapt an approach for classifying poor performing sites similar 
to that of Austin et al. (2001) [16]. Decisions are based on the threshold and the 
probability of exceeding the threshold. A medical site is considered an outlier (yes or no) 
if the probability of adverse events exceeds a pre-determined threshold with at least a 
specified probability level.  
Some authors have employed methods equivalent to identifying a provider as unusual 
based on large posterior probability of its rate being greater (or less) than average [19, 20, 
21, 22]. Morris and Christiansen (1996) worked within the estimation framework but 
suggested that comparisons with the population mean are inappropriate, arguing instead 
in favor of comparisons with an external target or interval standard [12, 23, 24]. In 
contrast, as measures of performance of sites we compare the posterior estimates from 
Bayesian methods to the posterior estimates from the True Bayesian Posterior. 
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Performance of the methods are summarized using operating characteristics like 
sensitivity, specificity, positive predictive value and negative predictive value for 
classifying sites as outliers. 
Chapter 4 focuses on multiple binary outcomes in multi-center clinical trials setting. 
Multiple outcomes are increasingly collected both in randomized clinical trials and 
observational studies in order to characterize treatment or intervention effectiveness, or to 
investigate the association of the outcomes with other variables of interest. The decision 
to include more than one outcome arises for several reasons, including a lack of 
consensus on the most important clinical outcomes or a desire to demonstrate 
effectiveness on more than one outcome. The outcomes can be combined into a single 
composite endpoint using a variety of pooling rules or scoring algorithms. Several types 
of composite endpoints exist, such as taking a simple average of the outcomes or using 
conjunctive or compensatory rules 
(http://archiv.aplimat.com/2011/Proceedings/Statistical_methods/Hudrlikova_Fischer.pdf
).  Another frequently adopted option is to consider each outcome separately by analyzing 
each independently of the others [25]. Individual indicators are useful in identifying 
specific areas for improvement and tracking improvement progress; however, to assess 
overall performance, it is useful to aggregate individual quality indicators (QIs) into a 
composite measure (Institute of Medicine 2006). A composite measure provides a useful 
summary of the extent to which management has created a culture of quality and 
designed processes to ensure quality throughout the organization. It allows senior leaders 
to benchmark their organization’s performance against high-performing organizations 
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and to monitor changes over time. For individual patients, who must select one facility 
for their care, a composite measure is a way of combining diverse information into one 
more easily processed number. Also, composite measures allow researchers to identify 
and then study characteristics of high- performing organizations, departments, or teams 
and to develop models to guide organizational transformation [15]. 
This paper is built on the method proposed by Shwartz et. al (2012) [15] where composite 
scores calculated from 28 Nursing Home quality indicators (QI) are compared using both 
observed rates and shrunken rates derived from a Bayesian multivariate normal-binomial 
model. We evaluate whether the model and the method choice-the Bayesian multivariate 
normal-binomial model with MCMC or the commonly used multivariate normal model 
with MLE make a difference to the estimation of outcome in a variety of settings even in 
these simple models when we analyze the outcomes simultaneously. Coverage is utilized 
to reveal how well the variance of the parameters is estimated under the different 
parametric settings. In the multivariate setting instead of calculating coverage using 
confidence intervals, confidence regions are used for the vector of the parameters. In 
trying to estimate the parameters we evaluate whether the true values are contained in the 
95% credible or confidence region around the mean vector by incorporate the correlations 
between the estimated parameters. The second half of the paper focuses on utilizing the 
methods of estimation in detecting sites that are outliers.  
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Chapter 2 
 
Statistical Methods of Estimation on Binomial Counts of Adverse Events in 
Multicenter Clinical Trials for single outcomes setting 
2.1  Background 
 
Binomial response data are frequently encountered in clinical trials in testing the 
efficacy of new medical regimens.  For example, a new treatment may be intended to 
reduce the frequency of a poor clinical outcome such as death, infection, or re-
hospitalization. Efficacy studies, however, do not typically place primary emphasis on the 
relative occurrence of side-effects or other adverse events and those conducting 
randomized clinical trials may simply request adverse events to be tabulated and/ or listed 
as counts or proportions.  It may be useful to those conducting trials to take into 
consideration adverse events when evaluating whether or not in multi-center trials that a 
particular center is not performing well relative to the other centers in the study.  Higher 
rates of adverse events in a center may be indicative of poor management which could 
then affect the quality of the overall trial.  To determine factors that drive variation in the 
proportion for adverse outcome data between study sites, binomial statistical models can 
be applied to the data and the binomial mean can be modeled as a function of the source 
of variations. In some cases, these binomial models may identify larger variation than 
expected in adverse event rates between study sites. This phenomenon can arise due to 
chance alone or the extra variability may in fact be real.  With #,	representing proportion 
of patients at a study site, i, who have suffered an adverse event and with heterogeneous 
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#,’s, there are several ways to model the variation.  Given that study subjects are nested 
within study sites, hierarchical statistical models are often used to examine between-site 
variations.  The simplest hierarchical model, when no covariate is involved, is the beta-
binomial distribution.  Generalized linear models can be used to fit such hierarchical 
models.  Given the context, the aim of this study is to demonstrate the use of Bayesian 
and fixed effects statistical models to estimate the difference between study sites on the 
parameter, p, the proportion of subjects with an adverse event.  
Within each model and estimation method that we examine, we compute statistical 
performance metrics for site-specific estimates in simulation studies using scenarios from 
a motivating example data.  Using these metrics, we have specific interest in delineating 
the relative performance of Bayesian models with more easily implemented maximum 
likelihood (ML) approaches. The use of a Bayesian approach enables us to obtain a 
posterior distribution associated with a site’s estimate and derive several statistics based 
on it.  Bayesian hierarchical models borrow information across sites and thus works well 
for small sample sizes and often lead to different results than a fixed effects ML approach 
that does not employ hierarchical mixed effects [7]. For Bayesian methods, shrinkage is 
used to estimate the performance of the sites as the weighted average of the site's 
observed performance and the performance of all sites on the same indicator. In other 
words, a site's performance is pulled or shrunken towards the overall performance of the 
sites, the extent of which depends on the reliability of the site's observed proportion, 
which is a function of sample size and the distance between the site's performance and 
the overall performance.  This shrinkage estimate is envisioned to be a proper estimate of 
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adverse event rate per site having incorporated information from the site as well as the 
overall rate for the set of sites.  In a Bayesian framework, for a simple Natural 
Exponential Family with Quadratic Variance Function (NEF-QVF) with a conjugate prior 
(a binomial distribution with a beta prior or normal with a normal prior) the posterior 
mean is given by (1 − 1))* + 1 ∗ 5 
where y is the Binomial data, n is the sample size, 5 is the overall mean and w is the 
shrinkage. When the shrinkage is close to 0 the posterior mean is the individual expected 
value of the data while when shrinkage is close to 1 the posterior mean is closer to the 
overall mean, which means there is little difference between the sites.  
Several articles discuss and illustrate the value of these types of shrinkage 
estimators. Hierarchical models generalize the idea of shrinkage and provide a 
comprehensive framework for examining clustered data. If all units have large samples or 
samples of equal sizes, the effects of shrinkage are not informative because they are 
negligible or uniform. Shrinkage is important, however, when some sample sizes are 
small [26]. Denominator sizes vary considerably across the sites warrant the use of 
shrinkage estimators for clinical indicators data [27]. Shrinkage estimators also inform us 
whether there is variation between the sites and whether we should consider using 
hierarchical models. 
As noted above, the broad objective of the current study is to assess the 
performance of estimation methods – fixed effects model with MLE and Bayesian 
models with MCMC using simulation studies. A bowel resection dataset from a 
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multicenter trial provides motivation for our work. The outline of this article is as 
follows. In Section 2.2, we describe the statistical methods and models used. Section 2.3 
is then devoted to the describing the data generation models. Section 2.4 presents the 
methods of estimation. The derivation of the posterior distributions for the Bayesian 
models is shown in Section 2.5. Section 2.6 discusses model estimation and Section 2.7 
describes the operating characteristics used to compare the methods. We present the 
results of the simulation studies comparing and evaluating the methods under different 
parametric settings in Section 2.8.  
Sensitivity analyses of the priors for the Bayesian analyses are presented in Section 2.9.  
In Section 2.10, we present analyses of the motivating data set utilizing the analytic 
models compared in our simulation study. In Section 2.11 we summarize the performance 
of the methods based on the simulated data and Section 2.12 is a discussion on the 
application of the methods to the motivating data set. All the analyses have been 
performed with R-3.0.0 and WinBUGS14 software 
Motivating Example Dataset 
 
Adverse event (AE) data from a multi-site clinical trial in bowel resection patients 
treated by drug A (anonymous) are used as an example dataset for demonstration. There 
have been reports that postoperative recovery in bowel surgery patients is influenced by a 
variety of conditions: intra-operative anesthesia, surgical stress, manipulation of the 
gastrointestinal (GI) tract in surgery, and use of opioids for pain control, which are 
associated with a variety of side effects including diminished bowel function [28].  There 
are many adverse events (AEs) that may occur after GI surgery, including post-operative 
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ileus (intestinal obstruction), wound infection, anastomotic leak, nausea, vomiting, and 
abdominal pain [29].  The data come from six multi-site double blinded placebo-control 
studies to evaluate the impact of drug “A” versus placebo after bowel resection. In this 
study, we only considered AEs that are listed in the clinical trial database as there may be 
GI-related AEs that were not represented in the database. There were a total of 63 clinical 
sites, but the total number of subjects enrolled in the study was unknown. This meant that 
the total number of subjects at each site and the adverse events proportions by site were 
unknown. The dataset only provided us with the number of adverse event cases or 
numerator on each category. This dataset has been used as a motivating dataset to 
facilitate the theoretical analyses. The term, “provider”, has been used generically to refer 
to a clinical site or center or facility. The table below shows the summary statistics for 
four of the several adverse events in the motivating dataset. In this study, we will focus 
only on a single outcome-one type of adverse event, nausea.  
Table 1: Count of Adverse Events from Motivating Example Dataset 
Number of sites=63 
Nausea Fever Vomit Abdominal Distension 
669  237  275  162  
2.2  Methods and Models 
 
In this paper, we consider an adverse event in a clinical trial as a patient-level 
outcome with a Bernoulli distribution that at the site level is the count of adverse events 
which follows a binomial distribution. Our interest is the counts of adverse events for two 
outcomes at the site-level. We evaluate four different statistical approaches to assess 
statistical estimates of the sites’ proportions of adverse events: 
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1. a Bayesian beta-binomial (B-B) model with Markov Chain Monte Carlo (MCMC) 
estimation; 
2. a Bayesian binomial logit-normal (B-LN) model with MCMC estimation; 
3. a fixed effects model with maximum likelihood estimation using normal 
approximation; and 
4. a fixed effects with maximum likelihood estimation method using exact 
computation. 
For the first set of studies, we simulate data with the number of sites fixed at N=63 while 
varying 
a. the number of subjects per site,	*, for sites $ = 1, … ,9 (with equal subjects per 
site: 10 or 60, or unequal subjects per site varying between 10 and 60 or between 
150 and 200) 
b. the true expected site-level adverse event proportion, E(#,) for sites $ = 1,… , 9 
(0.05, 0.17 and 0.50) and 
c. the average shrinkage over sites, 1, for sites $ = 1,… , 9 at 
i. 0.11, 0.26, 0.37, 0.68 for E(#,)=0.05 
ii. 0.03, 0.09, 0.14, 0.38 for E(#,) =0.17 and 0.50, 
since varying the number of subjects per site impacts the variation in shrinkage for i and 
ii above.  
In order to evaluate the impact of the number of sites on the estimates of the 
proportion of adverse events at the site-level (since this will affect shrinkage for estimates 
at that level), in the next set of simulation studies we simulated data by fixing the number 
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of subjects per site at 60, varying the number of sites from 20 sites with very little 
between-site information to 100 sites, with lot of between-site information, for expected 
proportion of adverse events, E(#,) at 0.05 and 0.50.  
For data generated with chosen parameter values per scenario, the two maximum 
likelihood (ML) and two Bayesian estimation approaches were compared in terms of 
statistical performance using several operating characteristics (described in Section 2.7)-
non-coverage of 95% confidence and credible intervals; average confidence interval 
width; standardized squared error risk; and absolute bias of estimation. 
These four methods of estimation were also evaluated using the motivating example 
dataset as an illustration of the analysis in a single, real-world data set. Figure 1 shows 
the process utilized in the simulation study for fixed number of sites. Figure 2 shows the 
simulation process for the impact of the number of sites on the estimates, keeping the 
number of subjects per site equal and fixed at 60. 
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Figure 1: Simulation Studies for Fixed Number of Sites 
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Figure 2: Simulation Studies for Varying Number of Sites 
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2.3  Data Generation Models 
Data 
We assume there are N clinical sites, with *, subjects observed for the $th site and 
a total of ),	adverse events across the *,subjects. Let  #, be the probability of adverse 
event at the ith site. We assume that the outcomes, ),	are independently distributed given #,	as 	),|*,, #,~<$*(#,, *,)                   i=1,.,N                                  (1) 
     
For fixed effects models, the 	#, s are fixed while for the models that line up with a 
Bayesian distribution, we assume that given the true adverse event proportion (i.e, 
probability of adverse event) at site i, the outcomes ‘	),’ are independent and 	#, or 
logit(	#,) are a random sample from a common population distribution. 
Distribution of  !" 
2.3.1 Model 1 (Binomial logit-normal): B-LN 
 
Under the B-LN model, the logit of  #,  has a normal distribution with mean  => +?, and variance @A where bC′s are the random effects for site i. The values of the individual 
hyperparameters are obtained from matching moments with B-B hyperparameters 
discussed later in this section 																																									%&' F GHIJGHK~N(=> + ?,	, 	@A)             i=1,.,N                         (2) 
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2.3.2 Model 2 (Beta-binomial): B-B 
 
Under Model 2, #,  has a Beta distribution with the mean of Beta, MMNO  where the 
hyperparameter values were chosen based on the true expected proportion of adverse 
events. 																																															#,~<(=, P)                                   i=1,.,N                  (3) 
2.3.3 Fixed Effects Binomial Model 
 
The fixed effects binomial model is simply given by 
 																																				),|*,, #,~<$*(#,, *,)	                                  i=1,.,N        (4)      
 
The data in our simulations were generated using both fixed effects and Bayesian 
model assumptions. The data which follows a Binomial distribution as denoted in 
Equation (1), under any fixed parameter settings, were simulated based on a true 
expected proportion of adverse event, equal/unequal subjects per site, fixed number of 
sites and varying shrinkage (see Table 2). For each simulation scenario, we simulated 
1000 samples consisting of an average of N sites. 
Data generation from models that line up with B-LN and B-B distributions began 
with the generation of #, from models 1 and 2 (B-LN and B-B). Then given those #,‘s 
Binomial counts,		),Q  were generated for each site i. Thousand beta-binomial datasets 
were simulated with a true proportion #,,	such that #,~Beta(=, P), with mean, µ =SSNT		and variance, @A = U(IJU)SNTNI with a subject volume of *,as discussed in Model 1. The 
hyperparameters =, P were chosen such that the expected prior mean and the average 
shrinkage equal specified values to improve the understanding of how model specificity 
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relate fixed effects models and methods for binomial data. For example, for a true 
expected adverse event proportion of 0.17, we chose = = 1	and P = 5 such that	µ =
SSNT = 0.17 and shrinkage = (MNO)(MNONZ) = 0.14	or 0.09 with average number of subjects per 
site at n=36 or 60. When shrinkage is 0.09, the data are close to the fixed effects 
assumption that the data are 	),|*,, #,~<$*(#,, *,) with fixed p. Conditional on a site’s 
true proportion and subject volume, we then simulated a true number of events, ),  as 
demonstrated in Equation (1). We know that BUGS, the software that we used to fit our 
Bayesian models, is restricted to models whose sampling distributions are discrete, 
conjugate or log-concave (BUGS Manual, Section 3, 
http://users.aims.ac.za/~mackay/BUGS/Manual05/Manual05/manual05.sec-
3.html#section3_2). BUGS determine the complete conditional distributions by default 
using Adaptive Rejection Sampling (ARS). ARS is a method for efficiently sampling from 
any univariate probability density function which is log concave. If the density is not log 
concave, BUGS uses the Metropolis-Hastings Algorithm. In our simulation study ARS is 
used. 
We also simulated 1000 binomial logit-normal (B-LN) datasets from the true #,, where 
logit(#,) follows normal distribution with mean,	5 and variance, @A using Model 2. The 
hyperparameter values => and \ for the model (model 2) were obtained from matching 
moments (discussed below) to match the first two moments of the B-B model. Given a 
site’s true proportion and number of subjects per site, true number of events, ),  were 
simulated as demonstrated in Equation (1). For beta-binomial with hyperparameter values = = 1 and P = 5, the equivalent hyperparameter values for B-LN model were 5 = −1.87 
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and @ = 0.98, obtained by matching the first two moments of the two distributions 
described below. 
The prior mean for the B-B model is given by MMNO	and the prior variance by	_(IJ_)MNONI. 
The prior mean for the B-LN model is given by  5 = α> + 	? and the prior variance is σA . 
We matched the first two moments of the distributions to obtain comparable 
hyperparametric values. These hyperparameters were then used to simulate the data using 
the two different models. Table 2 show the values of the hyperparameters corresponding to 
the true proportion, the mean and variance of the functional form of #	and shrinkage at 
varying number of subjects per site for the Bayesian models.  
From the B-LN model we have,  GIJG ~b9(5, @A)      (5) 
 
And from B-B model we have,																														 GIJG ~ ST c(2=, 2P)       (6) 
 
For an F-distribution (F (υ1, υ2)),  
mean= ef	efJA = 5∗ , for 	gA > 2 and variance = AU∗f(eiNefJA)ei(efJj) , for 	gA > 4 
Now for a Log-Normal distribution, mean=k	UN	lf Am  and variance =nklfJIo(kAUNlf) 
Using Equations (5) and (6) and equating the first two moments of the above distributions 
gives the estimates of the parameters 5 and @2 for B-LN when we choose values of α and 
β for B-B. 
																																																																												5 = %&'pSq(rJI)rq(SNI)      (7) 
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																																																																																							@A = %&'pr(SNI)S(rJI)                     (8) 
where s = P − 1 
 
Table 2: Parametric Conditions used for simulation of p 
E(pi) Prior Distributions Average Shrinkage 
n=10 n=60 n~U(10,60)1 n~U(150,200)2 
0.05 Beta(1,20) LN(-3.32,0.75) 0.68 0.26 0.37 0.11 
0.17 Beta(1,5) LN(-1.87,0.98) 0.38 0.09 0.14 0.03 
0.50 Beta(3,3) LN(-0.085,0.981) 0.38 0.09 0.14 0.03 
1 Assuming unequal number of subjects per site with an average of n=36 
2 Assuming unequal number of subjects per site with an average of n=175 
  n=number of subjects per site   
 
To sharpen our comparison of the estimation methods we also generated data under the 
fixed effects framework with a nonhierarchical Binomial model, the commonly used 
approach assuming a fixed expected proportion (#,). Given those #,‘s , Binomial counts 
were generated for each site i as indicated in Equation (4). For zero numerator problems in 
the commonly used ML approach a continuity correction factor of 0.5 was applied, 
whereby both the numerator(y) and denominator (n) were increased by a factor of 0.5. 
2.4  Methods of Estimation 
Bayesian Methods 
 
2.4.1  Method 1 (B-LN Model with MCMC method) 
 
Method 1 utilizes a B-LN model with the MCMC method of estimation, specifically the 
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Gibbs sampler.  The logit of  #,  has a normal distribution with mean  => + ?, and variance @A .The individual hyperparameter α> is distributed as normal with mean 0 and variance 10t	and the random effect of site, ?, is distributed as normal with mean 0 and variance @A. The precision = \ = I	lf follows a gamma distribution. 	%&' F GHIJGHK ~N(=> + ?,	, 	@A),                                                   
      ?,~9(0, 	@A),                      				=>~9(0, 10t), 																																																							@A = Iu 1ℎkwk	\ = #wks$Q$&*            (9) 																																																																					\~xyzzy(0.1,0.1),                                                          
     As in standard Bayesian hierarchical models (Morris and Normand, 1992; Gelman et. 
al., 1995; Smith, Speigelhalter, and Thomas, 1995; Berry, 2000) we assign a prior 
distribution to the hyper parameters bi, α0 and  	@A, as	specified above. We choose some 
vague priors for the mean and variance after performing sensitivity analysis discussed in 
section 2.9. 
 
2.4.2  Method 2 (B-B Model with MCMC method) 
 
Method 2 utilizes a B-B model with the MCMC method of estimation, again 
specifically the Gibbs sampler. Each  #,  has a Beta distribution with the mean of Beta, MMNO 
, distributed as Uniform with parameters 0 and 1 and the scale of the Beta distribution, α +β , as a Pareto with parameters 1.5 and 1. #,~<(=, P), 
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== + P~}(0,1), 																																																															= + P~~ywk(&(1.5,1),                                      (10) 
For the mean and scale of beta-binomial, we used diffuse priors on the hyperparameters. 
 
Maximum Likelihood Estimation (MLE) Methods 
 
2.4.3  Method 3 (MLE Approach Using Normal Approximation Method) 
 
In Method 3, using the Delta Method,  #Ä = ÅHÇH ~9 F#,, GH(IJGH)ÇH K                             (11) 
The fixed effects approach of estimating parameters is in terms of null hypothesis tests or 
confidence intervals. We chose 95% confidence interval for our implementation of fixed 
effects MLE approach. 95% binomial approximated confidence intervals are calculated 
using the Normal approximation for #, given the data.  
The 100(1-α) % confidence interval for pi is		#Ä ± ÑS Am pGÖÜ(IJGÖÜ)ÇH                                                   (12) 
where Zα/2 denotes the (1-α/2) quantile of the standard normal distribution. 
This is also called Wald confidence interval for p since it results from inverting the Wald 
test. 
2.4.4  Method 4 (MLE Approach Using an Exact Method) 
 
In Method 4, we calculate 95% binomial exact confidence interval for #, given the 
counts data ),. As Coull and Agresti (1998) suggest we use the Clopper-Pearson exact 
confidence interval for p, based on inverting an equal-tailed binomial test for H0: p=p0. 
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This method gives endpoints that are solutions to p0 in the Equations 
áF*+K#àÇàâÅ (1 − #)ÇJà = = 2m  
and  
																	á F*+K#àÅàâ> (1 − #)Ç = = 2m 																																																								(13) 
except that the lower bound is 0 when ) = 0 and upper bound is 1 when ) = *. This 
interval estimator is guaranteed to have coverage probability of at least 1-α for every 
possible value of p. When ) =1,2,…,n-1 the confidence interval equals 
										ã1 + ÇJÅNIÅåfç,f(éèçêi),ièë fm íJI < # < ã1 + ÇJÅ(ÅNI)åf(çêi),f(éèç),ë fm íJI                               (14) 
Where F a,b,α denotes the 1- α quantile from the F distribution with degrees of freedom a 
and b. Equivalently, the lower end point is the α/2 quantile of a beta distribution with 
parameters y and n-y+1and the upper end point is 1- α/2 quantile of the beta distribution 
with parameters y+1 and n-y. 
2.5  Determination of Estimates 
 
The estimates of  #, were obtained under both Bayesian and ML framework. In 
Bayesian analyses, the estimates were obtained from posterior p which has a distribution, 
while in fixed effects, the estimates were the maximum likelihood estimates, sample 
mean,ÅHÇH  that was obtained from the data. 
Bayesian 
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Model 1 (Binomial logit-normal): B-LN 
 
For the B-LN model, the posterior distribution, is proportional to the product of 
the likelihood function and the specified prior distributions does not yield itself to a 
closed form solution; MCMC simulation methods (Gelman et al., 2005) are utilized to 
draw samples from the posterior distributions of the unknown parameters.	We used a 
normal-normal (N-N) conjugate framework. So if all one wants is the distribution of %&'$((#), given the data, this can be done using a N-N Bayes model. Below is a standard 
integral approximation to the approach used. 
 If 	),|*,, #,~<$*(#,, *,)	, for i=I,..,N 
i.e, <$*()|#) = FÇÅK	#Å(1 − #)ÇJÅ where y=count of adverse event, 0<y<n, 
                                      then %&'$( FÅÇK~9î%&'$( FÅÇK , ïÅ(ÇJÅ)Çq ñI/Aò (see Appendix A for 
complete derivation) 																																																							bk(	%&'$( FÅÇK = ô and let %&'$((#) = ö ô~9(ö, ζJI) %&'$((#)~9(5, úJI	) ö~9(5, úJI	) #(ö|ô) ∝ #(ö)#(ô|ö) 
∝ kïJIAûü(†JU)fN°(¢J†)f}ñ 
            = kïJifû†f(üN°)JA§(•_N¶°)Nß}ñ 
= k®JIA©(üN°)(§J(•_N°¶)•N° )fNß}™ 
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which is the density function of a Normal distribution. ´&	ö|ô~9(51,ú1JI) 
1ℎkwk	51 = (ú5 + ζu)φ + ζ = 15 + (1 − 1)ô ú1 = ú + ζ 																																																																													1 = ü•N°      (15) 
Thus the posterior distribution of %&'$((#) is also normal with the posterior mean being 
the weighted average of the prior mean (5)	and the data %&'$( FÅÇK =ô,	weighted by their 
relative precisions also known as shrinkage (1). The posterior precision is the sum of the 
prior and sample precisions. 
Model 2 (Beta-binomial): B-B 
 <$*()|#) = FÇÅK	#Å(1 − #)ÇJÅ      where y=count of adverse event, 0≤y≤n 
The Beta distribution is used as a prior to #, since the beta distribution is conjugate to 
binomial distribution. 
<k(y(#|=, P) = 		 #SJI(1 − #)TJI<k(y(=, P)  
The marginal likelihood term corresponding to the conjugate is the beta-binomial 
distribution 
Æ <$*I> ()|#)<k(y(#|=, P)Ø#
= Æ î*)ò	#Å(1 − #)ÇJÅ#(SJI)(1 − #)(TJI)Ø# <k(y(=, P)mI>  
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= Æ î*)ò	#ÅN(SJI)(1 − #)ÇJÅN(TJI)Ø# <k(y(=, P)mI>  = î*)ò 	<k(y(= + ), * − ) + P) <k(y(=, P)m  
Thus the posterior distribution is simple a <k(y(= + ), * − ) + P) 
Posterior Mean=	 SNÅSNTNÇ = 1µ + (1 − 1) ÅÇ; where 5 = SSNT  and 1= (SNT)(SNTNÇ)      (16) 
Thus the posterior mean is the weighted average of the prior mean (5 = SSNT) and the data FÅÇK and the weights are known as the shrinkage, given by (SNT)(SNTNÇ). The proportionate 
shrinkage of the $th site towards the grand mean depends on the site’s sample size and the 
between-site variations. 
Once the posterior distribution of #, is obtained, point estimates and interval estimates can 
be directly derived from the posterior. 
Fixed Effects ML 
 
Under the fixed effects ML framework, the point estimates are simply the individual site 
sample meanQ, FÅHÇHK,	from the data. 
2.6  Estimation and Model Fit 
 
To estimate the model parameters, fit and appropriateness of priors of Bayesian 
hierarchical model, Gibbs sampling was used. The sampler was implemented using 
BUGS software to estimate parameters in Bayesian models [18]. The model is fit to the 
binary outcome from the simulated data with Markov chain Monte Carlo sampling using 
BUGS (Gliks, Thomas and Spiegelhalter 1994). We examined several convergence 
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diagnostics, especially on the potential scale reduction (PSR) statistic proposed by 
Gelman and Rubin (1992) as well as the trace plots. We obtained inferences for the model 
parameters by combining 2 parallel chains with a burn-in of 5,000 iterations and a further 
7,000 iterations. Convergence of the Gibbs sampler was assessed according to graphical 
plots as well as Monte-Carlo error and the Gelman-Rubin statistic for couple of the 
datasets. Starting values for parameters were chosen based on the maximum likelihood 
estimates. Our focus of inference being the site, we calculated summary statistics at the 
site level. Sensitivity analyses with reasonable modifications of priors were also carried 
out for the two random effects models to assess the impact of the priors on the posterior 
distribution discussed later in section 2.9.  
Using maximum likelihood and Bayesian MCMC estimates of proportion of 
adverse events in site four methods were compared as described previously in section 2.2. 
The results were then compared to the true, the parameter values used to generate the 
data. 
2.7  Comparison of Methods using Operating Characteristics: non-
coverages; interval widths; and risk functions. 
 
Operating characteristics in the results section were calculated as average of the averages 
across simulations. For each site each of the characteristics were averaged across 1000 
simulations to get an average summary characteristic at the site level. This was then 
averaged across the number of sites to get an overall summary characteristic for each 
parametric setting.  
 31 
The non-coverage is defined as the proportion of times the interval estimate fail to 
cover the true values of #	, for N sites for 1000 simulated datasets. 
               1 − I∞×I>>> ∑ ∑ n≥(#̂,,>.>Aµ < #	, < #̂,,>.∂∑µ|Øy(y)o∞,âII>>>I                           (17) 
where I is an indicator function such that 
I =      1 if #̂,,>.>Aµ < #	, < #̂,,>.∂∑µ        
  
           0 otherwise 
Thus non-coverage is calculated as the overall percentage of NX1000 intervals (1000 
simulations and N sites) that do not contain their true values. 
The average interval width is the average of the averages of the interval widths for N sites 
for 1000 simulated datasets. 
                  															 I∞×I>>> ∑ ∑ n#̂,,>.∂∑µ 	− #̂,,>.>Aµo∞,âII>>>I                                                (18) 
The average squared error risk is the average of the averages of the standardized squared 
error of N sites for 1000 simulated datasets. 																																			 I∞×I>>> ∑ ∑ F	(GHJG∏H)fGπ∫ªé K∞,âII>>>I 																																																																					 (19) 
The absolute bias is the average of the averages of the absolute bias of N sites for 1000 
simulated datasets.  																																								 I∞×I>>> ∑ ∑ (|#, −	 #̂,|)∞,âII>>>I                       (20) 
2.8  Results 
 
Fixed Number of Sites 
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For each of the combinations of the parameter settings a simulation study was initiated. 
There were 36 different scenarios, keeping the number of sites fixed at 63 –Three types 
of data generation models -B-B, B-LN and fixed effects; 3 true fixed proportion of 
adverse events 0.50, 0.17, 0.05; 4 types of subjects per site conditions-equals subjects at 
10 and 60 and unequal subjects between 10-60 and 150-200.  For comparison, a set of 
three tables depending on the model used to generate the data- B-B, B-LN or fixed effects 
were assessed with certain fixed and certain variable conditions. For instance, Table 3 
compares four different methods of estimation with fixed expected proportion of adverse 
events at 0.50, a fixed number of sites at 63 and varying subjects per site from equal 
number (10 or 60) to unequal number (between 10-60 or 150-200) on B-B simulated data 
while Table 4 does the same comparisons on B-LN simulated data and Table 5 on fixed 
effects generated data.  For the next set of three tables (Tables 6-8), methods are 
compared with the fixed expected proportion of adverse events at 0.17, a fixed number of 
sites at 63 and varying subjects per site. Since 95% confidence or credible intervals were 
calculated, it was expected the proportion of confidence or credible interval covering the 
true value should be at 95%. With 1000 simulations over N=63 sites, the expected non-
coverage lies between 0.049 and 0.051. Hence, results show that depending on the 
method of estimation coverage is more or less than 95%.  
With a high expected adverse event proportion of 0.50, for equal number of subjects per 
site the B-B model with MCMC method performed similarly as B-LN model with 
MCMC method for both B-B and B-LN generated data, showing perfect coverage of 
95%, wider average interval width, smaller squared error risk and small bias (Table 3 and 
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4). The common maximum likelihood approach with exact method overestimates the 
variance of the parameter,	#	for B-B or B-LN data under equal and unequal number of 
subjects per site showing less than 5% non-coverage and wider intervals. With the 
expected proportion of 0.50 with equal number of subjects per site at 60 and shrinkage of 
only 0.09, there is more weight towards the overall mean and less information is obtained 
from the prior.  The data are similar to the fixed effects assumption. Hence common 
approach with normal approximation demonstrated perfect coverage, wider average 
interval width, smaller squared error risk and small bias. Poor coverage, larger squared 
error risk and higher bias of the normal approximated MLE method was seen compared 
to the Bayesian methods (Table 3) for smaller (n=10) and unequal events per site ranging 
from 10 to 60 (average n=36) when shrinkage was 0.38 and 0.14 respectively. When the 
number of subjects was increased to 150 to 200 with average shrinkage of 0.03, very 
similar to fixed effects data, common method with normal approximation showed perfect 
coverage, moderate interval width, smaller squared error risk and absolute bias. Similar 
results were obtained with B-LN datasets at the true proportion of adverse events of 0.50 
and 63 sites. Thus with high expected proportion of adverse event of 0.50 and sample 
sizes 60 or above, it does not matter which method of estimation is chosen- Bayesian 
MCMC or the MLE approach with normal approximation for data generated under 
Bayesian framework. For data generated using the fixed effects binomial model (Table 
5), the exact method show consistently more coverage than 95% except for smaller 
sample sizes, similar to the results obtained under Bayesian data. The exact method 
appears to be more conservative than the other methods with wider confidence intervals. 
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With equal or unequal number of subjects per site, both Bayesian methods of estimation 
over shrink the prior variance showing under coverage and large absolute bias.  
With the expected adverse event proportion of 0.17 and average shrinkage ranging from 
0.03 to 0.38 for data generated using B-B or B-LN model, the B-B method performed 
slightly better than the B-LN both for B-B and B-LN datasets showing perfect coverage, 
wider intervals, comparable squared error risk and absolute bias (Table 6-7). The 
common ML approach using normal approximation performs closely to B-B method of 
estimation while the exact method show over coverage, wider confidence intervals, 
moderately large bias and squared error risk with higher shrinkage. For fixed effects 
binomial simulated data, both the Bayesian methods have higher absolute bias and poor 
coverage compared to the common approaches (Table 8). 
At the expected true proportion of 0.05 and average shrinkage of 26%, the B-B model 
demonstrate 95% coverage, has a smaller average interval width, comparable squared 
error risk and average bias both against the B-B and B-LN datasets compared to the B-
LN model (Table 9-10). When the number of subjects per site is as low as 10 with the 
same true proportion of 0.05 and average shrinkage of 68%, the maximum likelihood 
(ML) methods of estimation show under coverage, wider interval width, large squared 
error risk and absolute bias for both B-B and B-LN datasets. In all the above 
comparisons, the number of study sites was kept fixed at 63. 
Analysis of the B-B data permits a fairer evaluation of the B-B BUGS method and 
B-LN data permits fair evaluation of the B-LN BUGS method as expected since the data 
were generated from its own family of distributions. But in all the different scenarios the 
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B-LN underperforms compared to B-B in the B-B datasets. The B-LN model 
underestimates the within variance and hence the shrinkage when the data is B-B.  The 
common MLE approach with the exact method, in all situations, over estimates the 
variances producing a greater than 95% coverage, very wide intervals, larger squared 
error risks and higher bias. The price of guaranteeing 95% coverage for the exact method 
for each combination of *	and #  results loss of precision in the sense that intervals are on 
average wider than necessary to achieve the desired coverage. Despite its conservatism 
the preservation of nominal coverage is often preferred. The common ML approach using 
Normal Approximation performed poorly in the settings of varying subjects per sites 
except under the overall proportion of 50%. When the overall proportion goes from 0.05 
to 0.50, B-LN MCMC method tends to perform better and closer to B-B MCMC method 
for data generated under B-B model. The wider intervals account for the hyperparameter 
uncertainty and are partly responsible for its better coverage. Figure 1shows which 
method has better model properties and hence may be recommended compared to others 
under different parametric settings. 
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Figure 3: Results from Simulation Study (Number of sites fixed at 63) 
 
Varying Number of Sites 
To evaluate the impact of varying the number of sites, data were generated with 
fixed number of subjects per site at 60 using the Bayesian models for expected proportion 
of adverse events at 0.50 and 0.05. When the number of study sites was varied from 20 to 
63 to 100 at the true adverse event proportion of 0.50 and number of subjects per site 
fixed at 60, all methods except the exact method performed close to each other showing a 
non-coverage probability ranging from 0.05-0.07 for both B-B and B-LN simulated data. 
The empirical coverage of B-LN MCMC method was around only 0.89 against B-B data 
for the true proportion of 0.05 with varying number of sites while B-B with MCMC 
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method demonstrate 94%-96% coverage for both B-B and B-LN data.  
Figure 4: Results from Simulation Study by varying the number of sites 
 
Clearly the B-B model is the best analytic choice; it was virtually unbiased in all 
settings except when the number of centers was small. If we had no idea about the form 
of the data, knowing the total number of sites and total number of subjects per site, the B-
B model performs better than the B-LN model- has a better coverage, wider intervals and 
smaller squared error risks. 
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Table 3: True Expected Proportion of AE=0.50, Number of sites =63 (B-B) Data 
(Varying the number of subjects per site) 
Estimates for Beta-Binomial (B-B) simulated dataset 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 9%  
B-LN with MCMC 0.051 0.220 0.007 0.046 
B-B with MCMC 0.051 0.220 0.007 0.045 
MLE Approach Using 
Exact* 
0.028 0.347 0.016 0.069 
MLE Approach Using  
Normal Approx** 
0.059 0.229 0.007 0.047 
Equal subjects per site (n=10), resulting in average shrinkage of 38% 
B-LN with MCMC 0.057 0.448 0.029 0.097 
B-B with MCMC 0.050 0.453 0.028 0.096 
MLE Approach Using 
Exact* 
0.035 0.240 0.007 0.047 
MLE Approach Using  
Normal Approx** 
0.098 0.523 0.040 0.113 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
14% 
B-LN with MCMC 0.055 0.301 0.013 0.064 
B-B with MCMC 0.053 0.303 0.013 0.064 
MLE Approach Using 
Exact* 
0.028 0.347 0.016 0.069 
MLE Approach Using  
Normal Approx** 
0.072 0.327 0.016 0.069 
Unequal subjects per site, n from uniform(150,200), resulting in average 
shrinkage of 3% 
B-LN with MCMC 0.053 0.133 0.002 0.027 
B-B with MCMC 0.053 0.133 0.002 0.027 
MLE Approach Using 
Exact* 
0.041 0.141 0.002 0.028 
MLE Approach Using  
Normal Approx** 
0.055 0.136 0.002 0.028 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *,  
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Table 4:True Expected Proportion of AE=0.50, Number of sites =63 (B-LN Data) 
(Varying the number of subjects per site) 
Estimates for Binomial Logit-Normal (B-LN) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 9% 
B-LN with MCMC 0.052 0.215 0.006 0.045 
B-B with MCMC 0.051 0.215 0.006 0.045 
MLE Approach Using Exact* 0.035 0.233 0.007 0.046 
MLE Approach Using  
Normal Approx** 0.058 0.221 0.007 0.045 
Equal subjects per site (n=10), resulting in average shrinkage of 38% 
B-LN 0.056 0.455 0.030 0.098 
B-B 0.051 0.458 0.029 0.097 
MLE Approach Using Exact* 0.018 0.546 0.040 0.113 
MLE Approach Using  
Normal Approx** 0.112 0.506 0.038 0.109 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
14% 
B-LN 0.054 0.297 0.013 0.063 
B-B 0.052 0.298 0.013 0.063 
MLE Approach Using Exact* 0.029 0.335 0.544 0.323 
MLE Approach Using  
Normal Approx** 0.076 0.313 0.015 0.066 
Unequal subjects per site, n from uniform(150,200), resulting in average shrinkage 
of 3% 
B-LN 0.049 0.130 0.002 0.027 
B-B 0.049 0.130 0.002 0.027 
MLE Approach Using Exact* 0.041 0.136 0.002 0.027 
MLE Approach Using  
Normal Approx** 0.058 0.131 0.002 0.027 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 5:True Expected Proportion of AE=0.50, Number of sites =63 (Fixed effects Data) 
(Varying number of subjects per site) 
Estimates for fixed effects Binomial datasets  
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subs per site (n=60)  
B-LN with MCMC 0.175 0.147 0.033 0.068 
B-B with MCMC 0.175 0.120 0.032 0.063 
MLE Approach Using 
Exact* 0.027 0.262 0.008 0.051 
MLE Approach Using  
Normal Approx** 0.053 0.251 0.008 0.051 
Equal subs per site (n=10) 
B-LN with MCMC 0.174 0.287 0.034 0.078 
B-B with MCMC 0.173 0.294 0.035 0.078 
MLE Approach Using 
Exact* 0.021 0.600 0.050 0.124 
MLE Approach Using  
Normal Approx** 0.111 0.582 0.050 0.123 
Unequal subs per site from uniform (10,60)  
B-LN with MCMC 0.175 0.184 0.033 0.070 
B-B with MCMC 0.174 0.163 0.032 0.066 
MLE Approach Using 
Exact* 0.032 0.374 0.019 0.075 
MLE Approach Using  
Normal Approx** 0.066 0.358 0.019 0.075 
Unequal subs per site from uniform (150,200) 
B-LN with MCMC 0.178 0.099 0.032 0.064 
B-B with MCMC 0.174 0.070 0.032 0.058 
MLE Approach Using 
Exact* 0.039 0.153 0.003 0.030 
MLE Approach Using  
Normal Approx** 0.051 0.149 0.003 0.030 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 6: True Proportion of AE=0.17, Number of sites=63 (B-B Data) 
 (Varying the number of subjects per site) 
Estimates for Beta-Binomial (B-B) simulated datasets 
Method of Estimation Non-
coverage 
Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 9% 
B-LN with MCMC 0.086 0.152 0.010 0.032 
B-B with MCMC 0.051 0.152 0.010 0.032 
MLE Approach Using Exact* 0.028 0.173 0.011 0.032 
MLE Approach Using  
Normal Approx** 
0.063 0.158 0.011 0.032 
Equal subjects per site (n=10), resulting in average shrinkage of 38% 
B-LN with MCMC 0.092 0.308 0.045 0.066 
B-B with MCMC 0.049 0.319 0.046 0.067 
MLE Approach Using Exact* 0.011 0.448 0.067 0.079 
MLE Approach Using  
Normal Approx** 
0.037 0.403 0.059 0.073 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
14% 
B-LN with MCMC 0.083 0.202 0.018 0.042 
B-B with MCMC 0.046 0.205 0.019 0.042 
MLE Approach Using Exact* 0.022 0.252 0.024 0.046 
MLE Approach Using  
Normal Approx** 
0.059 0.225 0.023 0.045 
Unequal subjects per site, n from uniform(150,200), resulting in average 
shrinkage of 3% 
B-LN with MCMC 0.078 0.092 0.004 0.019 
B-B with MCMC 0.052 0.092 0.004 0.019 
MLE Approach Using Exact* 0.036 0.098 0.004 0.019 
MLE Approach Using  
Normal Approx** 
0.098 0.092 0.004 0.019 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 7: True Proportion of AE=0.17, Number of sites=63 (B-LN Data) 
(Varying the number of subjects per site) 
Estimates for Binomial Logit-Normal (B-LN) simulated datasets 
Method of Estimation Non-
coverage 
Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 9% 
B-LN with MCMC 0.052 0.158 0.011 0.033 
B-B with MCMC 0.053 0.159 0.011 0.033 
MLE Approach Using Exact* 0.027 0.180 0.012 0.034 
MLE Approach Using  
Normal Approx** 
0.075 0.165 0.012 0.034 
Equal subjects per site (n=10), resulting in average shrinkage of 38% 
B-LN with MCMC 0.053 0.319 0.047 0.067 
B-B with MCMC 0.041 0.328 0.048 0.068 
MLE Approach Using Exact* 0.014 0.457 0.071 0.084 
MLE Approach Using  
Normal Approx** 
0.048 0.413 0.062 0.075 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
14% 
B-LN with MCMC 0.055 0.215 0.023 0.045 
B-B with MCMC 0.049 0.217 0.024 0.046 
MLE Approach Using Exact* 0.022 0.266 0.027 0.050 
MLE Approach Using  
Normal Approx** 
0.064 0.239 0.026 0.048 
Unequal subjects per site, n from uniform(150,200), resulting in average 
shrinkage of 3% 
B-LN with MCMC 0.051 0.097 0.004 0.020 
B-B with MCMC 0.053 0.096 0.004 0.020 
MLE Approach Using Exact* 0.038 0.104 0.004 0.020 
MLE Approach Using  
Normal Approx** 
0.066 0.098 0.004 0.020 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 8: True Proportion of AE=0.17, Number of sites=63 (Fixed effects Data) 
(Varying number of subjects per site) 
Estimates for fixed effects Binomial datasets  
Method of Estimation Non-
coverage 
Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Equal subs per site (n=60)  
B-LN with MCMC 0.175 0.103 0.409 0.120 
B-B with MCMC 0.175 0.092 0.408 0.118 
MLE Approach Using Exact* 0.036 0.201 0.014 0.039 
MLE Approach Using  
Normal Approx** 
0.056 0.187 0.014 0.039 
Equal subs per site (n=10) 
B-LN with MCMC 0.175 0.202 0.411 0.127 
B-B with MCMC 0.175 0.225 0.410 0.130 
MLE Approach Using Exact* 0.016 0.483 0.084 0.098 
MLE Approach Using  
Normal Approx** 
0.016 0.386 0.071 0.090 
Unequal subs per site from uniform (10,60) 
B-LN with MCMC 0.175 0.129 0.409 0.121 
B-B with MCMC 0.175 0.123 0.408 0.120 
MLE Approach Using Exact* 0.016 0.483 0.084 0.098 
MLE Approach Using  
Normal Approx** 
0.088 0.266 0.030 0.056 
Unequal subs per site from uniform (150,200) 
B-LN with MCMC 0.176 0.069 0.408 0.117 
B-B with MCMC 0.175 0.053 0.408 0.114 
MLE Approach Using Exact* 0.038 0.117 0.005 0.023 
MLE Approach Using  
Normal Approx** 
0.053 0.112 0.005 0.023 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 9: True Proportion of AE=0.05, Number of sites=63 (B-B Data) 
(Varying the number of subjects per site) 
Estimates for Beta-Binomial (B-B) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared Error 
Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 26% 
B-LN with MCMC 0.108 0.077 0.010 0.016 
B-B with MCMC 0.049 0.078 0.010 0.016 
MLE Approach Using Exact* 0.017 0.111 0.013 0.019 
MLE Approach Using  
Normal Approx** 
0.049 0.093 0.013 0.018 
Equal subjects per site (n=10), resulting in average shrinkage of 68% 
B-LN with MCMC 0.130 0.120 0.027 0.026 
B-B with MCMC 0.029 0.156 0.030 0.028 
MLE Approach Using Exact* 0.008 0.360 0.080 0.045 
MLE Approach Using  
Normal Approx** 
0.003 0.306 0.071 0.043 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
37% 
B-LN with MCMC 0.131 0.095 0.016 0.020 
B-B with MCMC 0.058 0.101 0.015 0.020 
MLE Approach Using Exact* 0.014 0.176 0.003 0.025 
MLE Approach Using  
Normal Approx** 
0.036 0.145 0.024 0.024 
Unequal subjects per site, n from uniform(150,200), resulting in average 
shrinkage of 11% 
B-LN with MCMC 0.091 0.050 0.004 0.011 
B-B with MCMC 0.050 0.050 0.004 0.010 
MLE Approach Using Exact* 0.027 0.059 0.005 0.011 
MLE Approach Using  
Normal Approx** 
0.069 0.053 0.005 0.011 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 10: True Proportion of AE=0.05, Number of sites=63 (B-LN Data) 
 (Varying the number of subjects per site) 
Estimates for Binomial Logit-Normal (B-LN) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Equal subjects per site (n=60), resulting in average shrinkage of 26% 
B-LN with MCMC 0.053 0.083 0.011 0.017 
B-B with MCMC 0.043 0.086 0.012 0.017 
MLE Approach Using Exact* 0.034 0.233 0.067 0.046 
MLE Approach Using  
Normal Approx** 
0.050 0.098 0.014 0.019 
Equal subjects per site (n=10), resulting in average shrinkage of 68% 
B-LN with MCMC 0.069 0.137 0.037 0.029 
B-B with MCMC 0.030 0.164 0.039 0.030 
MLE Approach Using Exact* 0.018 0.546 0.402 0.113 
MLE Approach Using  
Normal Approx** 
0.003 0.312 0.077 0.043 
Unequal subjects per site, n from uniform(10,60), resulting in average shrinkage of 
37% 
B-LN with MCMC 0.062 0.104 0.024 0.022 
B-B with MCMC 0.042 0.109 0.024 0.023 
MLE Approach Using Exact* 0.029 0.335 0.150 0.066 
MLE Approach Using  
Normal Approx** 
0.029 0.156 0.031 0.026 
Unequal subjects per site, n from uniform(150,200), resulting in average 
shrinkage of 11% 
B-LN with MCMC 0.054 0.054 0.005 0.011 
B-B with MCMC 0.049 0.055 0.005 0.011 
MLE Approach Using Exact* 0.041 0.136 0.023 0.026 
MLE Approach Using  
Normal Approx** 
0.076 0.057 0.005 0.012 
 * Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 11: True Proportion of AE=0.05, Number of sites=63 (Fixed effects Data) 
 (Varying number of subjects per site) 
Estimates for fixed effects Binomial simulated datasets  
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Equal subs per site (n=60)  
B-LN with MCMC 0.099 0.052 0.004 0.010 
B-B with MCMC 0.094 0.054 0.004 0.006 
MLE Approach Using Exact* 0.010 0.125 0.016 0.022 
MLE Approach Using  
Normal Approx** 
0.197 0.099 0.015 0.022 
Equal subs per site (n=10) 
B-LN with MCMC 0.008 0.104 0.007 0.014 
B-B with MCMC 0.001 0.138 0.010 0.011 
MLE Approach Using Exact* 0.012 0.371 0.067 0.032 
MLE Approach Using  
Normal Approx** 
0.001 0.236 0.065 0.032 
Unequal subs per site from uniform (10,60) 
B-LN with MCMC 0.049 0.065 0.004 0.011 
B-B with MCMC 0.033 0.073 0.005 0.011 
MLE Approach Using Exact* 0.013 0.194 0.035 0.033 
MLE Approach Using  
Normal Approx** 
0.044 0.160 0.028 0.028 
Unequal subs per site from uniform (150,200) 
B-LN with MCMC 0.006 0.035 0.005 0.004 
B-B with MCMC 0.0002 0.031 0.0004 0.003 
MLE Approach Using Exact* 0.039 0.153 0.029 0.030 
MLE Approach Using  
Normal Approx** 
0.078 0.064 0.006 0.013 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 12: True Proportion of AE=0.50, Varying Sites (B-B Data) 
Number of subjects per site=60, Average Shrinkage=9%, 
(Varying the number of sites) 
Estimates for Beta-binomial (B-B) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Number of sites=100 
B-LN with MCMC 0.056 0.220 0.015 0.052 
B-B with MCMC 0.060 0.220 0.014 0.052 
MLE Approach Using Exact* 0.035 0.242 0.007 0.048 
MLE Approach Using  
Normal Approx** 
0.060 0.230 0.007 0.048 
Number of sites=63 
B-LN with MCMC 0.051 0.220 0.007 0.046 
B-B with MCMC 0.051 0.220 0.007 0.045 
MLE Approach Using Exact* 0.028 0.347 0.016 0.069 
MLE Approach Using  
Normal Approx** 
0.059 0.229 0.007 0.047 
Number of sites=20 
B-LN with MCMC 0.055 0.224 0.007 0.046 
B-B with MCMC 0.051 0.224 0.007 0.046 
MLE Approach Using Exact* 0.037 0.246 0.007 0.048 
MLE Approach Using  
Normal Approx** 
0.061 0.234 0.007 0.048 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 13: True Proportion of AE=0.50, Varying Sites (B-LN Data) 
Number of subjects per site=60, Average Shrinkage=9%, 
(Varying the number of sites) 
Estimates for Binomial Logit-Normal (B-LN) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Number of sites=100 
B-LN with MCMC 0.061 0.217 0.007 0.047 
B-B with MCMC 0.060 0.217 0.007 0.047 
MLE Approach Using Exact* 0.034 0.236 0.007 0.046 
MLE Approach Using  
Normal Approx** 
0.065 0.223 0.007 0.046 
Number of sites=63 
B-LN with MCMC 0.052 0.215 0.006 0.045 
B-B with MCMC 0.051 0.215 0.006 0.045 
MLE Approach Using Exact* 0.035 0.233 0.007 0.046 
MLE Approach Using  
Normal Approx** 
0.066 0.221 0.007 0.046 
Number of sites=20 
B-LN with MCMC 0.056 0.218 0.007 0.046 
B-B with MCMC 0.053 0.219 0.007 0.045 
MLE Approach Using Exact* 0.036 0.239 0.007 0.047 
MLE Approach Using  
Normal Approx** 
0.068 0.226 0.007 0.047 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 14: True Proportion of AE=0.05, Varying Sites (B-B Data) 
Number of subjects per site=60, Average Shrinkage=26%,  
(Varying the number of sites) 
Estimates for Beta-Binomial (B-B) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Number of sites=100 
B-LN with MCMC 0.119 0.075 0.009 0.016 
B-B with MCMC 0.051 0.077 0.009 0.016 
MLE Approach Using Exact* 0.017 0.118 0.015 0.020 
MLE Approach Using  
Normal Approx** 
0.045 0.090 0.012 0.017 
Number of sites=63 
B-LN with MCMC 0.108 0.077 0.010 0.016 
B-B with MCMC 0.049 0.078 0.010 0.016 
MLE Approach Using Exact* 0.017 0.111 0.013 0.019 
MLE Approach Using  
Normal Approx** 
0.049 0.093 0.013 0.018 
Number of sites=20 
B-LN with MCMC 0.103 0.075 0.009 0.016 
B-B with MCMC 0.051 0.084 0.009 0.017 
MLE Approach Using Exact* 0.020 0.118 0.015 0.021 
MLE Approach Using  
Normal Approx** 
0.063 0.100 0.014 0.020 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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Table 15: True Proportion of AE=0.05, Varying Sites (B-LN Data) 
Number of subjects per site=60, Average Shrinkage=26%, 
(Varying the number of sites) 
Estimates for Binomial Logit-Normal (B-LN) simulated datasets 
Method of Estimation Non-coverage Avg. Interval 
Width 
Squared 
Error Risk 
Absolute 
Bias 
Number of sites=100 
B-LN with MCMC 0.066 0.082 0.011 0.017 
B-B with MCMC 0.054 0.084 0.012 0.017 
MLE Approach Using Exact* 0.017 0.116 0.015 0.020 
MLE Approach Using  
Normal Approx** 
0.058 0.098 0.014 0.019 
Number of sites=63 
B-LN with MCMC 0.053 0.083 0.011 0.017 
B-B with MCMC 0.043 0.086 0.012 0.017 
MLE Approach Using Exact* 0.034 0.233 0.067 0.046 
MLE Approach Using  
Normal Approx** 
0.050 0.098 0.014 0.019 
Number of sites=20 
B-LN with MCMC 0.047 0.065 0.007 0.013 
B-B with MCMC 0.037 0.073 0.008 0.014 
MLE Approach Using Exact* 0.018 0.104 0.011 0.017 
MLE Approach Using  
Normal Approx** 
0.030 0.085 0.010 0.016 
* Exact confidence interval from a Beta distribution 
** Normal approximation that includes a continuity correction factor of 0.5 when number 
of events is zero or *, 
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2.9  Sensitivity Analyses with different distribution for Hyperpriors 
 
Hierarchical models, linear or nonlinear, often consist of two levels, where the 
parameters in the first-level of the hierarchy reflect individual-level effects, which are 
assumed to be random effects and distributed according to a probability distribution 
characterized by the “hyperparameters” in the second-level of the hierarchy.  
Hyperparameters capture the variation of the facility-level random effects, and the mean 
of the random effects when there are no covariates in the second-level of the model, or 
how the covariates drive the sizes of the individual-level effects when there are 
covariates. In the previous section we compared beta-binomial and the binomial-logit 
normal models based on the estimation of the expected proportion (	#,) of adverse events 
for each site i. In this section we focus on the characteristics of hyperparameters and their 
estimation under different scenarios. Our main question here was whether the models 
were estimating the hyperparameters well rather than were the p’s being estimated well.  
In other words, we needed to determine whether better estimates, however defined, come 
from the beta-binomial models using MCMC method or from the more standard 
binomial-logit normal models using MCMC method. We also made suggestions for 
extension of this work to investigate both the situation of independent random effects and 
that of correlated random effects in the case of including treatment effect in the model.  
We considered some proposed non-informative as well as diffuse prior distribution for 
the hierarchical mean and variance parameters including the uniform and inverse-gamma 
families, in the context of an expanded conditionally-conjugate family. 
We started from shrinkage as low as 9% to as high 38% for the expected adverse 
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event proportion of 0.17 with 63 total sites and equal number of subjects per site at 10 
and 60 to evaluate the situations in which model estimates the hyperparameters well.  The 
beta-binomial model (as specified in section 2.3.2 Model 2) was fit to beta-binomial 
simulated datasets. 	), is the number of events of nausea out of n total events. The events 
occur independently with probability pi. Hence yi is drawn from a Binomial distribution 
(n, pi ) as noted in Equation (1). The probability of adverse events may vary due to 
differences in patients and sites. We assume that the probability of adverse occurrence is 
drawn from a common distribution which is a beta distribution that acts as prior. Instead 
of gamma, the hyperparameters now follow a number of different distributions with a 
range of non-informative or diffuse priors to informative priors. We perform a sensitivity 
analysis with the hyperprios to evaluate which prior works best under which scenario. 
For a Beta distribution, Gelman et al., 2003 chose uniform distributions on both the zky* = SSNT                (21) 
and  IºSNT 
This distribution is uniform on “expected adverse event probability” and “inverse root 
virtual sample size” (the latter is proportional to the standard deviation of “expected 
nausea probability”). A uniform prior distribution with a large upper bound on 
hyperparameters α and β results in a posterior distribution with almost all mass on very 
large values of α and β (Table 16-17). 
Various non-informative prior distributions for the variance, @A have been suggested in 
Bayesian literature and software, including an improper uniform density on σ (Gelman et 
al.,2003), proper distributions such as #(@A)~ inverse-gamma(0.001, 0.001) 
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(Spiegelhalter et al., 1994, 2003). Non-informative priors are generally defined as priors 
that only add a small amount of information, as compared to the likelihood. Intriguingly, 
the posterior distribution is the likelihood function if the prior is "diffuse", which is not 
the same as a "uniform" or "flat" prior. A "flat" prior indicates a uniform prior where all 
values in the range are equally likely. There are arguments about whether these are truly 
non-informative, since specifying that all values are equally likely is, in some way, 
information, and may be sensitive to how the model is parameterized. While a "diffuse" 
prior is not necessarily flat, and it expresses that a large range of values are plausible, 
rather than concentrating the probability mass around a highly specific range, essentially 
a prior with large variance. 
We use the slightly altered and simplified meaning of "diffuse" prior to mean one 
that would leave the posterior exactly the same as a normalized likelihood function, so 
that the non-Bayesian maximum likelihood estimation becomes the maximum point of 
the posterior for a Bayesian, if the likelihood function and the unnormalized posterior 
coincide. Similarly, in the beta prior case, B (1,1) is uniform, but may not be diffuse 
enough, because as we let both α, β starting from B (α=1,β=1) go to zero, the variance 
increases. For convenience, we re-parameterize the beta distribution using its mean SSNT	and scale	= + P. Given the mean and scale, we can derive α and β by: = = F SSNTK (= + P)= (mean) (scale)       (22) P = (= + P) F1 − SSNTK= (scale) (1-mean) 
We then put priors directly on the mean and scale. Because the mean has a range of 0 to 
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1, we can use a uniform prior: 
SSNT ~}(0,1) = <(1,1)        (23) 
We use some vague priors such as gamma priors of the positive reals for the sample size. 
Because the scale ranges from 0 to infinity, it’s impossible to have a (proper) uniform 
prior, because the integral would diverge. Instead, we try using a Pareto prior, = + P~~ywk(&(1.5,1)        (24) 
The Pareto distribution (Ω, +)  is defined on the interval [+,∞) by 
~ywk(&n)|Ω, +)~)J(¿NI)o 
In other words, the Pareto distribution is a power-law distribution with exponent	Ω + 1. 
This is a fairly diffuse prior, slightly favoring smaller values of the scale. 
The following tables show the behavior of the hyperparameters with a fixed hyper 
prior distribution for zky* = SSNT ~}(0,1) and varying the distribution of the prior 
variance or scale under different scenarios (varying the number of subjects per site and 
varying the shrinkage). It is evident that = + P~~ywk(&(1.5,1) performs better in all 
different situations; the estimated parameters are closer to the true values. 
For binomial-logit normal model (as specified in section 2.3.1 Model 1), we perform a 
sensitivity analysis by choosing a Normal prior for α0, 	α>~9(0,1.0¡ − 6) and we vary 
the priors for the variance.  We give a gamma prior to the precision and compare to a 
uniform prior to σ, the between-site standard deviation. Gamma prior produces better 
estimates.  
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Table 16: True Expected Adverse Event Proportion=0.17, Varying Priors (B-B Data) 
Number of sites=63, Number of subjects per site=60,  
resulting in average shrinkage of 38% 
Beta-binomial Model on beta-binomial (B-B) dataset 
 = + P ~~ywk(&(1.5)  IºSNT ~}(0,10000)  ISNT ~≥x(1,1)   ISNT ~≥x(.001, .001)  
True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
Estimated 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
7.32 
36.25 
43.58 
0.17 
0.001 
0.42 
10.80 
55.68 
66.49 
0.16 
0.002 
0.51 
2.77 
13.05 
15.82 
0.18 
0.01 
0.22 
11.82 
60.69 
72.51 
0.16 
0.002 
0.53 
Estimated/True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
1.22 
1.21 
1.21 
1.01 
0.93 
1.04 
1.80 
1.86 
1.85 
0.98 
0.63 
1.27 
0.46 
0.44 
0.44 
1.06 
2.38 
0.54 
1.97 
2.02 
2.01 
0.98 
0.57 
1.33 
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Table 17: True Expected Adverse Event Proportion=0.17, Varying Priors (B-B Data) 
Number of sites=63, Number of subs per site=10, 
resulting in average shrinkage of 38% 
Beta-binomial Model on beta-binomial (B-B) dataset 
 = + P ~~ywk(&(1.5)  IºSNT ~}(0,10000)  ISNT ~≥x(1,1)   ISNT ~≥x(.001, .001)  
True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
6 
30 
36 
0.17 
0.004 
0.4 
Estimated 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
6.06 
38.80 
43.58 
0.15 
0.006 
0.35 
23.03 
150.96 
66.49 
0.14 
0.005 
0.44 
0.92 
3.87 
0.20 
0.20 
0.03 
0.08 
31.08 
204.64 
72.51 
0.13 
0.002 
0.63 
Estimated/True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
1.01 
1.29 
1.21 
0.87 
1.72 
0.87 
3.84 
5.03 
1.85 
0.84 
1.23 
1.10 
0.15 
0.13 
0.44 
1.22 
8.43 
0.22 
5.18 
6.82 
2.01 
0.81 
0.45 
1.57 
 
  
 57 
Table 18: True Expected Adverse Event Proportion=0.17, Varying Shrinkage (B-B Data) 
Average Shrinkage=9%, 17%, 60%, Number of sites=10, Number of subjects per site=60 
Beta-binomial Model on beta-binomial (B-B) dataset 
 = + P ~~ywk(&(1.5)  1º= + P ~}(0,10000)  = + P ~~ywk(&(1.5)  
1º= + P ~}(0,10000) 
 
= + P ~~ywk(&(1.5) 
 
1º= + P ~}(0,10000) 
Shrinkage 9% 9% 17% 17% 60% 60% 
True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
1 
5 
6 
0.17 
0.020 
0.1 
1 
5 
6 
0.17 
0.020 
0.1 
2 
10 
12 
0.17 
0.011 
0.2 
2 
10 
12 
0.17 
0.011 
0.2 
15 
75 
90 
0.17 
0.002 
0.6 
15 
75 
90 
0.17 
0.002 
0.6 
Estimated 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
0.87 
4.43 
5.29 
0.17 
0.02 
0.10 
0.83 
4.26 
5.09 
0.17 
0.02 
0.09 
1.35 
6.63 
7.98 
0.17 
0.02 
0.13 
1.64 
7.48 
9.12 
0.18 
0.02 
0.14 
11.61 
59.49 
71.10 
0.16 
0.002 
0.52 
85.37 
442.76 
528.13 
0.16 
0.001 
0.79 
Estimated/True 
α 
β 
α+β 
Mean 
Variance 
shrinkage 
0.87 
0.89 
0.88 
0.99 
1.15 
0.95 
0.83 
0.85 
0.85 
0.99 
1.18 
0.92 
0.68 
0.66 
0.66 
1.00 
1.81 
0.65 
0.82 
0.75 
0.76 
1.09 
1.43 
0.72 
0.774 
0.793 
0.790 
0.941 
1.000 
0.867 
5.69 
5.90 
5.87 
0.97 
0.45 
1.31 
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2.10  Findings from the Example Dataset 
 
The motivating example dataset provided us with the number of adverse event 
cases or numerator on each category and the total number of sites, the number of subjects 
per site was unknown. We assumed equal number of subjects per site at 60 for some 
analysis and unequal subjects per site ranging from 10 to 60 for other analysis. The 
example dataset was used to compare primarily the performance of the Bayesian methods. 
Comparing the posterior distributions of the adverse event proportions, #,  's for the two 
random effects models showed that posterior means were larger using binomial logit-
normal model compared to beta-binomial model for facilities with fewer events. The 
lower the observed proportion for any facility, the higher the posterior mean and the 
shrinkage using binomial logit-normal model compared to beta-binomial model. The 
equality of the inter quartile range (IQR=p [i, 97.5]-p[i, 2.5]) from both of the posterior 
distributions suggested equal spread of the posterior means for the two models. The 
posterior mean for B-B model falling with the 95% posterior interval of B-LN model and 
vice-verse for all sites suggested that the models could be used interchangeably under the 
current settings. The two models show that facilities with fewer events have larger 
shrinkage estimates using logit-normal model compared to beta-binomial model. Thus for 
sites with fewer events, the shrinkage happens more towards the normal mean than the 
conjugate mean. In general, since the 1, (Equation 15) for logit-normal model is greater 
than the 1, (Equation 16) for the beta-binomial model, the average proportionate 
shrinkages are greater in the logit-normal model than the beta-binomial model, assuming 
the systematic variation in the proportions for the two models are similar. The difference 
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between the estimates from the two models will decrease as the mean proportion or the 
systematic variation decreases. Shrinkage is unimportant for sites with large sample size 
of site i because 1, → 0	with the increase in sample size. Thus the difference between the 
shrinkage estimators of the two models towards the mean of individual site is smaller with 
larger sample sizes. 
 Sensitivity analyses were carried out to investigate the impact on posterior 
inference of reasonable modifications of the priors. A standard criticism of Bayesian 
approaches to statistical inference is that their conclusions may be strongly dependent on 
the prior distribution chosen. Whatever the philosophical merits of this criticism, the 
practical answer to it is that, under certain conditions, the prior distribution of the 
parameters becomes irrelevant as the sample size grows, because the likelihood comes to 
dominate the posterior distribution. We changed the priors for the binomial logit-normal 
model, first changing the prior for the variance, σ2 and then varying the priors for the 
precision τ. Thus for σ with a uniform prior (1,1000), we obtain the same estimate as for 
uniform with (1,10). In this case we say logit(pi)~ Normal(-1.961, 52 /5002) when σ =
(>NI>)A  or σ = (>NI>>>)A . Given the distribution of σ, for U(0, 10) or U(0,1000), σ has an 
interval above 1 which is a-priori giving more information compared to U(0,1). Hence 
U(0,1) is not a good prior. Assigning priors for \, where \ =1/ σ2, the estimates for α0 and 
σ are almost identical and so are their posterior distributions. 
An attempt was made to study the models and the posterior distribution of the 
parameters by changing the number of subjects for each site and altering the overall 
proportion of the adverse event. Results with nausea as the outcome have been discussed 
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in the section below. 
For the beta-binomial model, when the number of subjects changes from 60 per site to 20 
per site, the posterior distribution for α becomes more concentrated around the median. 
The posterior distribution for β becomes wider with the reduction in number of subjects 
per site. 
For beta distributions, the sum of the two parameters is called the effective sample 
size. Thus Beta (α,β) distribution contains as much information as α+β observations. 
Keeping the overall proportion the same for each outcome and reducing the sample size to 
20 per site, α+β increases and hence there is more information in the prior. We can 
decompose the total variation as the sum of the within and between site variations, where 
the within variation is a function of the sample size. So with the denominator of 20, there 
is less within information than with a denominator of 60. Hence there is more between 
information for sample size of 20. When we reduce the overall proportion of nausea to 
0.05, the posterior estimates of α and β also go up. For the binomial-logit normal model, 
when the sample size changes from 60 subjects per site to 20 per site, the posterior 
distributions for both α0 and \ have unchanged spread. 
2.11 Summary and Discussion 
We extensively compared both fixed effects and Bayesian models in the single 
outcome settings under different parametric conditions for multicenter clinical trials. 
Knowing there were variations in the simulation study results, on an average, at the true 
expected proportion of 0.50 all models perform equally well, under different parameters- 
the results are very similar to each other, show equal coverage, average interval width and 
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average bias. The MLE method with the normal approximation, which makes no 
assumption about the distribution of the effect of site, is precise for large number of 
subjects per site with low average shrinkage, high overall adverse event proportion and 
large number of sites. We have shown, on an average, with the expected proportion of 0.17 
or 0.05, Bayesian beta-binomial model performs better compared to the other methods- 
Bayesian binomial logit-normal or MLE. All the four methods performed poorly when the 
number of sites was small, the commonly used MLE method with approximation being 
the worst. 
We discussed the sensitivity of the estimation of model parameters under different 
clinical trial settings by changing the priors. This is important because for Bayesian 
models the performance and interpretation of the model depends to a great extent on the 
role of the prior and its interaction with the likelihood. 
Some gaps remain in the current research especially in accounting for the interaction 
of treatment effect by site as well as patient and site characteristics. A DSMB probably 
also cares more about profiling sites on whether there are more adverse events in one 
treatment group as opposed to the other. Extending the application of the above methods 
in multiple outcomes settings also seems a useful area for future work. In terms of 
monitoring, it might be worthwhile focusing on the predictive distribution of a new patient 
in each site which would also be of interest to IRB or DSMB. 
2.12 Application 
 
As noted by J de Silva in 1998, “The success of any clinical trial depends on the 
 62 
care with which the trial protocol is designed and executed/implemented, and the trial data 
managed and analyzed. How well a protocol is executed or implemented rests largely with 
the study site and the site's interaction with the monitoring team. Site selection is, 
therefore, highly critical to the success of any clinical trial and should be made with 
utmost care. There is a concerted effort by regulatory agencies to facilitate the conduct of 
global clinical trials within their respective regions” [30]. Since the early 21st century, 
several initiatives ranging from encouraging adoption of new technological advances in 
the pharmaceutical industry to implementing risk-based approaches that focus both 
industry and Agency attention on critical areas were launched. Pharmaceutical cGMPs for 
the 21st Century, a multi-year FDA effort began in 2002 to enhance the regulation of 
pharmaceutical manufacturing and product quality. To ensure a risk management approach 
while allocating FDA inspectional resources, the agency used a quantitative risk-base site 
selection model for use in choosing sites for inspection. The model was piloted for human 
drugs (CDER) in October 2004. The model helped the FDA predict where its inspections 
are most likely to achieve the greatest public health impact. Thus choice of experimental 
sites or centers for randomized controlled trials has been a major topic of discussion in the 
clinical research field. Much work has been done so far but the issue of selecting a 
productive or risk-free investigational site has somehow remained in the background. 
Typically, the literature shows that the binomial logit-normal model has been used 
for binomial outcomes where the outcome is dependent on a set of covariates. The main 
aim of this paper is to recommend the model or method that finds the ‘true’ proportion of 
adverse events more often or has better coverage, smaller average interval width, has a 
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lower bias and smaller mean squared error in certain settings. Any setting with binomial 
data and no adjustment for regressors can apply the proposed model. This can also be 
applied to create a measure to identify medical sites providing poor quality of care, having 
a major number of adverse events and exclude them from the list of selected sites which 
would be addressed in our following paper. This would enable the investigators carry out a 
cost effective and efficient clinical trial. 
We have tried to answer the question as to if there is a safety issue related to 
adverse events and it could be attributed to individual sites, which method of estimation 
should be used under what parametric conditions. We intend that the Data Safety 
Monitoring Board (DSMB) make use of the proposed statistical summaries to support 
their recommendations on which method to use under which setting and to inform sites on 
how to increase success (however defined) and decrease adverse events. 
The need for such evaluation by the DSMB reflects the common practice of merely 
listing adverse events (AE’s) in the report to the DSMB.   The members usually focus on 
possible links between the AE’s and the treatment.   Seldom considered is how the 
measures of success balanced against the totality of AE’s reflect on the performance of the 
site.  The statistical results then serve to identify how the sites perform relative to one 
another and draw attention to strong and weak aspects.   DSMB members and site 
administrators can often improve performance and remedy issues once they have a clearer 
focus.    A site that does well can advise a site that performs less well.   A site should be 
removed from a study only in the extreme case that all remedies fail.   The statistical 
results should only play a minor part in such decisions.  
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Chapter 3 
 
Statistical methods for classification of outlier study sites for single adverse 
events outcome in multicenter clinical trials setting 
 
3.1  Background 
 
Provider profiling, i.e., profiling the medical providers based on the quality of 
care, has been rapidly evolving in the health care field in the last two decades. The 
resultant “report cards” are used to generate feedback for the medical providers and 
ultimately select the appropriate health care providers by individuals and managed care 
groups. The report cards also serve as quality performance indicators and are used by 
researchers, policy makers, and consumers to evaluate the health care providers. 
Consumer report cards are not a new phenomenon either; many organizations evaluate 
the quality of products and services and publish such information for consumers. 
Governments too have invested substantial resources in developing and disseminating 
quality report cards in a variety of settings, ranging from achievement of public school 
students to restaurant cleanliness to airline on-time performance (The National Bureau of 
Economic Research, February 2006).  
Although comparative performance measures of health care were proposed as 
early as 1916 [31], their use became more widespread with time. Hospitals regularly 
produce statistics regarding their performance in selected clinical areas and most of them 
survey their patients about their satisfaction with the care they receive [32, 33]. Insurers, 
particularly managed care companies, are routinely compared on how well they ensure 
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that preventive health services are delivered to their subscribers. The performance of 
surgeons and surgical groups is routinely monitored in terms of mortality and 
complication rates while ambulatory practices’ performance in holding down waiting 
times and providing patients’ with positive experiences is compared, particularly in 
highly competitive markets (Hannan et al., 1994; Marshall et al., 2000). Finally, nursing 
homes in the US are also being compared on numerous quality indicators derived from 
inspections as well as routinely collected clinical data [34]. Regulators, particularly the 
Centers for Medicare and Medicaid (CMS), have been aggressively pushing performance 
measurement. For example, much to the chagrin of hospitals throughout the country, 
CMS established several pay-for performance (P4P) initiatives beginning 2003, 
responding to the call of Institute of Medicine (IOM) released report in March 2001. 
Through various initiatives and demonstrations, such as the Hospital Quality Incentive 
Demonstration (HQID) and Chronic Care Improvement Program, CMS developed quality 
metrics that targeted hospital facilities, physician groups, and individual providers to 
improve practice habits.  
In an effort to instill quality initiatives among healthcare providers, CMS does not 
remain alone. Major corporations in multiple industries have joined efforts to improve 
quality of care. Purchasers and Managed Care Companies have been forced to prove that 
their networks provide quality care and the National Committee for Quality Assurance 
(NCQA) has promoted performance comparisons among managed care organizations 
across the country, making such comparative information to interested parties on the 
Internet [35]. Currently, P4P initiatives are aimed at creating market competition by 
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establishing high and low performers. The theory behind the model is to motivate groups 
to achieve above and beyond the threshold of their fellow competitors [36]. 
  A comprehensive provider profiling system serves as a quality management tool 
to support administrative and clinical processes, particularly when opportunities of 
improvements are identified. It has been further described as the process of identifying 
those providers who consistently meet established clinical and administrative standards 
based upon performance indicators and routine statistical data analysis (VBH-PA Quality 
Management Department, 2012).  
Traditional fixed effects statistical models involving fitting logistic regression models 
adjusting for patient case-mix have been used in the past to highlight providers whose 
performance significantly differed from the expected. Since the mid-1990s, hierarchical 
models [13, 14] have been used more for the purpose because of the structural 
relationship between providers and patients whereby a patient-level response is measured 
for clusters of patients treated by providers. The use of Bayesian hierarchical regression 
models has been suggested for institutional profiling by Burgess and others [23] for 
examining intensive care unit readmission rates and by Normand and others (1997) [13] 
for studying hospital-specific mortality rates following admission for AMI. Christiansen 
and Morris (1997) [12] propose the use of hierarchical regression models as an 
improvement over the existing methods of profiling. The development of new 
methodology coupled with advances in computational power and the availability of 
flexible and reliable software have led to a great increase in the application of Bayesian 
methods within the last three decades. Although, the advantages of hierarchical modeling 
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structure now seem clear, there remains disagreement in the literature about how 
individual units of interest should be identified and compared based on such models. 
In the current study, we employ the concept of provider performance evaluation 
based on statistical modeling used to profile health-care providers with unusually high 
rates of some measure in selecting sites for randomized controlled clinical trials. Such 
“report cards” could help sponsors choose the experimental centers while designing a 
study or to determine whether the participation of a specific site in a trial should be 
discontinued.  With this as motivation, we compare models on single binomial outcome 
setting and then identify providers providing poor quality of care, if any, as indexed by 
higher rates of these binomial outcomes representing adverse events. To perform this 
assessment, a summary measure based on the performance indices of the providers is 
constructed in a Bayesian framework which compares the posterior probability of adverse 
event for each provider to be greater than a critical threshold. We recommend 
improvements that are based on the use of the better statistical models among those 
compared. We utilize the program WinBUGS [37], which implements up-to-date and 
powerful Markov chain Monte Carlo (MCMC) algorithms that are suited to a wide range 
of target distributions for analyzing complex models, to illustrate the properties of each of 
the methods under different parametric conditions. An example dataset described below 
serves as a motivating example. 
(Ref: http://eprints.st-andrews.ac.uk/archive/00000450/03/GimenezetalWinBUGSv2.pdf) 
Both fixed effects and Bayesian statistical frameworks have been implemented for 
institutional profiling in the literature. One method used in acute myocardial infarction 
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(AMI) and surgery performance report cards is to compare the ratio of observed to 
expected mortality at each institution. Hospitals whose ratio differs significantly from one 
are classified as outliers in the logic of statistical hypothesis testing. A second approach is 
to compare the absolute difference between the observed and the expected. Cases where 
this difference is significantly different from zero are classified as performance outliers. 
Delong et al. (1997) [38] compared eight different frequentist approaches to hospital 
profiling for coronary artery bypass grafting surgery. Bayesian approaches to institutional 
profiling have also been studied extensively in the literature. Racz et al. (2010) [22] 
compare the frequentist and Bayesian indirect standardization methods to identify 
outlying hospitals. He et al. (2014) [39] assessed and compared the accuracy of several 
commonly used approaches to classifying hospitals into quality tiers.  
We assess and compare the detection of outliers under the two paradigms, 
maximum likelihood and Bayesian. The outline of this paper is as follows. In Section 3.2, 
we describe the methods and models used to identify potentially poor performers or sites. 
Section 3.3 will address how the data was generated in simulation studies, Section 3.4 
covers model estimation. Section 3.5 is related to determination of the true posterior in 
the Bayesian framework and in Section 3.6 we provide the methodology used for 
classifying outliers based on both frameworks. Section 3.7 is devoted to numerical 
illustration of the methods and models using both simulations and an example dataset. 
Section 3.8 presents a discussion and summary of the findings. All analyses have been 
performed with R-3.0.0 and WinBUG14 programs. 
As a motivating example for the analyses, an adverse event data set from a multi-
 69 
site clinical trial in bowel resection patients treated by an anonymous drug was utilized, 
the details of which has been described in Chapter 1 (Section 2.1). 
3.2  Methods and Models 
For the purposes of the current study, the relative performance of ML and 
Bayesian analytic methods of interest in designating sites as outliers are compared under 
various settings for a total number of 63 sites. We evaluate four statistical methods, the 
same methods as discussed in section 2.2: 
1. a Bayesian beta-binomial (B-B) model with Markov Chain Monte Carlo (MCMC) 
estimation, 
2. a Bayesian binomial logit-normal (B-LN) model with MCMC estimation, 
3. a common approach with maximum likelihood estimation method using normal 
approximation and 
4. a common approach with maximum likelihood estimation method using exact 
method 
We simulate data with 
a. true expected site-level adverse event proportion, E(#,) = 0.05 for sites $ =1,… , 9  
b. fixed number of sites at N=63 
c. varying number of subjects per site,	*, for sites $ = 1,… , 9 per site (unequal 
subjects from 10 to 60 observations per site)  
and classify sites as outliers based on the two methods using simulation studies 
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i. applying a threshold (cutoff points) of 0.07, 0.10 and 0.15 for the true 
adverse event rate of 0.05 for the fixed effects and Bayesian framework; 
ii. applying the sample adverse event rate for the threshold and using 
confidence intervals in a standard fixed effects method.  
For data generated from the two Bayesian models and the exact fixed effects model with 
chosen parameter values, statistical performance of MLE and Bayesian MCMC 
approaches are compared using several operating characteristics (described in Section 7) 
-Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value. 
3.3  Data Generation Models 
Data 
 
We assume there are N clinical sites, with *, subjects observed for the $th site and 
a total of ),	adverse events across the *,subjects. Let  #, be the probability of adverse 
event at the ith site. We assume that the outcomes, ),	are independently distributed given #,	as in Equation (1).     
For the models that line up with a Bayesian distribution, we assume that given the true 
adverse event proportion (i.e, probability of adverse event) at site i, the outcomes ‘	),’ are 
independent and 	#, or logit(	#,) are a random sample from a common population 
distribution. 
Distribution of  #, 
3.3.1 Model 1 (Binomial logit-normal): B-LN 
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Model 1 is same as Model 1 in Chapter 2 stated in Equation (2) (Section 2.3.1)  
3.3.2 Model 2 (Beta-binomial): B-B 
 
Model 2 is same as Model 2 in Chapter 2 stated in Equation (3) (Section 2.3.2)  
Data generation from models that line up with the B-LN and BB models began 
with the generation of #, from models 1 and 2 (B-LN and B-B). Then, given those #,	‘s 
Binomial counts of adverse events were generated for each site, i. Three hundred beta-
binomial datasets were simulated with a true proportion #,,	such that #,~Beta(=, P), with 
mean, µ = SSNT		and variance, @A = U(IJU)SNTNI with a subject volume of *,as discussed in 
Model 1. The hyperparameters =, P were chosen such that the expected prior mean and 
the average shrinkage equal specified values to improve the understanding of how model 
specificity relate fixed effects models and methods for binomial data . For example, for a 
true expected adverse event proportion of 0.05, we chose = = 1	and P = 20 such 
that	µ = SSNT = 0.05 and shrinkage = (MNO)(MNONZ) = 0.37	with average number of subjects per 
site at 36.  
We also simulated 300 binomial logit-normal (B-LN) datasets from the true #,, where 
logit(#,) follows normal distribution with mean,	5 and variance, @A using Model 2. The 
hyperparameter values => and \ were obtained from matching moments (discussed 
below) to match the first two moments of the B-B model. Conditional on a site’s true 
proportion and number of subjects per site, we then simulated a true number of events, ), 
demonstrated in Equation (2). For Beta-Binomial with hyperparameter values = = 1 and P = 20, the equivalent hyperparameter values for B-LN model were 5 = −3.32 and @ =
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0.75, obtained by matching the first two moments of the two distributions as discussed in 
Chapter 2 (Section 2.3). The data were generated using the two Bayesian models such 
that of the 63 sites, 52 sites had a true expected proportion of 0.05 while 11 sites had an 
expected proportion of 0.07. For the outlier sites, the hyperparameter values for B-B 
model were chosen to be = = 1 and P = 12,  with the equivalent hyperparameter values 
for B-LN model were 5 = −2.79 and @ = 0.88. 
The fixed effects approach of data generation involved two situations to match the 
implicit assumptions. The data were generated using the Beta Binomial model such that 
of the 63 sites, 11 sites were outliers. We call it the fixed effects approach as the data was 
generated to either have full shrinkage or no shrinkage similar to fixed effects data. 
1. Shrinkage=1. This means, under the fixed effects framework implicitly, all 
sites have the same expected rate with no a priori variation, which means the 
prior variance is zero in the limit. This can be interpreted as sites having 
extremely large a priori information relative to the number of subjects per 
site. We generated the data under this scenario from a beta-binomial with very 
large hyperparameters, = = 100,000	and 	P = 20,00000. 
2. Shrinkage=0. This means, under the fixed effects framework implicitly, that 
there is high between site information compared to within sites. This happens 
when the site-level sample size is very large or when there is very high 
variability in rates between sites. This is similar to = + P being very small 
compared to the number of subjects per site, n. Data were generated under this 
scenario by choosing = = 1 and 	P = 20 but increasing the average number of 
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subjects per site to approximately 3000 by multiplying the number of subjects 
per site by a factor of 100. 
3.4  Methods of Estimation 
For both Bayesian and ML methods of estimation, we utilize the same methods as 
described in Section 2.4. 
3.5  Determination of Estimates 
In Bayesian analyses, the estimates were obtained from posterior #, which has a 
distribution, while in fixed effects, the estimates were the sample mean,ÅHÇH obtained from 
the data. The derivations of posteriors have been described in Section 2.5. 
3.6  Model Estimation and Fit 
3.7  Outlier Classification 
The outlier classification was based on two different threshold definitions- one a fixed 
chosen value for threshold utilized for both fixed effects and Bayesian framework and the 
other the overall sample mean commonly used for traditional fixed effects approach.  
Fixed chosen value for threshold  
The threshold, t, was defined as the cut-off value for proportion of adverse event 
beyond which site was classified as an outlier. In practice, the threshold often represents 
the performance of the population mean value, estimated as a weighted average of the 
data, although other threshold combinations could theoretically be chosen. For 
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illustrations, we chose a fixed critical value and defined the site’s poor performance if it 
was more likely than not that the adverse event proportion exceeded this value. 
The fixed effects method of outlier classification involves the use of maximum 
likelihood estimates where the parameter estimates are those that maximize the likelihood 
function, for a fixed set of data and underlying statistical model. Confidence intervals are 
utilized to identify outliers in this method. For each estimate of  #, for site i, 95% exact 
confidence interval was calculated. A site was flagged as an outlier if the lower bound of 
the 95% confidence interval exceeded the fixed threshold value. 
In contrast, the Bayesian paradigm combines the observed data and the 
parameters from the prior distribution to obtain a posterior probability distribution of the 
parameters. An advantage of Bayesian analysis is the ability to estimate any function of 
the posterior parameters, particularly the uncertainty associated with it.  We adapted an 
approach for classifying sites as poor performers motivated by Austin et al. (2001). 
Decision on outlier status here was based on the probability of exceeding the threshold. A 
site was considered an outlier (yes or no) if the probability of adverse events exceeded a 
pre-determined threshold with at least a specified probability level. Since the Bayesian 
framework allows probabilistic statements about the parameters, we define if pi as the 
probability of adverse event in site i, using the threshold, t, we are able to calculate the 
posterior distribution of pi such that 																																																																								~(#, > () ≥ 0.50              (25) 
classifies a site as an outlier. For example for the overall adverse event proportion of 
0.05, threshold values of t= 0.07, 0.10 and 0.15 were chosen above the overall mean 
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adverse event proportion. The three thresholds chosen to represent low, moderate and 
high adverse event proportion were somewhat subjective to the overall mean adverse 
event proportion. The level of probability was chosen to represent moderate evidence that 
the site exceeded the given threshold. 
Some authors have used methods equivalent to identifying a provider as 
“unusual” based on large posterior probability of its rate being greater (or less) than 
average (Simpson et al. 2003; Smits et al. 2003; Darlow et al. 2005; Racz and Sedransk 
2010). Morris and Christiansen (1996) but suggested that comparisons with the 
population mean are inappropriate, arguing instead in favor of comparisons with an 
external target or interval standard (Morris and Christiansen 1996; Christiansen and 
Morris 1997b; Burgess et al. 2000).  
Threshold based on overall sample mean 
In the fixed effects approach, a site was also classified as an outlier if the 95% confidence 
interval failed to cover the mean weighted by sample size from the data, ∑ ÅH∆H«i∑ ÇH∆H«i . 
One dataset from the 300 simulated datasets was chosen at random as a sample to 
compare the methods of estimation utilizing bias of posterior estimate of proportion of 
adverse event for each site, and classify performance using sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV). Site-specific 
estimates between the true and the estimated methods were compared with respect to 
volume to evaluate the impact the number of subjects per site to being classified as an 
outlier. One dataset enabled us to evaluate site-specific bias with respect to volume.  
Sensitivity was defined as the probability that sites that were true outliers were 
 76 
classified as outliers by the estimation. Specificity was the probability that sites that were 
not outliers were not classified as outliers. PPV was the probability that sites that were 
classified as outliers by estimation are in fact true outliers. NPV was the probability that 
sites not classified as outliers were not true outliers. Table 19 shows the definitions in a 2 
by 2 format. 
 
 
Table 19. Definitions of Sensitivity, Specificity, Positive Predictive Value (PPV), 
and Negative Predictive Value (NPV) 
 Estimated 
True  Outlier Not an Outlier Total 
Outlier y ? y + ? 
Not an Outlier s Ø s + Ø 
Total y + s ? + Ø y + ? + s + Ø 
Sensitivity y(y + ?)   
Specificity Ø(s + Ø)   
PPV y(y + s)   
NPV Ø(? + Ø)   
 
The letters in each cell above denotes the number of sites with given the true status were 
classified according to the classification denoted in the corresponding row (outlier versus 
not an outlier).  
The validity of the developed method was then assessed across three hundred simulated 
datasets. The operating characteristics - sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were also summarized across the simulated 
datasets. 
 77 
3.8  Results Using Simulated Datasets  
3.8.1 Beta-Binomial Data 
 
Figure 5 shows the bias of the estimates for proportion of adverse events for each 
site for the Bayesian methods on a single beta-binomial generated dataset. Bias was 
defined as the difference between the posterior mean # and the true #, where # was the 
proportion of adverse events. It was evident that with fewer adverse events per site, the 
bias for the B-LN model was greater than the B-B model, with the posterior for the B-LN 
overestimated for sites with zero adverse events and underestimated otherwise.  
Figure 5. Bias of the true posterior p on a random B-B simulated dataset 
 
 
Table 20 presents the results of B-B and B-LN model of estimation on 1 
realization of B-B simulated data for the expected Proportion of adverse event Rate at 
0.05 and a threshold of 0.07. The threshold approach is utilized to flag sites as outliers. 
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As shown in this realization, of the 11 sites classified as outliers by the true, 100% of 
them were flagged by the B-B method of estimation while 10 of them were flagged by B-
LN method of estimation.  
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Table 20. B-B and B-LN method of estimation on 1 B-B generated data with expected 
proportion of adverse event rate 0.05 and threshold 0.07 
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Table 21 and 22 summarizes the outlier detection results for one random B-B 
simulated dataset at the true adverse event proportion of 0.05 and a threshold level of 0.07 
and 0.10. It compares each of two Bayesian methods using MCMC- the beta-binomial (B-
B) and binomial-logit normal (B-LN) to the true B-B posterior on sensitivity, specificity, 
positive predictive value and negative predictive value. The B-B generated data for a 
threshold of 0.07, 0.10 and 0.15 had on an average 12, 5 and 3 outlying sites respectively 
of a total of 63 sites. 
For one B-B dataset with a true proportion of 0.05 and threshold of 0.07, of the 11 
sites identified as outliers by true posterior, 100% of them were identified as outliers by 
the B-B while 10 were designated as outliers by B-LN method.  Of the 52 cases that were 
not identified as outliers by true posterior method were also non-outliers according to B-B, 
one was declared as an outlier by the B-LN method (Table 21).  
With the true proportion of 0.05 and the threshold level of 0.10, table 5 contrasts the 
detection of outliers when hospital effects are modeled as random effects using Bayesian 
methods versus the true posterior mean. Of the 5 sites classified as outliers by the true, 
100% of them were outliers using both B-B and B-LN method.  Three of the 5 outlying 
sites had 10-29 subjects per site and 2 sites had 30-50 subjects per site. Of the 58 sites not 
designated as outliers by true, 98% of them were non-outliers according to B-LN and B-B 
method. With the cutoff of 0.15, the only site detected as outlier by true posterior mean 
was not an outlier according to either of the Bayesian methods. 
With the threshold of 0.07 for one simulated B-B dataset, it is clear that detection 
of outliers is not strongly contingent upon on the methods of estimation-B-B model versus 
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B-LN model for estimation, although, B-B method had marginally greater sensitivity and 
NPV compared to B-LN model. Sensitivity, specificity, PPV and NPV remained same for 
both B-B and B-LN model for estimation for the threshold of 0.10.  
 
  
Table 21. True Proportion=0.05 Threshold(t)=0.07 (B-B 
Data) 
(A random B-B simulated dataset) 
 
B-B model for estimation B-LN model for estimation 
True 
Posterior 
Mean 
Outlier Not an Outlier 
Total 
Outlier Not an Outlier Total 
 Outlier 11 0 11 10 1 11 
Not an 
Outlier 0 52 52 0 
 
52 52 
Total 11 52 63 10 53 63 
Sensitivity 1.00 
  
0.91   
Specificity 1.00 
  
1.00   
PPV 1.00 
  
1.00 
  NPV 1.00 
  
0.98 
   
 
 
Table 22. True Proportion=0.05, Threshold(t)=0.10 (B-B 
Data 
 (A random B-B simulated dataset) 
 
B-B model for estimation B-LN model for estimation 
True 
Posterior 
Mean 
Outlier Not an Outlier 
Total 
Outlier Not an Outlier Total 
 Outlier 5 0 5 5 0 5 
Not an 
Outlier 1 57 58 1 57 58 
Total 6 57 63 6 57 63 
Sensitivity 1.00 
  
1.00   
Specificity 0.98 
  
0.98   
PPV 0.83 
  
0.83 
  NPV 1.00 
  
1.00 
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When comparing the estimates of the hyperparameters to the true values (Table 23) for 
the overall true rate of 0.05, it was evident that the Bayesian methods underestimates the 
hyperparameters and hence it was difficult to classify sites as outliers using the Bayesian 
approach compared to the true posterior approach, more commonly for sites with larger 
(>35) number of subjects for the B-B method.  
 
Table 23. Comparison of true to estimated parameters for B-B Data 
Parameters True Estimates = 1 0.61 P 20 11.51 
 
We also examined the overall summary of the percent of times each of the 63 sites 
were designated as outliers for 300 B-B constructed datasets using the true as the gold 
standard, for B-B and B-LN methods.  Table 24 presents the results for 9 of the high 
outlying sites, sites with greater than 50% chance of being designated as outliers.  There is 
a reduction in outlier detection when using the Bayesian models for estimation for higher-
volume sites compared to the true. Sites with number of subjects greater than 35 were 
detected as outliers more often by the B-B model for estimation compared to the B-LN 
model. The B-B performed closer to the true in the percent of times sites were identified 
as outliers. This was true for all threshold levels -0.07, 0.10 or 0.15. 
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Table 24. Percent of times sites declared as outliers of the 300 simulated B-B datasets 
sorted by subjects per site 
(True Proportion=0.05, Threshold(t)=0.07) 
Site Subjects per site prior 
True 
Posterior 
Mean 
Percent of 
times B-B 
model detects 
as outlier 
Percent of times 
B-LN model 
detects as outlier 
1 21 .0356 62% 81% 76% 
2 39 .0273 71% 72% 62% 
3 43 .0018 91% 86% 79% 
4 44 .0395 51% 40% 30% 
5 47 .0845 96% 87% 83% 
6 48 .0349 62% 42% 39% 
7 52 .0043 51% 27% 24% 
8 56 .0088 73% 43% 30% 
9 58 .0089 52% 28% 19% 
 
To summarize the findings across 300 simulations, we compared the distribution 
of the average operating characteristics between the methods of estimation. On an 
average with threshold of 0.07 and 0.10, with high overall specificity, the B-B model has 
higher sensitivity and lower PPV on the B-B generated datasets compared to the B-LN 
model and ML methods of estimation. The B-B model with the MCMC method was able 
to correctly identify 62% and 46% of the outlying sites respectively for the threshold of 
0.07 and 0.10 compared to 52% and 40% by the B-LN (Table 25-26). 
Under the fixed effects framework, for both methods of estimation, sensitivity 
decrease with the increase in the threshold level, with the exact method showing greater 
sensitivity compared to the normal approximation method. Far fewer sites get classified 
as outliers by either of the MLE methods. This may be attributed to the 95% confidence 
intervals approach chosen for the study. The 95% confidence interval widths using the 
exact method, on an average, are wider compared to the normal approximation. Also, the 
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normal approximation method produces lower confidence limit bounds which are 
negative, which is an impossible value for the parameter for which the interval is 
constructed and hence presents as an inferior approach in identifying outliers. Across all 
methods, sensitivity decreases and NPV increases with the increase in threshold level.  
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Table 25. Operating Characteristics of the methods of estimation, Threshold 
=0.07 (B-B Data)  
300 simulated B-B datasets 
 True Proportion=0.05, Shrinkage=0.37, Threshold(t)=0.07 
Average number of subjects per site=36, Number of sites=63 
 MLE Bayesian MCMC 
 Normal Approx. 
method 
Exact method B-B model B-LN model 
Sensitivity 0.08 0.15 0.62 0.52 
Specificity 1.00 1.00 0.96 0.98 
PPV 0.95 1.00 0.82 0.88 
NPV 0.82 0.83 0.92 0.90 
 
 
 
Table 26. Operating Characteristics of the methods of estimation, Threshold=0.10, 
0.15                (B-B Data) 
300 B-B simulated datasets 
 True Proportion=0.05, Shrinkage=0.37 Average number of subjects per site=36, Number of sites=63 
 Threshold(t)=0.10 Threshold(t)=0.15 
 MLE Bayesian MCMC MLE Bayesian MCMC 
 
Normal 
Approx 
method 
Exact 
method 
B-B 
model 
B-LN 
model 
Normal 
Approx 
method 
Exact 
method 
B-B 
model 
B-LN 
model 
Sensitivity 0.06 0.11 0.46 0.40 0.02 0.03 0.25 0.25 
Specificity 1.00 1.00 0.98 0.99 1.00 1.00 1.00 0.99 
PPV 0.98 0.95 0.77 0.82 0.59 0.71 0.63 0.61 
NPV 0.90 0.91 0.94 0.93 0.97 0.97 0.98 0.98 
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3.8.2 Binomial Logit-Normal Data 
To sharpen our comparison of the Bayesian methods with true, we constructed 
300 data sets using the B-LN model. This exercise was done to mimic the B-B experience 
as much possible with a different source dataset. For B-LN model since the posterior 
distribution does not yield itself to a closed form solution or a known distribution, to 
calculate the true posterior we used two different approximation methods: 
a. True posterior using Normal-Normal Conjugate framework (see section 2.5, 
Model 1) 
b. MCMC BUGS with hyperparameters values fixed at the true values of the 
parameters  
 
3.8.2.1 Normal-Normal Conjugate Framework 
 
In the Normal-Normal Conjugate method of estimation for B-LN model, we use 
the true posterior distribution which is normal and assign sites as outliers based on true, 
whether the normal quantile exceeds the threshold by 50%. Figure 6 shows that the bias 
of the estimates of adverse event rates for each site, compared to the normal 
approximated true, for B-B method is greater than B-LN method on binomial logit-
normal generated data. The posterior estimates are underestimated for sites with zero 
events and overestimated for sites greater than zero events. Table 27 below compares the 
point estimates of the true values of the hyperparameters to the estimated values, showing 
that they are underestimated. 
B-LN generated data for a threshold of 0.07, 0.10 and 0.15 had on an average 11, 8 
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and 4 outlying sites respectively of a total of 63 sites. 
With one B-LN generated dataset, at the overall rate of 0.05 and threshold of 0.07, 
using normal approximation, the B-B method shows similar sensitivity and NPV but 
smaller specificity and PPV compared to the B-LN method (Table 28). With normal 
approximation for the true posterior, the B-B method is more likely to flag sites as 
outliers than the truth. 
Figure 6.Bias of the posterior p on B-LN one random simulated dataset (Normal-Normal 
Conjugacy) 
 
 
 
Table 27.Comparison of true to estimated parameters for B-LN 
dataset 
Parameters True Estimates => -3.32 -3.62 \ 0.86 0.7 
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Table 28. True Proportion=0.05, Threshold(t)=0.07  
(A random BLN simulated dataset) 
 
B-LN model for 
estimation B-B model for estimation 
True Posterior 
Mean* 
Outlier Not an Outlier Total Outlier 
Not an 
Outlier Total 
 Outlier 11 0 11 11 0 11 
Not an Outlier 0 52 52 1 51 52 
Total 11 52 63 12 51 63 
Sensitivity 1.00 
  
1.00 
  
Specificity 1.00 
  
0.98 
  
PPV 1.00 
  
0.92 
  NPV 1.00 
  
1.00 
  * Posterior obtained using the Normal-Normal Conjugate framework 
 
3.8.2.2  BUGS with fixed hyperparameters Framework 
 
In the MCMC BUGS analyses with the fixed hyperparameters method of 
estimation for the B-LN model, the true posterior distribution is the posterior distribution 
with the hyperparameter values fixed at 5 = −2.79 and @ = 0.88.	Sites are designated as 
outliers for the true based on whether the posterior estimate of p’s exceeds the threshold 
by 50%. With the overall rate of 0.05 and threshold of 0.07, for one simulated B-LN 
dataset, the B-B method show similar sensitivity and NPV but smaller specificity and 
PPV compared to the B-LN method (Table 29). A site is more likely to be labeled as an 
outlier using both the B-LN method and the B-B method on B-LN data compared to the 
true. For a single realization of the B-LN, the bias of the posterior estimates of the 
adverse event rate increases with the increase in the number of events per site. Both 
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Bayesian methods slightly underestimate the truth with fewer events per site and largely 
overestimate with increasing events per site, with bias of the B-B estimates being greater 
than the B-LN estimates (Figure 7).  
Sites with number of subjects greater than 35 are designated as outliers more 
often by either of the Bayesian methods compared to the true using Normal 
Approximation (Table 30). We choose sites which have greater than 50% of being called 
an outlier and the B-B model for estimation seems to perform closer to either of the true 
in designating sites as outliers compared to the B-LN model. 
Figure 7. Bias of posterior p on one random B-LN simulated dataset (BUGS using fixed 
hyperparameters) 
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Table 29. True Proportion=0.05, Threshold(t)=0.07  
(A random B-LN simulated dataset) 
 
B-LN model for estimation B-B model for estimation 
True 
Posterior 
Mean 
Outlier Not an Outlier Total 
Outlier Not an Outlier Total 
 Outlier 11 0 11 11 0 11 
Not an 
Outlier 0 52 52 2 50 52 
Total 11 52 63 12 51 63 
Sensitivity 1.00 
  
1.00   Specificity 1.00 
  
0.96   PPV 1.00 
  
0.84 
  NPV 1.00 
  
1.00 
   
 
 
Table 30. Percent of times Outlier of the 300 simulated B-LN datasets  
sorted by subjects per site 
(True Proportion=0.05, Threshold(t)=0.07) 
 # 
Subjects 
True Posterior Mean 
(Normal-Normal 
Conjugacy) 
True Posterior Mean 
(BUGS with fixed 
hyperparameters) 
Percent of times 
B-LN model 
detects as outlier 
Percent of times 
B-B model 
detects as outlier 
21 25 58% 57% 55% 58% 
31 36 78% 78% 72% 81% 
36 39 58% 56% 54% 58% 
47 48 88% 88% 82% 92% 
51 52 100% 100% 98% 100% 
52 52 93% 93% 86% 93% 
57 56 100% 100% 99% 100% 
59 56 75% 62% 65% 75% 
 
 
 
Overall across 300 simulations, on average with B-LN generated data, the B-B 
analysis shows greater sensitivity and NPV using both approximations for the truth with a 
threshold of 0.07 or 0.10 (Table 31-32). Sensitivity is higher on an average on the 
binomial logit-normal randomly generated data. Sensitivity using both approximations 
for the truth decreases with the increase in threshold level from 0.07 to 0.10. The NPV 
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increases using normal-normal conjugate method but decreases using BUGS (with fixed 
hyperparameter) method with increase in threshold level, specificity and the PPV 
remaining high overall. 
 
 Table 31. Operating Characteristics for the methods of estimation, Threshold =0.07 
on 300 B-LN simulated datasets  
Threshold(t)= 0.07 
 True Proportion=0.05, Shrinkage=0.37 
Average number of subjects per site=36, Number of sites=63 
 Using BUGS with fixed 
hyperparameters for the True 
Using Normal-Normal Conjugacy for the 
True 
 MLE Bayesian MCMC MLE Bayesian MCMC 
 Normal 
Approx. 
method 
 
Exact 
method 
B-B 
model 
B-LN 
model 
Normal 
Approx. 
method 
 
Exact 
method 
B-B 
model 
B-LN 
model 
Sensitivity 0.35 0.41 1.00 0.76 0.30 0.35 1.00 0.97 
Specificity 1.00 1.00 0.94 0.95 1.00 1.00 0.97 1.00 
PPV 1.00 1.00 0.75 0.74 1.00 1.00 0.87 0.99 
NPV 0.90 0.91 1.00 0.96 0.87 0.88 1.00 0.99 
 
 Table 32. Operating Characteristics for the methods of estimation, Threshold=0.10 
on 300 B-LN simulated datasets  
Threshold(t)= 0.10 
 True Proportion=0.05, Shrinkage=0.37 
Average number of subjects per site=36, Number of sites=63 
 Using BUGS with fixed hyperparameters 
for the True 
Using Normal-Normal Conjugacy for  
the True 
 MLE Bayesian MCMC MLE Bayesian MCMC 
 Normal 
Approx. 
method 
 
Exact 
method 
B-B 
model 
B-LN 
model 
Normal 
Approx. 
method 
 
Exact 
method 
B-B 
model 
B-LN 
model 
Sensitivity 0.22 0.26 0.73 0.66 0.34 0.39 1.00 0.96 
Specificity 1.00 1.00 1.00 1.00 1.00 1.00 0.99 1.00 
PPV 1.00 1.00 1.00 1.00 1.00 1.00 0.91 0.97 
NPV 0.88 0.89 0.95 0.94 0.93 0.94 1.00 1.00 
  
 92 
It was evident that both the sensitivity and the NPV of the B-LN method were 
inferior to the B-B method using both the B-B and B-LN generated datasets for a cut-off 
of 0.07, 0.10 or 0.15. In medical sites profiling for multicenter trials, it is important to be 
able to correctly identify those sites that are not outliers as well as those that are true 
outliers. Sites with low adverse event rates need to be identified correctly so that the 
reasons for high performance can be elucidated and can be utilized for the improvement 
of the poor performers. 
In general, the shrinkage for the binomial-logit normal model is greater than the 
beta-binomial model that is 1, from equation (15) is greater than 1, from equation (16), 
assuming the within-variation in the proportions for the two models are similar. The 
difference between the estimates from the two models decrease as the mean proportion or 
the within-variation decrease (1, → 0, @A → 0).  The Bayesian B-LN MCMC method 
shrinks the sites’ estimates of adverse event more towards the average adverse event rate 
in the population of sites, reducing the apparent between-site variability and the 
probability of lying above a threshold compared to the B-B method.  It is for this reason 
the B-B method performs closer to the true and has a higher chance of designating sites 
true outliers as outliers compared to the B-LN method. 
3.8.3 Fixed Effects Data 
 
For classifying sites as outliers in the fixed effects data, we applied the 95% 
probability interval approach. Sites were labeled as outliers if the 95% exact confidence 
interval for MLE method or 95% credible intervals for the Bayesian method exceeds the 
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threshold value for proportion of adverse events (0.07 in this case). The fixed effects data 
were generated using the beta-binomial Bayesian model under two implicit assumptions- 
full shrinkage and no shrinkage scenario. Table 33 presents the results using the ML 
method and the Bayesian MCMC method of estimation for shrinkage=1 and Table 34 for 
shrinkage=0 on one simulated fixed effects dataset. Columns show the site indicator; the 
number of subjects per site; the number of adverse events per site; the point estimate; the 
95% confidence interval using the exact method; the B-LN Bayesian credible interval, 
the B-B Bayesian credible interval. Using the implicit assumption of the prior with 
shrinkage=1, the exact method assigned only one site (site 55) as an outlier as the lower 
limit of the confidence interval is above 0.07 (threshold) and none of the other methods 
designate any outliers. Using the implicit assumption of prior with shrinkage=0, of the 12 
cases identified by the exact method as outliers, 100% of them are also designated as 
outliers by both the Bayesian methods. The two Bayesian methods assigned the same 
outlier status to the 12 of the 63 sites as the MLE method.
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Table 33. Comparison of ML and Bayesian MCMC methods of estimation for outlier detection against fixed effects 
data True Proportion=0.05, Shrinkage=1, Threshold=0.07 
Average number of subjects per site=36, Number of sites=63 
Site Number of Subjects 
Number of 
Adverse 
Events 
Point Estimate               
(Number of adverse 
events/Number of 
subjects) 
Exact 95% 
Confidence Interval 
BLN 95% Credible 
Interval 
BB 95% 
Credible Interval 
1 15 2 0.1333 0.0017 0.3195 0.0280 0.0923 0.0257 0.0953 
2 44 2 0.0455 0.0143 0.1866 0.0303 0.0903 0.0287 0.0920 
3 23 1 0.0435 0.0011 0.2195 0.0267 0.0889 0.0243 0.0907 
4 47 2 0.0426 0.0052 0.1454 0.0273 0.0814 0.0260 0.0830 
5 47 4 0.0851 0.0052 0.1454 0.0267 0.0818 0.0253 0.0886 
6 18 3 0.1667 0.0014 0.2729 0.0272 0.0958 0.0253 0.0913 
7 58 5 0.0862 0.0000 0.0616 0.0203 0.0682 0.0121 0.0694 
8 39 1 0.0256 0.0063 0.1732 0.0276 0.0873 0.0250 0.0900 
9 44 1 0.0227 0.0056 0.1547 0.0266 0.0824 0.0247 0.0849 
10 18 1 0.0556 0.0000 0.1853 0.0222 0.0841 0.0186 0.0843 
11 12 1 0.0833 0.0021 0.3848 0.0273 0.0925 0.0273 0.0977 
12 19 3 0.1579 0.0013 0.2603 0.0274 0.0932 0.0263 0.0946 
13 48 1 0.0208 0.0000 0.0740 0.0200 0.0701 0.0150 0.0706 
14 37 0 0.0133 0.0000 0.0949 0.0213 0.0756 0.0165 0.0733 
15 35 2 0.0571 0.0000 0.1000 0.0232 0.0778 0.0177 0.0753 
16 58 3 0.0517 0.0108 0.1438 0.0282 0.0888 0.0265 0.0878 
17 14 2 0.1429 0.0000 0.2316 0.0233 0.0813 0.0187 0.0859 
18 37 1 0.0270 0.0454 0.2877 0.0375 0.1168 0.0383 0.1185 
19 54 4 0.0741 0.0045 0.1275 0.0275 0.0781 0.0241 0.0782 
20 15 2 0.1333 0.0017 0.3195 0.0271 0.0943 0.0262 0.1000 
21 32 2 0.0625 0.0008 0.1622 0.0249 0.0807 0.0214 0.0834 
22 25 2 0.0800 0.0010 0.2035 0.0268 0.0890 0.0231 0.0873 
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23 21 0 0.0233 0.0012 0.2382 0.0267 0.0918 0.0240 0.0937 
24 51 0 0.0097 0.0048 0.1346 0.0265 0.0812 0.0247 0.0807 
25 15 1 0.0667 0.0433 0.4809 0.0350 0.1192 0.0331 0.1149 
26 54 2 0.0370 0.0045 0.1275 0.0254 0.0791 0.0232 0.0840 
27 46 1 0.0217 0.0137 0.1790 0.0319 0.0905 0.0278 0.0931 
28 56 1 0.0179 0.0044 0.1231 0.0262 0.0794 0.0242 0.0833 
29 16 2 0.1250 0.0016 0.3023 0.0283 0.0912 0.0248 0.0961 
30 57 2 0.0351 0.0110 0.1462 0.0300 0.0860 0.0278 0.0886 
31 43 1 0.0233 0.0000 0.0822 0.0203 0.0722 0.0168 0.0741 
32 14 0 0.0345 0.0018 0.3387 0.0273 0.0888 0.0236 0.0936 
33 39 2 0.0513 0.0063 0.1732 0.0279 0.0898 0.0253 0.0839 
34 20 1 0.0500 0.0013 0.2487 0.0257 0.0872 0.0244 0.0905 
35 22 2 0.0909 0.0012 0.2284 0.0265 0.0921 0.0242 0.0930 
36 36 1 0.0278 0.0068 0.1866 0.0301 0.0911 0.0264 0.0890 
37 18 1 0.0556 0.0000 0.1853 0.0233 0.0818 0.0171 0.0870 
38 38 2 0.0526 0.0166 0.2138 0.0316 0.0991 0.0307 0.0978 
39 17 0 0.0286 0.0015 0.2869 0.0274 0.0914 0.0254 0.0914 
40 33 0 0.0149 0.0192 0.2433 0.0300 0.0971 0.0318 0.1038 
41 46 1 0.0217 0.0137 0.1790 0.0303 0.0962 0.0302 0.0912 
42 52 1 0.0192 0.0047 0.1321 0.0260 0.0816 0.0213 0.0789 
43 57 3 0.0526 0.0110 0.1462 0.0285 0.0829 0.0270 0.0878 
44 32 1 0.0313 0.0351 0.2899 0.0356 0.1139 0.0354 0.1174 
45 28 1 0.0357 0.0009 0.1835 0.0260 0.0857 0.0225 0.0879 
46 56 5 0.0893 0.0044 0.1231 0.0258 0.0787 0.0233 0.0801 
47 54 1 0.0185 0.0045 0.1275 0.0261 0.0779 0.0245 0.0783 
48 43 2 0.0465 0.0259 0.2214 0.0344 0.1076 0.0328 0.1045 
49 52 4 0.0769 0.0121 0.1595 0.0296 0.0868 0.0290 0.0880 
50 52 2 0.0385 0.0214 0.1854 0.0314 0.0981 0.0330 0.0978 
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üSite designated as outlier by the exact method based on threshold of 0.07 and the overall adverse event rate of 0.05 
 
  
51 34 2 0.0588 0.0072 0.1968 0.0282 0.0893 0.0268 0.0911 
52 25 0 0.0196 0.0010 0.2035 0.0263 0.0875 0.0251 0.0909 
53 55 2 0.0364 0.0005 0.0972 0.0230 0.0736 0.0188 0.0733 
54 35 5 0.1429 0.0070 0.1916 0.0288 0.0879 0.0261 0.0910 
ü55 10 1 0.1000 0.1216 0.7376 0.0381 0.1375 0.0398 0.1394 
56 39 5 0.1282 0.0162 0.2087 0.0286 0.0935 0.0306 0.1004 
57 32 1 0.0313 0.0198 0.2502 0.0322 0.0988 0.0329 0.1097 
58 36 6 0.1667 0.0175 0.2247 0.0296 0.0985 0.0339 0.1003 
59 14 1 0.0714 0.0000 0.2316 0.0228 0.0818 0.0212 0.0881 
60 47 1 0.0213 0.0355 0.2310 0.0344 0.1061 0.0357 0.1105 
61 13 1 0.0769 0.0000 0.2471 0.0239 0.0849 0.0220 0.0898 
62 56 3 0.0536 0.0198 0.1729 0.0302 0.0911 0.0315 0.0956 
63 50 2 0.0400 0.0049 0.1371 0.0253 0.0823 0.0258 0.0819 
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Table 34.Comparison of ML and Bayesian MCMC methods of estimation for outlier detection against fixed effects data, True 
Proportion=0.05, Shrinkage=0, Threshold=0.07 
Average number of subjects per site=3317, Number of sites=63 
Site Number of Subjects 
Number of 
Adverse 
Events 
Point Estimate 
(Number of adverse events/ 
Number of subjects) 
Exact 95% Confidence 
Interval 
BLN 95% Credible 
Interval 
BB 95% Credible 
Interval 
1 3816 113 0.0296 0.0245 0.0355 0.0245 0.0354 0.0249 0.0355 
†2 2468 174 0.0705 0.0607 0.0813 0.0614 0.0809 0.0604 0.0807 
†3 2754 189 0.0686 0.0595 0.0787 0.0596 0.0780 0.0592 0.0788 
4 1395 75 0.0538 0.0425 0.0669 0.0433 0.0654 0.0428 0.0665 
5 5126 193 0.0377 0.0326 0.0432 0.0323 0.0426 0.0325 0.0425 
†*6 2321 223 0.0961 0.0844 0.1088 0.0842 0.1083 0.0844 0.1076 
7 2319 138 0.0595 0.0502 0.0699 0.0503 0.0694 0.0507 0.0699 
†*8 1451 151 0.1041 0.0888 0.1209 0.0871 0.1199 0.0884 0.1203 
9 3304 5 0.0015 0.0005 0.0035 0.0007 0.0038 0.0006 0.0036 
10 4457 130 0.0292 0.0244 0.0345 0.0244 0.0336 0.0246 0.0347 
11 5244 65 0.0124 0.0096 0.0158 0.0096 0.0156 0.0098 0.0156 
†12 2230 137 0.0614 0.0518 0.0722 0.0514 0.0710 0.0518 0.0727 
†*13 4254 362 0.0851 0.0769 0.0939 0.0761 0.0931 0.0764 0.0933 
14 4400 136 0.0309 0.0260 0.0365 0.0260 0.0364 0.0261 0.0363 
15 1522 47 0.0309 0.0228 0.0409 0.0233 0.0404 0.0222 0.0398 
16 1559 54 0.0346 0.0261 0.0450 0.0269 0.0445 0.0267 0.0451 
17 2078 90 0.0433 0.0350 0.0530 0.0348 0.0524 0.0350 0.0524 
18 1650 86 0.0521 0.0419 0.0640 0.0420 0.0630 0.0420 0.0627 
19 4331 130 0.0300 0.0251 0.0355 0.0247 0.0350 0.0251 0.0353 
20 3438 53 0.0154 0.0116 0.0201 0.0116 0.0195 0.0119 0.0200 
21 2766 0 0.0002 0.0000 0.0013 0.0001 0.0020 0.0000 0.0013 
22 5735 206 0.0359 0.0313 0.0411 0.0313 0.0406 0.0312 0.0406 
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Table 34.Comparison of ML and Bayesian MCMC methods of estimation for outlier detection against fixed effects data, True 
Proportion=0.05, Shrinkage=0, Threshold=0.07 
Average number of subjects per site=3317, Number of sites=63 
Site Number of Subjects 
Number of 
Adverse 
Events 
Point Estimate 
(Number of adverse events/ 
Number of subjects) 
Exact 95% Confidence 
Interval 
BLN 95% Credible 
Interval 
BB 95% Credible 
Interval 
†*23 1559 325 0.2085 0.1885 0.2295 0.1891 0.2298 0.1866 0.2268 
24 3819 19 0.0050 0.0030 0.0078 0.0031 0.0077 0.0032 0.0076 
25 5241 26 0.0050 0.0032 0.0073 0.0034 0.0073 0.0034 0.0072 
26 3558 186 0.0523 0.0452 0.0601 0.0455 0.0594 0.0454 0.0603 
27 4332 161 0.0372 0.0317 0.0432 0.0318 0.0428 0.0318 0.0429 
28 1132 18 0.0159 0.0095 0.0250 0.0098 0.0245 0.0100 0.0245 
29 1532 22 0.0144 0.0090 0.0217 0.0091 0.0210 0.0094 0.0214 
30 4477 201 0.0449 0.0390 0.0514 0.0387 0.0513 0.0390 0.0515 
31 2366 65 0.0275 0.0213 0.0349 0.0218 0.0347 0.0215 0.0347 
32 4724 87 0.0184 0.0148 0.0227 0.0147 0.0222 0.0150 0.0229 
33 4726 0 0.0001 0.0000 0.0008 0.0001 0.0013 0.0000 0.0007 
34 1833 67 0.0366 0.0284 0.0462 0.0284 0.0456 0.0283 0.0451 
35 5899 21 0.0036 0.0022 0.0054 0.0024 0.0054 0.0023 0.0054 
36 3973 49 0.0123 0.0091 0.0163 0.0093 0.0162 0.0093 0.0164 
37 4441 116 0.0261 0.0216 0.0312 0.0212 0.0311 0.0218 0.0309 
38 1859 59 0.0317 0.0242 0.0407 0.0243 0.0405 0.0243 0.0405 
39 1208 4 0.0033 0.0009 0.0085 0.0014 0.0087 0.0014 0.0076 
40 1949 74 0.0380 0.0299 0.0474 0.0297 0.0467 0.0297 0.0476 
41 4807 282 0.0587 0.0522 0.0657 0.0520 0.0653 0.0520 0.0652 
†42 3797 246 0.0648 0.0572 0.0731 0.0573 0.0725 0.0574 0.0723 
43 3527 21 0.0060 0.0037 0.0091 0.0039 0.0092 0.0037 0.0092 
44 5864 145 0.0247 0.0209 0.0290 0.0209 0.0288 0.0209 0.0287 
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Table 34.Comparison of ML and Bayesian MCMC methods of estimation for outlier detection against fixed effects data, True 
Proportion=0.05, Shrinkage=0, Threshold=0.07 
Average number of subjects per site=3317, Number of sites=63 
Site Number of Subjects 
Number of 
Adverse 
Events 
Point Estimate 
(Number of adverse events/ 
Number of subjects) 
Exact 95% Confidence 
Interval 
BLN 95% Credible 
Interval 
BB 95% Credible 
Interval 
45 1403 8 0.0057 0.0025 0.0112 0.0032 0.0108 0.0028 0.0110 
†*46 3786 329 0.0869 0.0781 0.0963 0.0777 0.0962 0.0784 0.0974 
47 5480 198 0.0361 0.0313 0.0414 0.0311 0.0418 0.0317 0.0411 
†*48 1539 223 0.1449 0.1277 0.1635 0.1274 0.1618 0.1268 0.1602 
49 3246 96 0.0296 0.0240 0.0360 0.0237 0.0357 0.0244 0.0357 
50 2544 12 0.0047 0.0024 0.0082 0.0029 0.0083 0.0027 0.0082 
51 2164 48 0.0222 0.0164 0.0293 0.0163 0.0294 0.0164 0.0292 
†*52 5140 678 0.1319 0.1228 0.1415 0.1225 0.1416 0.1222 0.1414 
†*53 2627 339 0.1290 0.1165 0.1425 0.1169 0.1414 0.1158 0.1426 
54 3479 30 0.0086 0.0058 0.0123 0.0059 0.0124 0.0060 0.0120 
†*55 1539 139 0.0903 0.0765 0.1058 0.0757 0.1033 0.0762 0.1045 
56 4716 142 0.0301 0.0254 0.0354 0.0252 0.0350 0.0257 0.0357 
†57 4472 286 0.0640 0.0570 0.0715 0.0570 0.0706 0.0566 0.0717 
58 3696 25 0.0068 0.0044 0.0100 0.0045 0.0097 0.0046 0.0097 
59 3667 205 0.0559 0.0487 0.0638 0.0491 0.0636 0.0489 0.0635 
†*60 5083 972 0.1912 0.1805 0.2023 0.1804 0.2020 0.1799 0.2025 
†*61 5208 816 0.1567 0.1469 0.1668 0.1469 0.1669 0.1470 0.1660 
†*62 2507 335 0.1336 0.1205 0.1476 0.1198 0.1461 0.1202 0.1462 
†63 1431 94 0.0657 0.0534 0.0798 0.0535 0.0782 0.0530 0.0794 
*Sites designated as outliers by all three methods based on threshold of 0.07 
† Sites designated as outliers by all three methods based on threshold of overall sample adverse event rate of 0.05 
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Overall across 300 simulations, the sensitivity and NPV of the MLE method is 
greater than both the B-B method and the B-LN method on the fixed effects data for both 
shrinkage=1 and shrinkage=0. Among the Bayesian methods, the B-LN has inferior 
sensitivity and NPV compared to the B-B, consistent with our findings from the Bayesian 
approach (Table 35). 
 
 
Table 35. Operating Characteristics of methods of estimation  
on 300 simulated fixed effects datasets 
 Threshold(t)= 0.07 
 Shrinkage=1 Shrinkage=0 
 MLE Exact method 
B-B 
MCMC 
B-LN 
MCMC 
MLE Exact 
method 
B-B 
MCMC 
B-LN 
MCMC 
Sensitivity 0.10 0.00 0.00 0.63 0.49 0.23 
Specificity 0.97 1.00 1.00 0.83 0.87 0.90 
PPV 0.45 1.00 1.00 0.45 0.44 0.34 
NPV 0.84 0.83 0.83 0.91 0.89 0.85 
 
 
Fixed Effects Methodology 
The fixed effects MLE method to site classification involves constructing 95% 
confidence or credible intervals around the estimates. Those sites whose lower 
confidence or credible limits are above the overall sample adverse event rate of 0.05 are 
labeled as outliers. Table 27 and 28 shows the results using the MLE method of outlier 
classification for data generated under the fixed effects way. For zero shrinkage on a 
single simulated dataset, only one site was flagged as an outlier. Under the full shrinkage 
scenario, 17 sites excluded the overall adverse event rate and were designated as outliers. 
More sites were classified as outliers using the standard MLE method compared to 
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applying a threshold level. 
Overall across 300 simulations sensitivity and NPV of the MLE method is marginally 
greater than both the B-B method and the B-LN method on the fixed effects data for 
shrinkage=1. With zero shrinkage, all methods performed close to each other with almost 
identical moderate sensitivity, specificity, low PPV and high NPV (Table 36). 
 
 
 
Table 36. Operating Characteristics of methods of estimation  
on 300 simulated fixed effects datasets 
 based on true adverse event rate=0.05 
 Shrinkage=1 Shrinkage=0 
 MLE Exact method 
B-B 
MCMC 
B-LN 
MCMC 
MLE Exact 
method 
B-B 
MCMC 
B-LN 
MCMC 
Sensitivity 0.15 0.01 0.01 0.72 0.73 0.73 
Specificity 0.95 1.00 1.00 0.73 0.75 0.75 
PPV 0.41 0.78 0.77 0.37 0.38 0.39 
NPV 0.82 0.81 0.81 0.93 0.93 0.93 
 
3.9  Results Using Example Dataset 
We performed some analyses with the motivated example dataset. We ranked the 
sites based on the posterior probability of the posterior mean exceeding the overall mean 
adverse event rate and the posterior probability of the posterior mean exceeding the 
highest mean. The highest mean was chosen as the posterior mean of a facility with 
highest posterior mean and a tighter 95% credible interval. Ranking the sites based on the 
two criteria did not change the rankings for the two models significantly except for sites 
with low event rates. 
High correlation in the range of 0.941-0.996 between the ranks was evident from the two 
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methods. The higher the rank the worse is the performance of the facility, for example, of 
the total 63 sites, a rank of 63 is the worst. Lower the numerator, greater was the 
variability between the ranks and wider the credible intervals. The true ranks fell within 
the 95% credible interval of the posterior ranks 100% of the time. The better the 
performance of the sites, that is the lower the number of adverse events, the higher the 
rank starting from 1 to 63. 
3.10 Discussion 
Under the Bayesian framework, we compared two models of profiling sites and 
assessed the agreement of the estimation methods to the true. The methods included 
comparing two Bayesian methods, the beta-binomial model and the binomial logit-
normal model. Use of Bayesian hierarchical models for profiling providers has been a 
growing topic of interest in the medical literature. Despite the usage of hierarchical 
models for profiling performances, there remains some confusion about how to identify 
‘outliers’ based on them. The Bayesian approach shrinks the site’s estimate of adverse 
event to the average adverse event rate, thus reducing the between site variability 
compared to the fixed effects MLE approach. To identify outliers using the Bayesian 
approach we compute the probability that the site’s adverse event rate is above a certain 
threshold is 50%. While for the traditional fixed effects MLE approach we use the 
confidence interval method and declare site as outliers if the lower bound 95% 
confidence or credible interval is above a certain threshold.  
In summary, in this study, among the two Bayesian models, we show that 
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sensitivity and negative predictive value of beta-binomial is superior to binomial logit-
normal model, regardless of how the data is generated using beta-binomial or binomial 
logit-normal model. For data generated using the fixed effects model with no shrinkage, 
all the methods performed similarly. Under the full shrinkage scenario, MLE method 
shows slightly higher sensitivity and negative predictive value. Bayesian methods have 
greater PPV than the MLE method which is reflective of its higher specificity. 
Considering the intense scrutiny and public attention that are faced by sites classified as 
high outliers in multicenter clinical trial recruitment phase, it is important that a high 
proportion of those sites that are identified as outliers be true outliers. Furthermore, 
because of the expense associated with conducting internal performance audits, one 
would want to target such interventions only at centers that had unacceptably high 
adverse event rates. 
There were several limitations to the study. The outlier sites have been assessed at 
a very low overall adverse event proportion of 0.05. The methods have been compared 
with the number of subjects per site at 35 on average leading to moderate shrinkage of 
0.37. The degree of shrinkage being directly related to sample size, greater shrinkage 
would be observed for low-volume sites leading to low sensitivity for the Bayesian 
MCMC methods compared to the fixed effects MLE. Further research could be utilized to 
evaluate the performances of the methods by varying the overall rate, varying the number 
of subjects per site to reflect high-volume and low shrinkage as well as varying the 
number of sites. We have shown that the B-B outperforms other methods of estimation 
showing higher sensitivity and NPV. Overall, the choice between Bayesian or maximum 
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likelihood methods of estimation to correctly identify clinical sites as outliers depends on 
several factors- overall adverse event rate, site’s sample size, threshold method applied. 
 
3.11 Application 
As part of central statistical monitoring of multicenter clinical trial data, 
procedure based on the beta-binomial distribution for the detection of centers with 
atypical values for the probability of some event have been proposed which have been 
shown to have high sensitivity and high specificity if the contamination rate is small and 
the atypical event proportions are the result of some systematic shift in the underlying 
data generating mechanism [68]. 
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Chapter 4 
Statistical methods for estimating multiple binary adverse outcomes and 
identifying outlier sites in multicenter clinical trials 
4.1  Background  
Multiple outcomes are increasingly collected both in randomized clinical trials and 
observational studies in order to characterize treatment or intervention effectiveness, or to 
investigate adverse events. The decision to include more than one outcome arises for 
several reasons, including a lack of consensus on the most important clinical outcomes or 
a desire to demonstrate effectiveness or a pattern of problems based on more than one 
outcome. While a single measure may not be sufficient to describe the quality of care for 
a particular site [42], the use of multiple measures can be challenging to consumers and 
to regulators with respect to the interpretation of clinical relevance [43].  
One of two statistical strategies is usually adopted to the analysis of multiple 
outcomes. Either the outcomes are combined into a single composite end point using a 
variety of pooling rules and scoring algorithms or, alternatively, the outcomes are 
analyzed separately using univariate statistical tools for each outcome. Combining into a 
single composite endpoint using a variety of pooling rules or scoring algorithms include 
taking simple average of the outcomes or using conjunctive or compensatory rules [44]. 
Statistical challenges arise when summarizing all the measures into the unidimensional 
composite score. This composite score needs to be a valid and reliable overall measure of 
quality of care for a provider, and provide an objective procedure to compare quality of 
care delivered by different institutions [45].  But this pooling strategy has the 
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disadvantage of reducing the information collected and potentially attenuating important 
information available from the data. In contrast, although the simplicity of analyzing each 
end point separately is appealing, the correlation between the outcomes is effectively 
ignored. Rather a multivariate approach which maintains the meaning and scale of the 
individual outcomes but appropriately models the correlation between the outcomes may 
be the most pragmatic option. But the question is how to simultaneously model these 
multiple responses, how to summarize the information and how to select inferiorly 
performing institutions based on the strategy chosen. 
This concept of modeling multiple outcomes is applicable in clinical trial settings 
when analyzing multiple types of adverse events experienced by patients in clinical trials 
and devising a way to summarize and use the information. The individual types of 
adverse events often measure different dimensions of quality that reflect the multiple 
objectives of provider organizations and the needs of diverse stakeholders. Individual 
indicators are useful in identifying specific areas for improvement and tracking 
improvement progress; but to assess overall performance for a site, it is useful to 
consolidate the information by considering individual indicators simultaneously. 
Simultaneously considering outcomes allow for a way to combine diverse information 
from multiple domains. In this paper, we test multivariate methods between whether the 
adverse event rates are assumed to fixed versus random, where the uncertainty of these 
parameters are made part of the modeling assumption. For a Bayesian framework, we 
build upon the method proposed by Shwartz et al. 2012 while for a fixed effects approach 
we consider a standard multivariate normal model. We use MLE and Bayesian MCMC 
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methods of estimation to compare the estimating properties as well to identify sites that 
are outliers. 
The work is organized into two major sections-comparing the estimation 
properties of the methods under various parametric conditions and assessing the 
classification accuracy of the methods with regard to outlier detection. In Section 4.2, we 
describe the statistical methods and models used. Section 4.3 is devoted to generation of 
data in our simulation studies. Section 4.4-4.5 discusses methods of estimation and model 
fit. Operating characteristics comparing the methods for analyzing multiple outcomes are 
covered in Section 4.6. Results of the simulation study are discussed in section 4.7. 
Sensitivity analyses of the prior distributions for parameters in our Bayesian models are 
presented in section 4.8. In the second half, Section 4.9 is devoted to the study of the two 
methods of estimations discussed in Section 4.4 in detecting sites as outliers. This section 
is organized in a similar way with method and models, followed by data generation and 
estimation and then discussion of results. The original motivating data set is also 
analyzed with the different models and the results are presented based on possible 
scenarios consistent with the motivating example in Section 4.10. We conclude in Section 
4.11 followed by an application in Section 4.12. 
The motivating example dataset includes adverse events data from a multi-site 
clinical trial in bowel resection patients treated with an anonymous drug. The data comes 
from six multi-site double blinded placebo-control studies with multiple outcomes from 
different patients. Adverse events listed in the clinical trial database were considered for 
the motivating analysis. There were a total of 63 clinical sites, but the total number of 
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subjects enrolled in the study was unknown. For simulation study, we assumed the 
number of subjects per site to be 60. The dataset was used as an example dataset to select 
parameters of the simulation studies. 
4.2  Methods and Models 
An adverse event in a clinical trial is a patient-level outcome. But in this work, our interest 
is the counts of adverse events for two outcomes at the site-level. We evaluate the 
accuracy of two statistical approaches in estimating the outcomes, the proportion of 
adverse events at site level: 
i.a Bayesian multivariate normal-binomial model proposed by Shwartz et al. 2012 [15] 
with Markov Chain Monte Carlo (MCMC) estimation; 
ii.a multivariate approach with maximum likelihood estimation. 
 We simulate data with the number of subjects per site fixed at 60 and number of sites 
fixed at 20	while varying the correlation between outcomes from as low as 0.17, to 
medium 0.50, to as high as 0.99. The difference between the outcomes is 0.19. 
Performance of the models and estimation methods is measured by the proportion of times 
the pair of true parameter values at each site is contained within the 95% confidence or 
credible ellipse. 
4.3  Data Generation Models 
Data 
In our data simulation, we assume there are i=1,…,N = 20 clinical sites, with "#$ = n = 60 
subjects observed for the %th outcome in the ith site and a total of &#$ 	adverse events 
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across the "#$  subjects. Let  '#$ be the proportion of adverse events for the kth outcome at 
the ith site. The data are the counts of adverse events observed at the site-level,&#$ . The 
correlation (()*)	between outcomes are varied from 0.17 to 0.50 to 0.99 in the simulation 
study. The values of the correlation were chosen to show low to medium to high 
correlated scenarios of which the correlation of 0.17 is obtained from the motivational 
dataset. 
The data are generated using both fixed effects and Bayesian model assumptions 
under three different correlation scenarios. Three hundred multivariate normal-binomial 
Bayesian datasets and 300 correlated binomial datasets are simulated with fixed true 
proportions in the fixed effects data simulation and random true proportions in the 
Bayesian data simulation. 
 Distribution of  p-. 
4.3.1 Bayesian Model (Multivariate Normal-Binomial): M-LN 
 
We generate binomial counts of  /#$s such that logit of each true rates ('#$0), for adverse 
event type, k, for site, i follow a bivariate normal distribution with the mean vector γ and 
covariance matrix 1). The model is given by /#$~34"('#$, "#$) 																																																		789:4;(')$), 89:4;('*$)<(=, 1))>~?*(=, 1))        (26) 
with = and 1) defined below for varying correlation scenarios. Table 37 shows the mean 
and covariance matrix values for 89:4;0('#$)0 and Table 38 shows the mean vector and 
covariance matrix values for the corresponding '#$0   in the proportion scale for the same 
 110 
model for three different correlations (()*) scenarios. The starting values of the mean 
vector and covariance matrix for '#$0	were based on estimates from analysis of the 
example dataset. The mean and covariance of '#$0  were transformed into mean and 
covariance of 89:4;('#$)0 using the Delta Method of Approximation (see Appendix B). 
 
Table 37.Values of Mean Vector and Covariance Matrix for logit('#$)s 
Correlation Mean Vector (=) Covariance Matrix (1)) 
High (()* = 0.99) (−0.85,−2.09) H0.72 0.570.57 0.46L 
Medium (()* = 0.50) (−0.85,−2.09) H0.72 0.290.29 0.46L 
Low (()* = 0.17) (−0.85,−2.09) H0.72 0.100.10 0.46L 
 
Table 38.Values of Mean Vector and Covariance Matrix for '#$ 
Correlation Mean Vector  Covariance Matrix  
High (()* = 0.99) (0.30, 0.11) H0.032 0.0110.011 0.004L 
Medium (()* = 0.50) (0.30,0.11) H0.032 0.0060.006 0.004L 
Low (()* = 0.17) (0.30,0.11) H0.032 0.0020.002 0.004L 
 
4.3.2 Correlated Binomial Model 
 
Data for counts of adverse events under the correlated binomial model was generated 
using the correlated binomial model. In this method we first generate correlated uniform 
data using the copula package in R. A copula is a multivariate distribution whose 
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marginals are all uniform over (0, 1). We then use the qbinom function to convert them 
into correlated binomial counts. 
In the data generation process, we correlate the rates of adverse events, '#$0 in the 
Bayesian method but under the fixed effects approach, we correlate the counts, /#$s.    
4.4  Methods of Estimation 
4.4.1 Bayesian Method (Multivariate Normal Binomial Model with MCMC 
method) 
 
This method utilizes fitting multivariate normal binomial model with MCMC method of 
estimation specifically the Gibbs sampler on the generated data. For data equal to zero, 
we add a correction factor of 0.5. Typically to approximate a discrete distribution by a 
continuous distribution, a continuity correction factor of 0.5 is applied. We follow the 
same rule since in this case the data were counts data at the site level. We specify a non-
informative multivariate normal prior for the mean vector = and a Wishart distribution 
with identity matrix and 3 degrees of freedom for the inverse covariance matrix, T =1)O), 
as used by Shwartz et al. 2012 [15]. The hyper parameter = has a bivariate normal hyper 
prior distribution with mean P and precision matrix Q. Under model (26) 789:4;(')$), 89:4;('*$)<(=, 1))>~?*(=, 1)) =~?*(P, Q) 
																																																																	Q = H. 001 00 . 001L                                                    P = (−1.59 −2.44) 
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   R = 1)O)~S* TH1 00 1L , 3U                                                     (27) 
4.4.2 Maximum Likelihood Method of estimation (MLE) 
 
This method utilizes multivariate normal model. For data equal to zero, we add a 
correction factor of 0.5. A continuity correction factor of 0.5 is applied to approximate the 
counts data with the normal data. The data are transformed into logit scale to enable like-
for-like comparison with the Bayesian model. The logit transformed data are then 
assumed to come from a multivariate normal model with the estimated mean and 
variance-covariance from the data. Multivariate samples are then drawn from the logit 
distribution and the maximum likelihood method of estimation is used to estimate the 
mean and variance. 
The estimates of logit( '#$)s are obtained under both Bayesian and MLE framework. 
In Bayesian analyses, the estimates of mean and variance-covariance are obtained from a 
posterior p which has a distribution, while in MLE, the estimates are the sample mean 
and sample variance obtained from the data. 
 
Derivation of Posterior for Multivariate Normal Binomial Model 
Under the multivariate normal binomial model (27), the posterior distribution, is 
proportional to the product of the likelihood function and the specified prior distributions 
does not yield itself to a closed form solution; MCMC simulation methods are utilized to 
draw samples from the posterior distributions of the unknown parameters. The 
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distribution of 89:4;('), given the data, can be obtained by a normal-normal conjugate 
framework. Below is an approximate derivation of the posterior distribution. 
 789:4;(')$), 89:4;('*$)<(=, 1))>~?*(=, 1)) =~?*(P, Q) 
 
            VW;	'$ = X 
f(=|X) ∝ [(=)∏[(X| =) = ]9"0; ∗ WO)/*(`Oa)bcde(`Oa) ∏ WO)/*(fO`)bgede(fO`) 
ln(f(=|X)) = 	− )* (= −P)hQO)(= −P) − )*∑(X − =)h1)O)(X − =)h 
=− )* =h7?1)O) + PO)>= + )* =h(?1)O)X̅ + QO)P ) 
Let A=	?1)O) +PO) 
B=	?1)O)X̅ + QO)P  
ln(f(=|X)) = − )* (=hl	= − =h3 − 3h=) 
= −)* (=hl	= − =h3 − 3h= + 3′lO)3) 
=− )* (=hl	= − =hllO)3 − 3hllO)= + 3′lO)3) 
Let lO)3 = no and lO) = ∑o  
ln(f(=|X)) = − )* (nh∑oO)	n − nh∑oO)	n − noh∑oO)	n + noh∑oO)	n) 
=− )* (n − no)′	∑oO)(n − no) 
Thus n|X~?(no, 1o) 
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4.5  Estimation and Model Fit 
To estimate the model parameters, fit and appropriateness of priors of Bayesian 
hierarchical model, Gibbs sampling was used. The model is fit to the counts of adverse 
events from the simulated data with Markov chain Monte Carlo sampling using BUGS 
[46, 47]. This Markov Chain Monte Carlo (MCMC) estimation method generates 
samples of model parameters from the posterior distribution of the parameters, given the 
data and prior distributions of the parameters. Because non-informative priors were 
placed on the parameters, the posterior distributions were driven by the data. We 
examined several convergence diagnostics, especially on the potential scale reduction 
(PSR) statistic proposed by Gelman and Rubin (1992) [48] as well as the trace plots. We 
obtained inferences for the model parameters by combining 2 parallel chains with a burn-
in of 5,000 iterations and a further 7,000 iterations. Convergence of the Gibbs sampler 
was assessed according to graphical plots as well as Monte-Carlo error and the Gelman-
Rubin statistic for couple of the datasets. Starting values for parameters were chosen 
based on the maximum likelihood estimates. Our focus of inference being the site, we 
calculated summary statistics at the site level. Sensitivity analyses with reasonable 
modifications of priors on the covariance matrix were also carried out for the Bayesian 
model to assess the impact of the priors on the posterior distribution discussed later in 
section 4.8.  
Using maximum likelihood estimates and Bayesian posterior estimates of 
proportion of adverse events by site, methods were compared as described previously in 
section 4.2. The results were then compared to the true parameter values. 
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4.6  Comparison of Methods using Operating Characteristics: non-coverages 
In the multivariate setting instead of calculating coverage using confidence intervals, 
confidence regions were used for the vector of the parameters, 89:4;('#$)0. The 
outcomes were considered simultaneously and in order to estimate 95% confidence or 
credible intervals some sort of density or contour plot was called for. To do this, we 
needed to generate an estimated density profile in order to assign a height (or z-value) 
over the (x,y) plane utilizing distributional assumption like a sum of Gaussian/normal 
distributions (one for each pair (89:4;('))	89:4;('*))	 ), taking into account the 
correlation among outcomes. For multivariate normal data, the resulting confidence 
region produces ellipsoidal shapes. Instead of determining an interval that covers the 89:4;	('#$)′0 separately with high probability, we determine a region that covers the 
vector (89:4;(')$)	89:4;('*$))	 with high probability.  
Two papers on assessing multiple outcomes simultaneously have been published. 
Everson and Morris, 2000 [49] used hospital profiling data on two outcomes (surgical 
and non-surgical problems) to show the effectiveness of their rejection sampling based on 
the improper flat prior on covariance matrix compared to the restricted maximum 
likelihood method. In this paper the authors’ state that they chose to use the independent 
sampling procedures by constructing separate 90% and 95% probability intervals 
approximated by posterior mean plus minus 1.645 or 1.960 posterior standard deviation 
estimates.  In another paper, Casella and Hwang developed J-dimensional confidence 
spheres based on James-Stein estimator that in classical sense cover the vector of 
parameters more often than the usual confidence sphere [50]. 
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For each site 4, a confidence or credible region was created for the vector of parameters 
(89:4;(')$)	89:4;('*$). The estimates of  89:4;('#$)0 = (89:4;(')$)	89:4;('*$)s  
obtained from section 4.4 were used to create the 95% ellipse (qr$,s.tu). We used the 
dataEllipse function from R 3.2.1 software for this purpose. The dataEllipse function in 
the car package generates ellipses by superimposing the normal-probability contours over 
a scatter plot of the data. Results reported in full here were reported on the results of 
applying the dataEllipse function.  
The estimated means and covariance matrix for each site were utilized to create the 
ellipse at the site level. For each site 4, if the true values 89:4;('#$)0 =(89:4;(')$)	89:4;('*$)s   fall within the 95% ellipse, it was counted as 1, else 0. The 
process was repeated across 20 sites and then across 300 simulated datasets. The average 
proportion of times the true	89:4;('#$)0 = (89:4;(')$)89:4;('*$)s	was outside of the 
ellipse (qv$,s.tu)  across 20 sites across 300 simulated datasets gives the average non-
coverage, defined as  
   1 − )w×yss ∑ ∑ 7z('	#$€	qr$,s.tu||};})>w$~)yss)       (28) 
where I is an indicator function such that 
I =      1 if '	#$€	qr$,s.tu         
           0 otherwise 
 We do that for each of the combinations of parametric settings for three different 
correlation scenarios for data generated using a correlated binomial model and a Bayesian 
multivariate normal binomial model. 
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Figure 8 shows the estimated 95% confidence ellipse on correlated binomial 
generated data for the low correlation scenario for two random sites. The outer boundary 
is the 95% confidence band and the bold text “X” shows a point corresponding to the true 
pair of values, (89:4;(')$), 89:4;('*$)) which falls inside the ellipse. Here we show two 
different scenarios both for Bayesian method of estimation on correlated binomial data, 
one where the true value is contained within the 95% estimated ellipse (left panel) and 
the other where it is not (right panel). The coverage for the first case was 1 and 0 for the 
second. 
Figure 8. 95% Confidence or Credible Ellipse
  
4.7 Results 
Fixed Number of Subjects per Site, fixed number of Sites and fixed number of 
Outcomes 
 
Table 39 summarizes the results of non-coverage for Bayesian MCMC and MLE methods 
of estimation, when the data are generated using either a fixed effects or Bayesian model. 
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The comparisons were made with expected proportion of adverse events at site-level at 
0.30 and 0.11 with equal number of subjects per site at 60 and number of sites being 20. 
The confidence level was set to 0.95. For data generated using Bayesian multivariate 
Normal-binomial model, the coverage rate for maximum likelihood method of estimation 
and Bayesian method of estimation were nominal across all correlation scenarios (range 
for non-coverage 0.029-0.055 for Bayesian; 0.045 to 0.092 for MLE). While generating 
the data using correlated binomial model, the maximum likelihood method of estimation 
shows 95% coverage and the Bayesian method of estimation shows greater than nominal 
coverage.  
 
Table 39. Non-Coverage for Two Outcomes with expected adverse event proportion at 
p1=0.30, p2=0.11 
Number of sites=20, Equal subjects per site (n=60) 
 Bayesian Multivariate 
Normal-Binomial 
generated data 
Correlated Binomial 
generated data 
Correlation between outcomes (()* = 0.99) 
MLE Method  0.092 0.042 
Bayesian Multivariate Normal-
Binomial with MCMC method of 
estimation 
0.029 0.009 
Correlation between outcomes (()* = 0.50) 
MLE Method 0.044 0.042 
Bayesian Multivariate Normal-
Binomial with MCMC method of 
estimation 
0.047 0.011 
Correlation between outcomes (()* = 0.17) 
MLE Method 0.045 0.041 
Bayesian Multivariate Normal-
Binomial with MCMC method of 
estimation 
0.055 0.010 
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4.8 Sensitivity Analysis on Inverse-Wishart prior 
This section illustrates the impact of some prior choices on the posterior inference of the 
covariance matrix in the multivariate model as proposed Shwartz et al. 2012 [15] (Section 
4.3.1). Inverse Wishart-priors are popular priors over covariance functions. In Bayesian 
literature, the most commonly used prior for a multivariate normal distribution is a 
normal prior for the normal mean and an inverse Wishart prior for the covariance matrix. 
Such priors are conjugate leading to easy computation, but lack flexibility and also lead 
to inferences of the same structure as those shown to be inferior as suggested by Stein 
[51]. These priors can be too restrictive because the combination assumes the same 
amount of prior information about every variance parameter. More importantly, it shows 
a prior relationship between the variances and correlations. These characteristic of the 
prior can impact posterior inferences about the covariance matrix. Even for simple 
models, the inverse Wishart prior may become an extremely informative prior resulting in 
biased inference for correlation and variances. In a scenario with small variability, the 
inverse Wishart might severely underestimate the correlation and overestimate variances. 
Yang and Berger (1994) [52] used a spectral decomposition for the covariance matrix and 
developed a reference prior for the component matrices. Barnard et al. (2000) [53] 
separated the covariance matrix in correlations and variances, with log-normal prior on 
the standard deviations and an independent prior for the correlation matrix, which is 
based on the inverse Wishart distribution transformed into a correlation matrix. O'Malley 
and Zaslavsky (2008) [54] proposed a scaled inverse Wishart approach based on the 
separation strategy which is recommended in Gelman and Hill (2007) [55]. A hierarchical 
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approach to covariance matrix parameters was proposed by Huang et al. (2013) [56] 
instead of decomposing the covariance matrix into correlation and variance. 
Based on the literature, we carried out a simulation-based analysis here to assess the 
performance of different strategies to impose covariance matrix prior. We start by 
studying a key aspect of prior’s distributions, followed by the relationship between 
standard deviation and correlation that each prior implies. Then we describe all the 
scenarios used to simulate data and finally present the results of the inference based on 
simulations. 
4.8.1 Generate Data for Prior  
We generated 300 Bayesian multivariate normal binomial data sets with low shrinkage of 
9% for 20 sites with 60 observations per site with expected proportion of adverse events 
p1=0.30 and p2=0.11. We then used the multivariate normal binomial Bayesian model 
with three different priors on the precision matrix for estimation and compared the 
estimates of mean and variance. This exercise was conducted to show how well the 
multivariate normal binomial Bayesian model with varying priors estimate the mean and 
variance parameters.  
4.8.2 Methods chosen for Priors 
Three different prior distributions for the covariance matrix were evaluated- the 
commonly used Inverse-Wishart (IW) prior with identity matrix and 3 degrees of 
freedom, scaled-inverse Wishart (sIW) prior with identity matrix and 3 degrees of 
freedom and separation strategy (SS) prior. As stated above, the standard inverse Wishart 
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prior has the limitation of not exactly being non-informative because of the association 
between standard deviations and correlation. The scaled inverse Wishart distribution is 
the same as inverse Wishart distribution except that it introduces additional parameters 
for flexibility [57]. For the scaled inverse Wishart 1) from equation 19 (Section 4.3.1) is 
defined as ΔΩΔ where Δ=diag(δ) is a diagonal matrix of standard deviations and Ω is a 
correlation matrix. Here, instead of modeling Ω as a correlation matrix, it is constrained 
to be positive semi-definite such that Δ and Ω jointly determine the standard deviations, 
but Ω still determines the correlations alone. This strategy uses the uniform prior on Δ but 
uses the inverse-Wishart distribution IW(3,R) on Ω which still induces marginally 
uniform correlations on the resulting covariance matrix. Theoretically this distribution 
also allows for some dependency between correlation and standard deviations. The third 
distribution we chose was what is referred to as “separation strategy” (SS). In the 
separation strategy Δ and Ω are modeled separately and then combined to form a prior on 
the covariance matrix [58]. A correlation matrix R is constructed from the inverse Wishart 
distribution such that Q~IW(3,I) and  R= ΔΩΔ. Then uniform distributions are assumed 
for the standard deviations. 
Priors are evaluated under different parametric conditions. The estimates from the 
bivariate Bayesian model with varying priors are compared to the true values that are 
used to generate data. There are three sets of comparisons with the number of subjects per 
site constant at 60, number of sites 20 and shrinkage 9%.  
4.8.3 Results comparing different priors 
Table 40 below summarizes the results comparing the true values of the parameters to the 
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estimated values. Both the posterior estimates of the mean and variance for the three prior 
distributions are similar between the priors. In all cases, Bayesian Multivariate Normal 
Binomial model over estimates the mean and underestimates the variances. Since there 
was not much of a variation between priors in terms of the posterior estimates, for 
simplicity and ease of use we chose to stay with the inverse-Wishart distribution as a 
prior for the covariance matrix.  The inverse-Wishart distribution is already built into 
statistical packages R and BUGS which were used in this paper and typically results in a 
conditionally conjugate model for the covariance matrix, allowing for a relatively simple 
analysis. 
Table 40. Comparison of True Values to The Estimated Values of Parameters  
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4.9 Comparison of methods of estimation on detecting outlier sites 
In the second part of this chapter, we focus on utilizing the same methods and models as 
discussed in Section 4.2 to compare the accuracy of methods of estimation for identifying 
sites as outliers. Outlier detection is an important criterion of an outcome’s usefulness in 
quality improvement platforms as well as to identify any deviations from the norm, 
because information from centers with statistically worse performance (high outliers) are 
frequently to identify quality improvement targets. As noted by Austin et al. (2003) [57] 
researchers and policy makers need to carefully consider the balance between false 
positives and false negatives when choosing statistical models for determining which 
hospitals have higher than acceptable mortality in performance profiling. 
4.9.1 Data Generation 
The correlated binomial model discussed in Section 4.3.2 was used to generate the data 
with the number of subjects per site fixed at 60, the number of sites fixed at 20 with 15 
defined as non-outlier sites and 5 defined as outlier sites, and the expected proportion for 
the two outcomes within a group within a simulation to be the same while varying 
i. The expected proportion of adverse events, ('), '*) for 15 non-outlier sites out 
of the 20 total number of sites as (0.30, 0.30) and (0.10, 0.10). We chose the 
expected proportions such that we had scenarios for high and low adverse 
event rates in clinical trials. 
ii. The relative increase in the expected proportion of adverse events for 5 outlier 
sites as 2-times and 1.5-times that of the non-outlier sites (0.60, 0.60), (0.45, 
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0.45), (0.20, 0.20), and (0.15, 0.15).   
iii. Correlation between the two outcomes,	()* of 0.50, 0.25, and 0.00. 
These choices resulted in 12 simulation studies (4 choices for the means, 3 choices for the 
correlation between the 2 outcomes for the outlier and non-outlier groups). 
In our data simulation, we assume there are i=1,…,N = 20 clinical sites, with "#$ = " 
=60 subjects observed for the %th outcome in the ith site and a total of &#$ 	adverse events 
across the "	subjects. Let  '#$ be the probability of adverse event at the ith site for the kth 
outcome. We assume that the outcomes, &#$ 	are independently distributed as correlated 
binomials as stated in Section 4.3.2. 
Data were generated assuming a correlated binomial model for two groups of sites-outliers 
and non-outliers. Data for 15 sites were generated from non-outlier distribution and the 
remaining 5 sites from the outlier distribution. 
For i=1,..,15 non-outlying sites   
I =      1 if 15 < i ≤ 20         (29) 
           0 if 1 ≤ i ≤ 15 
And then the mean vector is  
First element: n) + z(P − 1)n) = ')($) 
Second element:  n* + z(P − 1)n* = '*($) 
m = multiplier (either 2 or 1.5) n)=mean of first outcome n*=mean of second outcome 
n=number of subjects per site=60 
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()*=correlation between first and second outcome 
Data generation that is consistent with the multivariate correlated binomial model began 
with the generation of /#$‘s for kth outcome and ith site. Three hundred datasets were 
simulated corresponding to each of the parametric conditions described in Section 4.9.1. 
Figure 9 shows the data generation process. 
No Bayesian model data sets were generated for the simulation study, although the 
maximum likelihood estimation and the Bayesian model with MCMC method of 
estimations were utilized to estimate the proportion of adverse events for two outcomes at 
the site level. 
4.9.2 Estimation 
Both Bayesian and maximum likelihood methods of estimation as described in Section 
4.3 were used for estimation purposes. MCMC and maximum likelihood methods of 
estimation are utilized to obtain estimates of the proportion of adverse events for the two 
outcomes. Gibbs sampling was used, as described in Section 4.5 to estimate the 
parameters in Bayesian model and the model fit was assessed by several convergence 
statistics. 
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Figure 9. Data Generation Process using Correlated Binomial Model 
 
4.9.3 Identifying sites that are outliers 
Sites are classified as outliers based on Mahalanobis’ distance square, a statistical 
measure based on a chi-square distribution, assessed using p < .05. It accounts for the fact 
that the variances and covariance between variables and reduces to the familiar Euclidean 
distance for uncorrelated variables with unit variance. Data points further away from the 
center receive a larger Mahalanobis’ distance. A multivariate outlier point is the data 
value exceptionally far away from the center with respect to underlying covariance 
structure. The question is what is defined as being “exceptionally further away”.  
For multivariate normally distributed data the values are approximately chi-square 
distributed with 2 degrees of freedom (Ä**). We choose the top most quantile, 90% 
quantile Ä*,s.ts*  as the cutoff value. The 90th quantile was chosen to align this work for 
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what is used as standard in the quality of care field. Any point that has larger squared 
Mahalanobis’ distance than the cutoff is considered an outlier. The Mahalanobis’ distance ÅÇ(p$) tell us how far away p.	is from the center of the cloud, relative to the size of the 
cloud. Thus, a site was designated as outlier if the Mahalanobis’ distance for the site 
exceeded the threshold value. 
For identifying outliers, it thus becomes crucial as to how the mean and variance 
are estimated. Since the classical estimators of mean and variance are sensitive to 
outliers, they are not useful for the purpose of outlier detection [58]. Robust estimators of 
mean and variance coming from minimum covariance determinant (MCD) estimators are 
more reliable for the purpose. The minimum covariance determinant searches for a subset 
of observations which has the smallest determinant of their classical sample covariance 
matrix. The robust location estimator is then the mean of that subset of the observations 
and the robust covariance estimator is the variance of the observations. In our case, for 
the two-dimensional multivariate sample of the estimates for '#ÉÑ  (k =1,2), (i=1,..,20), the 
Mahalanobis’ distance squared was given by 
																																					ÅÇ(p$) = ('#ÉÑ − 'ÖÜáà)hâÖÜáäO)('#ÉÑ − 'ÖÜáà)               (30) 
with 'ÖÜáà	as the MCD estimate of location	and âÖÜáä  the MCD covariance estimate.  
When using R, there are multiple ways of calculating the Mahalanobis’ distance 
of a given data set. We used the R-3.1.2 package ‘chemometrics’ (Filzmoser & Varmuza, 
2009) [58]. The chemometrics package contains a function (Moutlier) for calculating and 
plotting both the Mahalanobis’ distance and a robust version of the Mahalanobis’ 
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distance. When using the Moutlier function, we simply supply the function with the numeric 
data frame (or matrix), the quantile cutoff point beyond which we want to identify points as 
outliers. The Moutlier function returns several elements, including the Mahalanobis’ distance 
and the robust Mahalanobis’ distance. The robust Mahalanobis’ distance is based on this 
minimum covariance determinant (MCD) estimate [59].  
For each scenario, for each simulated dataset, we flag sites that are outliers based on 
robust Mahalanobis’ distance measure. Of the sites which are true outliers, designated based 
on how the data was generated, we find out how many are classified as outliers by 
Mahalanobis’ measure, which gives us the sensitivity. This is repeated across 300 simulated 
datasets. For each scenario, for each simulated dataset, we calculate the sensitivity and 
specificity using each method of estimation and then take the average sensitivity and 
specificity across 300 simulated datasets. Austin et al. (2003)[57] has also used the 
percentage of correctly classified hospitals in terms of sensitivity and specificity to compare 
the fixed- and random-effects models when each hospital’s true status and classification were 
known by using their randomly generated data. Sensitivity was defined as the probability that 
a hospital that truly had higher than acceptable mortality was classified as such. Specificity 
was defined as the probability that a hospital that was in reality not a high outlier was 
correctly classified. We similarly define the sensitivity of classification of sites as outliers 
as the probability the sites that are true outliers are classified as outliers. Specificity is the 
probability the sites are true non-outliers are classified as non-outliers. The data were 
simulated from a mixture distribution as described in Section 4.9.1 such that out of a total 
of 20 sites, 5 sites were outlying and 15 were non-outlying.  
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4.9.4 Results of outlier detection 
Bayesian and maximum likelihood methods of estimation in classifying sites as outliers 
are summarized in Table 41, for data generated using a correlated binomial model. 
Twelve scenarios are compared by varying the expected proportion of adverse events for 
non-outlier sites, the multiplier difference in mean between the non-outlier and outlier 
sites, the correlation from zero correlation to 0.25 to 0.5. In all of these scenarios, the 
Bayesian MCMC method marginally performs better than the MLE method with regard 
to sensitivity and specificity. Specificity was high for both of the methods in all scenarios. 
With the expected proportion of adverse events as large as 0.30 for the non-outlier group 
and the expected proportion of outliers being two times different than the means of non-
outliers, both the methods of estimation seem to work well with high sensitivity and 
specificity. The two methods correctly classify outlying sites 94% to 97% of the time 
with a correlation between outcomes of 0 to 0.50 as shown under scenario 7, 8 and 9. The 
methods perform poorly with an expected adverse event rate of 0.10 for both outcomes 
for the non-outlier sites and an expected value for outliers that is 1.5 times that of non-
outliers in the three correlation scenarios with average sensitivity of only 0.35 for 
Bayesian MCMC method and 0.30 for the MLE method. With less of a difference in the 
means between the two groups of sites or lower expected proportion of adverse events, 
the probability of correctly classifying sites as outliers decreases for both the Bayesian 
MCMC and MLE method. Thus, the higher the expected proportion of adverse events for 
the non-outlier sites and the larger the difference between expected proportions of 
adverse events for non-outliers versus outliers, there are higher chances of a clear 
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distinction between non-outliers and outliers. This leads to higher chances of sites which 
are outliers to be at the top 10th percentile and be classified as outliers, increasing the 
sensitivity.  
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Table 41. Comparison of MLE and Bayesian MCMC methods of estimation on Sensitivity and Specificity on Correlated 
Binomial Data 
Scenario
First 
Element 
of mean 
of non-
outliers 
(μ1)
multiplier 
(m1)
correlation
(ρ12) (p1I(1≤j≤15),p2I(1≤j≤15)) (p1I(15<j≤20),p2I(15<j≤20)) sensitivity specificity sensitivity specificity
1 0.1 2 0.5 (.1,.1) (.2,.2) 0.64 0.94 0.541 0.943
2 0.1 2 0.25 (.1,.1) (.2,.2) 0.64 0.95 0.57 0.944
3 0.1 2 0 (.1,.1) (.2,.2) 0.7 0.95 0.614 0.945
4 0.1 1.5 0.5 (.1,.1) (.15,.15) 0.34 0.9 0.273 0.904
5 0.1 1.5 0.25 (.1,.1) (.15,.15) 0.35 0.9 0.3 0.916
6 0.1 1.5 0 (.1,.1) (.15,.15) 0.37 0.91 0.329 0.91
7 0.3 2 0.5 (.3,.3) (.6,.6) 0.94 0.96 0.941 0.966
8 0.3 2 0.25 (.3,.3) (.6,.6) 0.945 0.966 0.969 0.967
9 0.3 2 0 (.3,.3) (.6,.6) 0.995 0.966 0.987 0.97
10 0.3 1.5 0.5 (.3,.3) (.45,.45) 0.476 0.932 0.457 0.928
11 0.3 1.5 0.25 (.3,.3) (.45,.45) 0.543 0.935 0.497 0.93
12 0.3 1.5 0 (.3,.3) (.45,.45) 0.621 0.943 0.601 0.941
Mahalanobis' Distance 
Square with Bayesian 
MCMC
Mahalanobis' Distance 
Square with MLEParametric Conditions
Distribution of adverse event proportion 
(p)
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4.10   Results Using an Example Dataset  
In order to illustrate the use of the analytic methods presented here, we performed some 
analyses using the motivating example dataset. The motivating dataset, as described in 
section 2.1, includes data from a multi-site clinical trial in bowel resection patients 
treated by an anonymous drug. It consists of six multi-site double blinded placebo-control 
studies from a multi-center trial to evaluate the impact of drug “A” versus placebo after 
bowel resection. Adverse events that are listed in the clinical trial database are utilized for 
the analysis. There were a total of 63 sites but the number of subjects per site was 
unknown. Outcomes were measured on different patients from 6 different studies. The 
observed and the estimated values from the example dataset with two outcomes are 
presented in Table 42. The estimates were obtained by fitting the Bayesian multivariate 
binomial model with MCMC method of estimation, described earlier. Results show that 
the estimated values using the Bayesian method were close to the observed values. These 
values were later used to generate data for the simulation studies. 
Table 42.Comparison of Observed to estimated using Bayesian Multivariate Normal-
Binomial Model on Motivating Example Data set 
Parameters Observed Estimated 
Expected p1 0.30 0.27 
Expected p2 0.11 0.10 
Correlation between (p1, p2) 0.80 0.88 
Variance of p1 0.032 0.035 
Covariance of (p1, p2) 0.009 0.009 
Variance of p2 0.004 0.004 
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4.11 Discussion 
Profiling sites is an important activity in both research and practice. The purpose of this 
study is to assess and compare the accuracy of a standard and an advanced approach to 
estimate the proportion of adverse events in multicenter clinical trial setting and detect 
sites that are outliers for multiple outcomes. We first derive the accuracy of the methods 
in estimating the proportion of adverse events at the sites for bivariate outcomes in a 
multicenter clinical trial based on 95% confidence or credible ellipse and then assess the 
sensitivity and specificity of the methods in classifying the sites as outliers. Our 
simulation study results show that for data generated both under the correlated binomial 
and Bayesian models, the Bayesian method of estimation has smaller coverage for the 
proportion of adverse events compared to MLE method for varying correlation- low, 
medium or high. For data generated under correlated binomial model, Bayesian method 
shows marginally better sensitivity and specificity results compared to the MLE method 
in identifying outlier sites on adverse events. Both methods seem to work well when the 
expected proportion of adverse events is as high as 0.30 and the difference between the 
expected proportion of non-outlier and outliers is big (2 times), irrespective of the 
correlation between the outcomes under two different variance conditions. 
Our research serves as a building block and there exist several limitations that warrant 
future research. For instance, our simulation results for the bivariate outcome suggest that 
the Bayesian multivariate normal binomial model with MCMC show better coverage 
under both correlated binomial and Bayesian generated data. The method used to evaluate 
coverage was not comprehensive in the sense it evaluated if the pair of points fall outside 
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of the 95% confidence or credible ellipse. In reality, it may be worthwhile to demonstrate 
the estimation properties if one of the points is more or less likely to fall within the 
confidence or credible ellipse.  Also, in the second part of our paper we show that 
Bayesian method has better classification accuracy compared to the MLE method for data 
generated using a correlated binomial model. The classification of sites as outliers is 
performed only on fixed effects generated data and only on certain parametric conditions 
which prompts us to ponder the generalizability of the pattern.  
One future research topic is to evaluate the performance of the methods in 
classification by generating the data using a Bayesian model. The methods in this paper 
are developed for a bivariate outcome. This work can be extended to outcomes with 
dimension greater than two, the case in which multiple yet related indicators are used to 
assess the performance of clinical sites. A commonly used strategy in the hospital quality 
measure setting is to summarize these measures into a unidimensional composite score 
and to classify the programs using the summary score. The introduction of the paper 
discusses some of the commonly used strategies to combine measures. In conclusion, 
these results should be carefully considered by investigators and data safety monitoring 
boards in identifying poor performers during the recruitment phase for multicenter 
clinical trial studies. 
4.12 Potential application to the conduct of randomized clinical trials 
Poor site selection in multi-centre randomized clinical trials can result in delayed start-up, 
unmet target recruitment, poor data quality and/or research integrity, thereby contributing 
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to cost inefficiencies in resource and time allocation. Therefore, tracking a site’s 
operational performance from a sponsor perspective can identify ways to improve 
processes for future studies and to enable performance comparison between sites. Hence 
monitoring the site’s performance by identifying the key risks for the clinical study 
during centralized monitoring is crucial for successful implementation of the trial referred 
to as risk-based monitoring. Key Risk Indicators (KRIs) are an important tool within risk 
management to facilitate risk monitoring, reporting and mitigation process. One of the 
key risk indicators is safety reporting including reporting the rate of adverse events or 
serious adverse events. KRIs, predefined by the Sponsor, are summary statistics that 
potentially reveal deviations in the study conduct in certain centers. The methods 
discussed in this work can be utilized to estimate the rate of adverse events in multi 
center trials and facilitate risk monitoring by identifying sites that are outliers. This will 
help assess deviations from the current study as well recommend sites that are good 
performers for future recruitment.  
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Chapter 5 
Conclusions and Future Work 
 
In this thesis we addressed three motivating problems. The first motivating problem was 
assessing the range of site effects on proportion of adverse events utilizing Bayesian 
MCMC and MLE methods of estimation under different parametric conditions – varying 
sample sizes, varying number of medical sites, varying overall adverse event rate and 
varying shrinkages. We compare four methods- the Bayesian beta-binomial model with 
the MCMC method of estimation, the Bayesian binomial logit-normal model with 
MCMC, the commonly used fixed effects model with maximum likelihood method of 
estimation (MLE) and the exact model with MLE. With the overall rate of 0.50 for a 
single adverse event outcome, all four methods perform equally well, show larger 
coverage, wider 95% interval width and high absolute bias. At the overall rates of 0.17 
and 0.05, the Bayesian beta-binomial model with the MCMC method of estimation 
performs better with regard to the operating characteristics, compared to the other 
methods –the Bayesian logit-normal with MCMC estimation or the MLE methods with 
maximum likelihood estimation. The sensitivity of the estimation of model parameters 
was also assessed by applying different priors. 
The second problem that we addressed was to identify outlying sites utilizing the 
methods of estimations from problem 1. We apply a threshold method and a confidence 
or credible interval approach. We investigated the performance of provider profiling 
methods under both Bayesian and fixed effects framework. Data were generated using 
Bayesian models and fixed effects models with an expected adverse event rate of 0.05 for 
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60 subjects per site for 63 sites. Both MLE and Bayesian MCMC estimates incorporated 
uncertainty via confidence interval or posterior probabilities. We showed that sensitivity 
and negative predictive value of the beta-binomial model with the MCMC method of 
estimation is superior to the binomial logit-normal model, regardless of how the data 
were generated using Bayesian models. For data generated using the fixed effects model 
with no shrinkage, all of the methods performed similarly. Under the full shrinkage 
scenario, the MLE method shows slightly higher sensitivity and negative predictive 
value. The Bayesian MCMC methods have greater PPV than the MLE method which is 
reflective of its higher specificity. 
The third paper in this thesis evaluates the performance of MLE and Bayesian 
MCMC methods of estimation in estimating multiple outcomes at the site level and 
detecting sites that are outliers. We show that for data generated both under correlated 
binomial and Bayesian models, the Bayesian MCMC method of estimation has smaller 
coverage compared to the MLE method for varying correlation- low, medium or high. 
With regard to utilizing the methods to detect outlying sites for data generated under 
correlated binomial model, the Bayesian method shows marginally better sensitivity and 
specificity results compared to the MLE method in detecting sites as outliers. Both 
methods seem to be work well when the expected proportion of adverse events is as high 
as 0.30 and the difference between the expected proportion of non-outlier and outliers is 
big (2 times), irrespective of the correlation between the outcomes under two different 
variance conditions. 
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The limitations of the work presented in this dissertation provide opportunities for 
continued future research. For example, more work remains in accounting for interaction 
of treatment effect by site as well as incorporating patient and site characteristics.  
Profiling sites becomes more valuable and meaningful on whether there are more adverse 
events in one treatment group as opposed to the other. Our focus in inference in this 
thesis has been at the site level with counts of adverse events as outcome. In terms of 
monitoring, focusing on the predictive distribution of a new patient in each site might be 
of more interest to an IRB or DSMB. The second chapter designates sites as outliers 
using both MLE and Bayesian MCMC methods of estimation under the expected adverse 
event proportion of 0.05. This work could be extended to include a range of adverse event 
proportions from as low at 0.01 to as high as 0.30. 
The third chapter focused on the estimation properties of Bayesian MCMC and MLE 
methods have been assessed at the expected adverse event proportion of 0.30 and 0.11 as, 
motivated by the example dataset presents several opportunities to build upon our work. 
The proposed use of the Bayesian Multivariate Normal Binomial model for classifying 
sites as outliers under certain parametric conditions is only applied to one restricted 
scenario, where we assumed the expected proportion of adverse events for both outcomes 
were equal. In reality, in multicenter clinical trials, the adverse event rates for two 
outcomes are rarely equal. We compared the classification accuracy of two statistical 
methods for identifying poor performing sites applying the threshold method using 
simulated data. An obvious question is why we chose 90% as the threshold and what 
would happen if we chose another threshold. Another avenue for further improvement is 
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extending the outcomes for greater than two dimensions. We leave these for future 
research. 
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Appendix A: Derivation of Distribution of !"#$% &'() 
 	+,|.,, 0,~2$.(0,, .,) 																																																				5(+,) = .,0,, 									7(+,) = .,0,8, 																																																				5 &'9(9) = 0,,          7 &'9(9) = :9;9(9  5 <!"#$% =+,.,>? = !"#$%(0,)	7 <!"#$% =+,.,>? = < @@0, !"#$%(0,)?A 7 =+,.,> 
     =B CC:9 !"#$%(0,)DA :9;9(9  
                                                           									= & E:9;9)A :9;9(9  
=		 E(9:9;9 
 
Thus !"#$% &'9(9)~F00G"H$IF%J!+	K &!"#$%(0,), E(9:9;9) 
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Appendix B: Derivation of parameters using Delta method to represent in 
terms of logit(p)’s 
 7FG(!"#$%(0)) = 7FG(!. :EL:)=& CC: ln & :EL:)) ∗ PFG(0)=& E:(EL:))A ∗ PFG(0)   
 
If PFG(0) = 0.032  then from equation above,  PFG(!"#$%(0)) = 0.72 
 U"PFG(!"#$%(01)!"#$%(02))=& CC:EC:A ln & :EEL:E) ln & :AEL:A)) ∗coPFG(01,02)=& E:E(EL:E)) & E:A(EL:A)) ∗ coPFG(01, 02) 
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Appendix 2D: R Code Data Generation for Single Outcome (Chapter 2) 
Appendix 2D.1: Data Generation Using Beta-Binomial Model 
set.seed(111) #so that you can regenerate the same values 
k<-63 # number of sites 
n<-60 # Number of subjects per site 
x<-NULL 
 
p<-rbeta(k,3,3)# so that the mean nausea rate is alpha/(alpha+beta) 
for(i in 1:k) 
x<-cbind(x,rbinom(300,n,p[i])) # 300 datasets 
datamain<-as.data.frame(x) 
new.data<-datamain 
#write.table(new.data,"simuldatBB_3_3_100s.csv") 
#write.table(p,"p_BB_3_3_100s.csv") 
 
Appendix 2D.2: Data Generation Using Binomial Logit-Normal Model 
 
set.seed(111)  #so that you can regenerate the same values # another time if you need to 
k<-63 # number of sites 
x<-NULL 
eta<-rnorm(k,-3.32,.860)# equating moments to BB(3,3) 
p<-exp(eta)/(1+exp(eta)) 
min<-10 
max<-60 
n<-as.integer(runif(k,min,max)) # Number of subjects per site 
for(i in 1:k) 
x<-cbind(x,rbinom(300,n[i],p[i])) # 300 datasets 
datamain<-as.data.frame(x) 
new.data<-datamain 
 
write.table(new.data,"simuldatBLN_1_20_20s_vary10_60.csv") 
write.table(p,"p_BLN_1_20_20s_vary10_60.csv") 
 
Appendix 2D.3: Data Generation Using Fixed Effects Binomial Model 
 
set.seed(111) #so that you can regenerate the same values # another time if you need to 
k<-63 # sites 
x<-NULL 
m<-300 # datasets 
n<-60 # subjects per site 
p<-0.17 # true expected adverse event rate 
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for(i in 1:k) 
x<-cbind(x,rbinom(m,n,p)) 
x<-t(x) 
datamain<-as.data.frame(x) 
new.data<-datamain 
 
write.table(new.data,"simulBin.csv") 
 
Appendix 2E: R Code for Estimation of Single Outcome (Chapter 2) 
 
Appendix 2E.1: MCMC Estimation Using Beta-Binomial Model 
 
library("R2WinBUGS") 
 
#Set working directory 
setwd("G://Achaudhuri/Trial") 
 
trial.data <- read.table("simuldatBB_3_3_20s.csv", header=T) 
p_true<- read.table("p_BB_3_3_20s.csv",header=F) 
 
bugs.output <- list() 
for(i in 1:300){ 
       nausea <- as.integer(trial.data[i,]) 
       bugs.output[[i]] <- bugs( 
       data=list(nausea=nausea, N=20), # change for no of sites 
       inits=list( 
               list(theta=.300,mu=3), 
               list(theta=.350, mu=3) 
               ), 
       model.file="conj_nausea_script_2.txt",  
       parameters.to.save = c("alpha","p"), 
n.chains=2, n.iter=12000, n.burnin=5000, 
bugs.directory="G://Achaudhuri/winbugs14/WinBUGS14", 
working.directory=NULL) 
 
bugs.output[[i]]$sims.list$p_trans<-t(bugs.output[[i]]$sims.list$p) 
bugs.output[[i]]$sims.list$coverage<-matrix(data=0,nrow=20,ncol=1)# Change for no of 
sites 
bugs.output[[i]]$sims.list$int_width<-matrix(data=0,nrow=20,ncol=1)# change for no of 
sites 
bugs.output[[i]]$sims.list$sqr_err<-matrix(data=0,nrow=20,ncol=1) 
bugs.output[[i]]$sims.list$abs_bias<-matrix(data=0,nrow=20,ncol=1)# change for no of 
sites 
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bugs.output[[i]]$sims.list$p_true<-p_true 
 
for (j in 1:20) # change for no of sites 
 
{ 
 
if  
# define coverage 
((bugs.output[[i]]$sims.list$p_true[j,]>quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.0
25))) & 
(bugs.output[[i]]$sims.list$p_true[j,]<quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.97
5)))) 
 
bugs.output[[i]]$sims.list$coverage[j,]<-1 
 
else 
bugs.output[[i]]$sims.list$coverage[j,]<-0 
 
#define interval width 
bugs.output[[i]]$sims.list$int_width[j,]<-
(quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.975)))-
(quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.025))) 
 
# define sqr error loss 
bugs.output[[i]]$sims.list$sqr_err[j,]<-(((bugs.output[[i]]$sims.list$p_true[j,])-
mean(bugs.output[[i]]$sims.list$p_trans[j,]))^2)/0.50 # change with overall rate 
 
# define absolute bias 
bugs.output[[i]]$sims.list$abs_bias[j,]<-abs((bugs.output[[i]]$sims.list$p_true[j,])-
mean(bugs.output[[i]]$sims.list$p_trans[j,])) 
 
} 
 
} 
 
cov<-cbind(NULL) # initialize variable matrix cov before loop 
interval_width<-cbind(NULL) # initialize variable matrix cov before loop 
sqr_error_loss<-cbind(NULL) # initialize variable matrix square error loss 
absolute_bias<-cbind(NULL) # initialize variable matrix absolute bias 
 
for(i in 1:300){ 
 
cov<-cbind(cov, bugs.output[[i]]$sims.list$coverage) 
interval_width<-cbind(interval_width, bugs.output[[i]]$sims.list$int_width) 
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sqr_error_loss<-cbind(sqr_error_loss, bugs.output[[i]]$sims.list$sqr_err) 
absolute_bias<-cbind(absolute_bias, bugs.output[[i]]$sims.list$abs_bias) 
 
}  
 
# Average Coverage 
avg_cov<-apply(cov,1,mean) 
cov_prob<-mean(avg_cov) 
1-cov_prob 
 
# Average Interval Width 
avg_int_width<-apply(interval_width,1,mean) 
avg_interval_width<-mean(avg_int_width) 
avg_interval_width 
 
# Average Square error loss 
avg_err_loss<-apply(sqr_error_loss,1,mean) 
average_loss<-mean(avg_err_loss) 
average_loss 
 
# Average abosulte Bias 
avg_abs_bias<-apply(absolute_bias,1,mean) 
average_bias<-mean(avg_abs_bias) 
average_bias 
 
# conj_nausea_script_2.txt 
model 
{ 
for (i in 1 : N)  
 
{ 
nausea[i] ~ dbin(p[i],60) 
 
p[i] ~ dbeta(alpha, beta) 
} 
 
alpha<-theta*mu 
 
beta<-(1-theta)*mu 
 
theta ~ dbeta(1,1) 
 
mu~dpar(1.5,1) 
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shrink<-((alpha+beta+1)/(alpha+beta+61)) 
 
var<-(theta*(1-theta))/(alpha+beta+1) 
 
} 
 
Appendix 2E.2: MCMC Estimation Using Binomial Logit-Normal Model 
 
library("R2WinBUGS") 
 
#Set working directory 
setwd("G://Achaudhuri/Trial") 
 
trial.data <- read.table("simuldatBB_1_20_10sub.csv", header=T) 
p_true<- read.table("p_BB_1_20_10sub.csv",header=F) 
 
bugs.output <- list() 
for(i in 1:300){ 
       nausea <- as.integer(trial.data[i,]) 
       bugs.output[[i]] <- bugs( 
       data=list(nausea=nausea, N=63), # change for no of sites 
       inits=list( 
               list(alpha0=0,tau=1), 
               list(alpha0=1,tau=1) 
               ), 
       model.file="B-LN_model_trial.txt", 
       parameters.to.save = c("p"), 
n.chains=2, n.iter=12000, n.burnin=5000, 
bugs.directory="G://AChaudhuri/winbugs14/WinBUGS14", 
working.directory=NULL) 
 
bugs.output[[i]]$sims.list$p_trans<-t(bugs.output[[i]]$sims.list$p) 
bugs.output[[i]]$sims.list$coverage<-matrix(data=0,nrow=63,ncol=1)# Change for no of 
sites 
bugs.output[[i]]$sims.list$int_width<-matrix(data=0,nrow=63,ncol=1)# change for no of 
sites 
bugs.output[[i]]$sims.list$sqr_err<-matrix(data=0,nrow=63,ncol=1) 
bugs.output[[i]]$sims.list$abs_bias<-matrix(data=0,nrow=63,ncol=1)# change for no of 
sites 
bugs.output[[i]]$sims.list$p_true<-p_true 
 
for (j in 1:63) # change for no of sites 
 
{ 
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if  
# define coverage 
((bugs.output[[i]]$sims.list$p_true[j,]>quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.0
25))) & 
(bugs.output[[i]]$sims.list$p_true[j,]<quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.97
5)))) 
 
bugs.output[[i]]$sims.list$coverage[j,]<-1 
 
else 
bugs.output[[i]]$sims.list$coverage[j,]<-0 
 
#define interval width 
bugs.output[[i]]$sims.list$int_width[j,]<-
(quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.975)))-
(quantile(bugs.output[[i]]$sims.list$p_trans[j,],c(.025))) 
 
# define sqr error loss 
bugs.output[[i]]$sims.list$sqr_err[j,]<-(((bugs.output[[i]]$sims.list$p_true[j,])-
mean(bugs.output[[i]]$sims.list$p_trans[j,]))^2)/0.50 # change with overall rate 
 
# define absolute bias 
bugs.output[[i]]$sims.list$abs_bias[j,]<-abs((bugs.output[[i]]$sims.list$p_true[j,])-
mean(bugs.output[[i]]$sims.list$p_trans[j,])) 
 
} 
 
} 
 
cov<-cbind(NULL) # initialize variable matrix cov before loop 
interval_width<-cbind(NULL) # initialize variable matrix cov before loop 
sqr_error_loss<-cbind(NULL) # initialize variable matrix square error loss 
absolute_bias<-cbind(NULL) # initialize variable matrix absolute bias 
 
for(i in 1:300){ 
 cov<-cbind(cov, bugs.output[[i]]$sims.list$coverage) 
 
interval_width<-cbind(interval_width, bugs.output[[i]]$sims.list$int_width) 
 
sqr_error_loss<-cbind(sqr_error_loss, bugs.output[[i]]$sims.list$sqr_err) 
 
absolute_bias<-cbind(absolute_bias, bugs.output[[i]]$sims.list$abs_bias) 
}  
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# Average Coverage 
avg_cov<-apply(cov,1,mean) 
cov_prob<-mean(avg_cov) 
1-cov_prob 
 
# Average Interval Width 
avg_int_width<-apply(interval_width,1,mean) 
avg_interval_width<-mean(avg_int_width) 
avg_interval_width 
 
# Average Square error loss 
avg_err_loss<-apply(sqr_error_loss,1,mean) 
average_loss<-mean(avg_err_loss) 
average_loss 
 
# Average abosulte Bias 
avg_abs_bias<-apply(absolute_bias,1,mean) 
average_bias<-mean(avg_abs_bias) 
average_bias 
 
 
#B-LN_model_trial.txt 
model 
{ 
 for( i in 1 : N ) { 
 
  nausea[i] ~ dbin(p[i],60) 
   
  b[i] ~ dnorm(0.0,tau) 
    
logit(p[i]) <- alpha0 + b[i] 
 
   } 
 
  alpha0 ~ dnorm(0.0,1.0E-6) 
    
tau ~dgamma(0.1,0.1) 
 
sigma<-1/sqrt(tau)  
 } 
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Appendix 2E.3: MLE Estimation Using Common Fixed Effects Model using Normal 
Approximation 
 
set.seed(111) #so that you can regenerate the same values # another time if you need to 
k<-63 
n<-60 
x<-NULL 
 
p<-rbeta(k,1,20)# so that the mean nausea rate is alpha/(alpha+beta) 
for(i in 1:k) 
x<-cbind(x,rbinom(1000,n,p[i]))  
rate<-t(t(x)/n) 
se_rate<-sqrt(rate*(1-rate)/n) 
 
l_cl<-rate-(1.96*se_rate) 
u_cl<-rate+(1.96*se_rate) 
 
datamain<-as.data.frame(x) 
new.data<-datamain 
write.table(new.data,"simuldatBB_1_20.csv") 
write.table(p,"p_BB_1_20.csv") 
 
rate_t<-t(rate) 
l_cl_t<-t(l_cl) 
u_cl_t<-t(u_cl) 
coverage<-matrix(data=0,nrow=63,ncol=1000) 
int_width<-matrix(data=0,nrow=63,ncol=1000) 
sqr_err<-matrix(data=0,nrow=63,ncol=1000) 
abs_bias<-matrix(data=0,nrow=63,ncol=1000) 
 
for (i in 1:1000){ 
 
for (j in 1:63)                        # change for number of sites 
{ 
 
 
if ((p[j]>l_cl_t[j,i]) & (p[j]<u_cl_t[j,i])) 
{ 
coverage[j,i]<-1 
} 
else{ 
coverage[j,i]<-0 
 
} 
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int_width[j,i]<-u_cl_t[j,i]-l_cl_t[j,i] 
 
sqr_err[j,i]<-((rate_t[j,i]-p[j])^2)/0.05 
 
abs_bias[j,i]<-abs(rate_t[j,i]-p[j]) 
} 
} 
avg_cov<-apply(coverage,1,mean) 
cov_prob<-mean(avg_cov) 
1-cov_prob  # Non-Coverage Probability 
 
avg_int<-apply(int_width,1,mean) 
mean(avg_int)  # Average Interval width 
 
avg_sqr_err<-apply(sqr_err,1,mean) 
mean(avg_sqr_err) # Average Squared Error Loss 
 
 
avg_abs_bias<-apply(abs_bias,1,mean) 
mean(abs_bias) 
 
Appendix 2E.4: MLE Estimation Using Common Fixed Effects Model using Exact 
Method 
 
set.seed(111) #so that you can regenerate the same values # another time if you need to 
k<-10 
n<-60 
x<-NULL 
p<-rbeta(k,1,20)# so that the mean nausea rate is alpha/(alpha+beta) 
#min<-10 
#max<-60 
#n<-as.integer(runif(k,min,max)) 
for(i in 1:k) 
x<-cbind(x,rbinom(1000,n,p[i]))  
x<-t(x) 
rate<-t(t(x)/n) 
se_rate<-sqrt(rate*(1-rate)/n) 
 
# Exact Confidence Interval 
 
l_cl_exact<-qbeta(.025,x,n-x+1) 
u_cl_exact<-qbeta(.975,x+1,n-x) 
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for (i in 1:10){ 
 
for (j in 1:1000) 
{ 
 
if (x[i,j]==0)  
{ 
l_cl_exact[i,j]<-0 
u_cl_exact[i,j]<-u_cl_exact[i,j] 
} 
else if (x[i,j]==n[i])  
{ 
l_cl_exact[i,j]<-l_cl_exact[i,j] 
u_cl_exact[i,j]<-1 
} 
else 
l_cl_exact[i,j]<-l_cl_exact[i,j] 
u_cl_exact[i,j]<-u_cl_exact[i,j] 
 
#print(c(i,j)) 
 
} 
} 
Appendix 3D: R Code for Outlier Data Generation for Single Outcome 
(Chapter 3) 
 
Appendix 3D.1: Data Generation using Beta-Binomial Model 
 
set.seed(111) #so that you can regenerate the same values # another time if you need to 
m<-300 # Datasets 
k1<-52 # Non-outlier Sites 
x1<-NULL 
p1<-rbeta(k1,1,20)# so that the mean nausea rate is alpha/(alpha+beta) 
min<-10 # minimum subjects per site 
max<-60 # maximum subjects per site 
n1<-as.integer(runif(k1,min,max)) 
 
for(i in 1:k1) 
x1<-cbind(x1,rbinom(m,n1[i],p1[i])) 
 
p1_t<-(x1+1)/(n1+22) 
 
k2<-11 # Outlier Sites 
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x2<-NULL 
 
p2<-rbeta(k2,1,12)# so that the mean nausea rate is alpha/(alpha+beta) 
min<-10 
max<-60 
n2<-as.integer(runif(k2,min,max)) 
 
for(i in 1:k2) 
x2<-cbind(x2,rbinom(m,n2[i],p2[i])) 
 
p2_t<-(x2+1)/(n2+13) 
 
p2_t_t<-t(p2_t) 
 
x<-cbind(x1,x2) 
k<-63 
 
datamain<-as.data.frame(x) 
new.data<-datamain 
 
n<-c(n1,n2) 
 
#write.table(new.data,"C://Tina/USB_Backup_042213/trial/BB_implicit_300sim.csv") 
 
 
Appendix 3D.2: Data Generation using Binomial Logit-Normal Model 
 
Appendix 3D.3: Data Generation using Beta-Binomial Model with full shrinkage to make 
it close to fixed effects model with varying sample size 
 
set.seed(111) 
m<-300  
k1<-52 
x1<-NULL 
 
p1<-rbeta(k1,100000,2000000)# so that the mean nausea rate is alpha/(alpha+beta) 
n1<-c(15,44,23,47,47,18,58,39,44,18,12,19,48,37,35,58,14,37,54,15,32,25,21,51,15,54, 
46,56,16,57,43,14,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54,43,52,52,34,25) 
 
for(i in 1:k1) 
x1<-cbind(x1,rbinom(m,n1[i],p1[i])) 
 
p1_t<-(x1+100000)/(n1+2100000) 
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k2<-11 
x2<-NULL 
 
p2<-rbeta(k2,100000,1200000)# so that the mean nausea rate is alpha/(alpha+beta) 
n2<-c(55,35,10,39,32,36,14,47,13,56,50) 
 
for(i in 1:k2) 
x2<-cbind(x2,rbinom(m,n2[i],p2[i])) 
 
p2_t<-(x2+100000)/(n2+1200000) 
 
p2_t_t<-t(p2_t) 
 
x<-cbind(x1,x2) 
 
Appendix 3D.4: Data Generation using Beta-Binomial Model with no shrinkage to make 
it close to fixed effects model 
 
set.seed(111) 
m<-300  
k1<-52 
x1<-NULL 
p1<-rbeta(k1,1,20)# so that the mean nausea rate is alpha/(alpha+beta) 
min<-1000 
max<-6000 
n1<-as.integer(runif(k1,min,max)) 
 
for(i in 1:k1) 
x1<-cbind(x1,rbinom(m,n1[i],p1[i])) 
 
p1_t<-(x1+1)/(n1+22) 
 
k2<-11 
x2<-NULL 
 
p2<-rbeta(k2,1,12)# so that the mean nausea rate is alpha/(alpha+beta) 
min<-1000 
max<-6000 
n2<-as.integer(runif(k2,min,max)) 
 
for(i in 1:k2) 
x2<-cbind(x2,rbinom(m,n2[i],p2[i])) 
 
p2_t<-(x2+1)/(n2+13) 
 154 
 
p2_t_t<-t(p2_t) 
 
x<-cbind(x1,x2) 
k<-63 
 
datamain<-as.data.frame(x) 
new.data<-datamain 
 
n<-c(n1,n2) 
 
#write.table(new.data,"C://Tina/USB_Backup_042213/trial/BB_implicit_300sim.csv") 
 
Appendix 3E: R Code for Outlier Estimation for Single Outcome (Chapter 
3) 
 
Appendix 3E.1: True Posterior for Beta-Binomial model 
 
set.seed(111)  
k<-63 
x<-NULL 
p<-rbeta(k,1,20)# so that the mean nausea rate is alpha/(alpha+beta) 
min<-10 
max<-60 
n<-as.integer(runif(k,min,max)) 
for(i in 1:k) 
x<-cbind(x,rbinom(300,n[i],p[i])) 
 
p_t<-(x+1)/(n+21) 
 
p_t_t<-t(p_t) 
 
q1<-1-pbeta(0.07,x+1,n-x+20,lower.tail=TRUE) # True Bayesian Posterior exceeding the 
threshold of .07 
 
#write.csv(p_t_t,"C://Tina/USB_Backup_042213/Paper III/true_post_p.csv") 
 
#write.csv(q1,"C://Tina/USB_Backup_042213/Paper III/true_post_p_exc.csv") 
 
exceeds<-matrix(data=0,nrow=63,ncol=300) 
for (i in 1:300){ 
for(j in 1:k) 
{ 
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if (q1[i,j]>0.5) 
exceeds[j,i]<-1 
else 
exceeds[j,i]<-0 
} 
} 
 
avg_exceeds<-apply(exceeds,1,mean) 
avg_exceeds 
exceeds_prob<-mean(avg_exceeds) 
 
Appendix 3E.2: True Posterior for Binomial Logit Normal model for varying subjects per 
site (Normal-Normal Conjugate Approach) 
 
# Simulating BLN datasets and deriving the posterior distribution 
set.seed(111)   
k<-63  # sites 
m<-300   #datasets 
x<-NULL 
y<-matrix(data=0,nrow=m,ncol=k) 
tow<-matrix(data=0,nrow=m,ncol=k) 
mu1<-matrix(data=0,nrow=m,ncol=k) 
phi1<-matrix(data=0,nrow=m,ncol=k) 
sig1<-matrix(data=0,nrow=m,ncol=k) 
z<-matrix(data=0,nrow=m,ncol=k) 
 
mu<--3.32 
phi<-1/((.860)^2) 
eta<-rnorm(k,-3.32,.860) 
p<-exp(eta)/(1+exp(eta)) 
 
n<-c(15,44,23,47,47,
 18,58,39,44,18,12,19,48,37,35,58,14,37,54,15,32,25,21,51,15,54,46,56,16,57,43,1
4,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54,43,52,52,34,25,55,35,10,39,32,36,14,47,
13,56,50) 
 
for(i in 1:k) 
x<-cbind(x,rbinom(m,n[i],p[i]))  
datamain<-as.data.frame(x) 
new.data<-datamain 
 
#write.table(new.data,"C://Tina/USB_Backup_042213/Trial/simuldatBLN_1_20_vary10
_60_same_n_1sim.csv") 
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for (i in 1:m) 
{ 
 
for (j in 1:k) 
{ 
 
if (x[i,j]==0)  
{ 
x[i,j]<-(x[i,j]+0.5) 
 
n[j]<-(n[j]+0.5) 
 
} 
} 
} 
 
for (i in 1:m) 
{ 
 
for (j in 1:k) 
{ 
 
# Posterior dist of logit(p|x,hyperparameters)~N(p1,sig1) 
 
y[i,j]<-(log(x[i,j]/(n[j]-x[i,j]))) 
tow[i,j]<-(x[i,j]*(n[j]-x[i,j]))/n[j] 
mu1[i,j]<-((phi*mu)+(y[i,j]*tow[i,j]))/(phi+tow[i,j]) 
 
phi1[i,j]<-(phi+tow[i,j]) 
 
sig1[i,j]<-1/sqrt(phi1[i,j]) 
z[i,j]<-exp(mu1[i,j])/(1+exp(mu1[i,j])) 
} 
} 
 
#logit_p<-NULL 
 
#for(i in 1:k) 
 
#logit_p<-cbind(logit_p,rnorm(m,mu1[i],sig1[i]))  
 
#z<-exp(mu1)/(1+exp(mu1)) 
mean_z<-apply(z,2,mean)# true posterior mean 
for(i in 1:k) 
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q1<-1-pnorm(-2.586,mu1,sig1,lower.tail=TRUE) # True Posterior exceeding the 
threshold of .07 
mean_q1<-apply(q1,1,mean) 
exceeds<-matrix(data=0,nrow=m,ncol=k) 
for (i in 1:m){ 
for(j in 1:k) 
{ 
if (q1[i,j]>0.50) # should this be .5 or exp(.5)/1+exp(.5)  
 
exceeds[i,j]<-1 
 
else 
exceeds[i,j]<-0 
} 
} 
avg_exceeds<-apply(exceeds,2,mean) 
avg_exceeds # posterior prob of exceeding threshold is greater than .50 
 
exceeds_prob<-mean(avg_exceeds) 
 
 
Appendix 3E.3: True Posterior for Binomial Logit-Normal model for varying subjects per 
site (BUGS Approximation with Fixed Hyperparameter Approach) 
 
Set working directory 
setwd("C://Tina/USB_Backup_042213/Trial") 
 
trial.data <- read.table("simuldatBLN_1_20_vary10_60_same_n.csv", header=T) 
p_true<- read.table("p_BLN_1_20_vary10_60_same_n.csv",header=F) 
 
bugs.output <- list() 
for(i in 1:300){ 
       nausea <- as.integer(trial.data[i,]) 
       bugs.output[[i]] <- bugs( 
       data=list(nausea=nausea, N=63, 
n=c(15,44,23,47,47,18,58,39,44,18,12,19,48,37,35,58,14,37,54,15,32,25,21,51,15,54,46,
56, 
16,57,43,14,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54,43,52,52,34,25,55,35,10,39,32
, 
36,14,47,13,56,50)),  
       inits=list( 
               list(mu=0,tau=1) 
               ), 
       model.file="B-LN_model_trial_vary_rank_7%_true.txt", 
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       parameters.to.save = c("p","exceeds0.20"), 
n.chains=1, n.iter=12000, n.burnin=5000, 
bugs.directory="C://Tina/USB_Backup_042213/winbugs14/WinBUGS14", 
working.directory=NULL) 
 
bugs.output[[i]]$sims.list$p_trans<-t(bugs.output[[i]]$sims.list$p) 
bugs.output[[i]]$sims.list$exceeds0.20_trans<-t(bugs.output[[i]]$sims.list$exceeds0.20) 
bugs.output[[i]]$sims.list$mean_p<-matrix(data=0,nrow=63,ncol=1)# Change for no of 
sites 
bugs.output[[i]]$sims.list$mean_exceeds0.20<-matrix(data=0,nrow=63,ncol=1) 
bugs.output[[i]]$sims.list$coverage<-matrix(data=0,nrow=63,ncol=1) 
 
for (j in 1:63) # change for no of sites 
 
{ 
 
#define mean of p 
bugs.output[[i]]$sims.list$mean_p[j,]<-mean(bugs.output[[i]]$sims.list$p_trans[j,]) 
 
#define mean of exceeds0.20 
bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]<-
mean(bugs.output[[i]]$sims.list$exceeds0.20_trans[j,]) 
 
if  
# define coverage for exceeds 
(bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]>0.50) 
 
bugs.output[[i]]$sims.list$coverage[j,]<-1 
 
else 
bugs.output[[i]]$sims.list$coverage[j,]<-0 
 
} 
} 
mean_mean_p<-cbind(NULL) # initialize variable matrix cov before loop 
mean_mean_exceeds0.20<-cbind(NULL) # initialize variable matrix cov before loop 
cov<-cbind(NULL) # initialize variable matrix cov before loop 
 
for(i in 1:300){ 
 
mean_mean_p<-cbind(mean_mean_p, bugs.output[[i]]$sims.list$mean_p) 
mean_mean_exceeds0.20<-cbind(mean_mean_exceeds0.20, 
bugs.output[[i]]$sims.list$mean_exceeds0.20) 
cov<-cbind(cov, bugs.output[[i]]$sims.list$coverage) 
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}  
 
# Average Coverage 
avg_mean_p<-apply(mean_mean_p,1,mean) 
avg_mean_exceeds0.20<-apply(mean_mean_exceeds0.20,1,mean) 
avg_cov<-apply(cov,1,mean) 
 
Appendix 3E.4: Outlier Estimation Using Beta Binomial Model 
 
library("R2WinBUGS") 
 
#Set working directory 
setwd("C://Tina/USB_Backup_042213/Trial") 
 
trial.data <- read.table("simuldatBB_1_20_vary10_60_300sim.csv", header=T) 
p_true<- read.table("p_BB_1_20_vary10_60.csv",header=F) 
 
bugs.output <- list() 
for(i in 1:300){ 
       nausea <- as.integer(trial.data[i,]) 
       bugs.output[[i]] <- bugs( 
       data=list(nausea=nausea, 
N=63,n=c(15,44,23,47,47,18,58,39,44,18,12,19,48,37,35,58,14,37, 
54,15,32,25,21,51,15,54,46,56,16,57,43,14,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54
,43,52, 
52,34,25,55,35,10,39,32,36,14,47,13,56,50)),  
       inits=list( 
               list(theta=.300,mu=3), 
               list(theta=.350, mu=3) 
               ), 
       model.file="Conj_nausea_script_2_vary_rank_5%.txt", 
       parameters.to.save = c("p","exceeds0.20","alpha","beta","theta","mu","var"), 
n.chains=2, n.iter=12000, n.burnin=5000, 
bugs.directory="C://Tina/USB_Backup_042213/winbugs14/WinBUGS14", 
working.directory=NULL) 
 
 
bugs.output[[i]]$sims.list$p_trans<-t(bugs.output[[i]]$sims.list$p) 
bugs.output[[i]]$sims.list$exceeds0.20_trans<-t(bugs.output[[i]]$sims.list$exceeds0.20) 
 
bugs.output[[i]]$sims.list$mean_p<-matrix(data=0,nrow=63,ncol=1)# Change for no of 
sites 
bugs.output[[i]]$sims.list$mean_exceeds0.20<-matrix(data=0,nrow=63,ncol=1) 
bugs.output[[i]]$sims.list$coverage<-matrix(data=0,nrow=63,ncol=1) 
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bugs.output[[i]]$sims.list$alpha_trans<-t(bugs.output[[i]]$sims.list$alpha) 
bugs.output[[i]]$sims.list$beta_trans<-t(bugs.output[[i]]$sims.list$beta) 
bugs.output[[i]]$sims.list$var_trans<-t(bugs.output[[i]]$sims.list$var) 
bugs.output[[i]]$sims.list$theta_trans<-t(bugs.output[[i]]$sims.list$theta) 
bugs.output[[i]]$sims.list$mu_trans<-t(bugs.output[[i]]$sims.list$mu) 
 
for (j in 1:63) # change for no of sites 
 
{ 
 
#define mean of p 
bugs.output[[i]]$sims.list$mean_p[j,]<-mean(bugs.output[[i]]$sims.list$p_trans[j,]) 
 
 
#define mean of exceeds0.20 
bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]<-
mean(bugs.output[[i]]$sims.list$exceeds0.20_trans[j,]) 
 
if  
# define coverage for exceeds 
(bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]>0.50) 
 
bugs.output[[i]]$sims.list$coverage[j,]<-1 
 
else 
bugs.output[[i]]$sims.list$coverage[j,]<-0 
 
} 
 
} 
 
mean_mean_p<-cbind(NULL) # initialize variable matrix cov before loop 
mean_mean_exceeds0.20<-cbind(NULL) # initialize variable matrix cov before loop 
cov<-cbind(NULL) # initialize variable matrix cov before loop 
for(i in 1:300){ 
 
mean_mean_p<-cbind(mean_mean_p, bugs.output[[i]]$sims.list$mean_p) 
mean_mean_exceeds0.20<-cbind(mean_mean_exceeds0.20, 
bugs.output[[i]]$sims.list$mean_exceeds0.20) 
cov<-cbind(cov, bugs.output[[i]]$sims.list$coverage) 
}  
 
# Average Coverage 
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avg_mean_p<-apply(mean_mean_p,1,mean) 
avg_mean_exceeds0.20<-apply(mean_mean_exceeds0.20,1,mean) 
avg_cov<-apply(cov,1,mean) 
 
# Model statement Conj_nausea_script_2_vary_rank_5% 
model 
{ 
 
 
for (i in 1 : N)  
 
{ 
nausea[i] ~ dbin(p[i],n[i]) 
 
p[i] ~ dbeta(alpha, beta) 
} 
 
alpha<-theta*mu 
 
beta<-(1-theta)*mu 
 
theta ~ dbeta(1,1) 
 
mu~dpar(1.5,1) 
 
#shrink<-((alpha+beta)/(alpha+beta+n)) 
 
var<-(theta*(1-theta))/(alpha+beta+1) 
 
for (i in 1:N){ 
 
diff0.20[i] <- p[i] - 0.05 # change according to threshold value 
 
diffaverage[i] <- p[i] - mean(p[]) 
 
exceeds0.20[i] < - step(diff0.20[i]) 
 
exceeds.average[i] <- step(diffaverage[i]) 
 
ranks[i] <- rank(p[],i) 
 
} 
 
} 
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Appendix 3E.5: Outlier Estimation Using Binomial Logit-Normal Model 
 
library("R2WinBUGS") 
 
#Set working directory 
setwd("C://Tina/USB_Backup_042213/Trial") 
 
trial.data <- read.table("simuldatBLN_1_20_vary10_60_same_n.csv", header=T) 
p_true<- read.table("p_BLN_1_20_vary10_60_same_n.csv",header=F) 
 
bugs.output <- list() 
for(i in 1:300){ 
       nausea <- as.integer(trial.data[i,]) 
       bugs.output[[i]] <- bugs( 
       data=list(nausea=nausea, 
N=63,n=c(15,44,23,47,47,18,58,39,44,18,12,19,48,37,35,58,14,37, 
54,15,32,25,21,51,15,54,46,56,16,57,43,14,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54
,43,52, 
52,34,25,55,35,10,39,32,36,14,47,13,56,50)),  
       inits=list( 
               list(alpha0=0,tau=1), 
               list(alpha0=1,tau=1) 
               ), 
       model.file="B-LN_model_trial_vary_rank_7%.txt", 
       parameters.to.save = c("p","exceeds0.20"), 
n.chains=2, n.iter=12000, n.burnin=5000, 
bugs.directory="C://Tina/USB_Backup_042213/winbugs14/WinBUGS14", 
working.directory=NULL) 
 
 
bugs.output[[i]]$sims.list$p_trans<-t(bugs.output[[i]]$sims.list$p) 
bugs.output[[i]]$sims.list$exceeds0.20_trans<-t(bugs.output[[i]]$sims.list$exceeds0.20) 
bugs.output[[i]]$sims.list$mean_p<-matrix(data=0,nrow=63,ncol=1)# Change for no of 
sites 
bugs.output[[i]]$sims.list$mean_exceeds0.20<-matrix(data=0,nrow=63,ncol=1) 
bugs.output[[i]]$sims.list$coverage<-matrix(data=0,nrow=63,ncol=1) 
 
for (j in 1:63) # change for no of sites 
 
{ 
#define mean of p 
bugs.output[[i]]$sims.list$mean_p[j,]<-mean(bugs.output[[i]]$sims.list$p_trans[j,]) 
 
#define mean of exceeds0.20 
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bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]<-
mean(bugs.output[[i]]$sims.list$exceeds0.20_trans[j,]) 
if  
# define coverage for exceeds 
(bugs.output[[i]]$sims.list$mean_exceeds0.20[j,]>0.50) 
 
bugs.output[[i]]$sims.list$coverage[j,]<-1 
 
else 
bugs.output[[i]]$sims.list$coverage[j,]<-0 
} 
} 
 
mean_mean_p<-cbind(NULL) # initialize variable matrix cov before loop 
mean_mean_exceeds0.20<-cbind(NULL) # initialize variable matrix cov before loop 
cov<-cbind(NULL) # initialize variable matrix cov before loop 
 
for(i in 1:300){ 
mean_mean_p<-cbind(mean_mean_p, bugs.output[[i]]$sims.list$mean_p) 
mean_mean_exceeds0.20<-cbind(mean_mean_exceeds0.20, 
bugs.output[[i]]$sims.list$mean_exceeds0.20) 
cov<-cbind(cov, bugs.output[[i]]$sims.list$coverage) 
}  
 
# Average Coverage 
avg_mean_p<-apply(mean_mean_p,1,mean) 
avg_mean_exceeds0.20<-apply(mean_mean_exceeds0.20,1,mean) 
avg_cov<-apply(cov,1,mean) 
 
 
# Model Statement B-LN_model_trial_vary_rank_7% 
 
model 
{ 
 for( i in 1 : N ) { 
 
  nausea[i] ~ dbin(p[i],n[i]) 
   
  b[i] ~ dnorm(0.0,tau) 
     
logit(p[i]) <- alpha0 + b[i] 
  } 
   alpha0 ~ dnorm(0.0,1.0E-6) 
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tau ~dgamma(0.1,0.1) 
 
sigma<-1/sqrt(tau) 
 
for (i in 1:N){ 
 
diff0.20[i] <- p[i] - 0.07 # change according to threshold value 
 
diffaverage[i] <- p[i] - mean(p[]) 
 
exceeds0.20[i] < - step(diff0.20[i]) 
 
exceeds.average[i] <- step(diffaverage[i]) 
 
ranks[i] <- rank(p[],i) 
 
}  
 } 
 
 
Appendix 3E.6: Outlier Estimation Using Fixed Effects Model with Exact Method 
 
#Set working directory 
setwd("C://Tina/USB_Backup_042213/Trial") 
 
set.seed(111) 
m<-300  
k1<-52 
x1<-NULL 
 
p1<-rbeta(k1,100000,2000000)# so that the mean nausea rate is alpha/(alpha+beta) 
n1<-
c(15,44,23,47,47,18,58,39,44,18,12,19,48,37,35,58,14,37,54,15,32,25,21,51,15,54,46,56, 
16,57,43,14,39,20,22,36,18,38,17,33,46,52,57,32,28,56,54,43,52,52,34,25) 
 
for(i in 1:k1) 
x1<-cbind(x1,rbinom(m,n1[i],p1[i])) 
 
p1_t<-(x1+100000)/(n1+2100000) 
 
k2<-11 
x2<-NULL 
 
p2<-rbeta(k2,100000,1200000)# so that the mean nausea rate is alpha/(alpha+beta) 
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n2<-c(55,35,10,39,32,36,14,47,13,56,50) 
 
for(i in 1:k2) 
x2<-cbind(x2,rbinom(m,n2[i],p2[i])) 
 
p2_t<-(x2+100000)/(n2+1200000) 
p2_t_t<-t(p2_t) 
 
x<-cbind(x1,x2) 
k<-63 
n<-c(n1,n2) 
#q1<-1-pbeta(0.07,x1+100000,n1-x1+2000000,lower.tail=TRUE) # True Bayesian 
Posterior exceeding the threshold of .07 
 
#q2<-1-pbeta(0.07,x2+100000,n2-x2+1200000,lower.tail=TRUE) # True Bayesian 
Posterior exceeding the threshold of .07 
#write.csv(p_t_t,"C://Tina/USB_Backup_042213/Paper III/true_post_p.csv") 
 
l_cl_exact<-qbeta(.025,x,n-x+1) 
u_cl_exact<-qbeta(.975,x+1,n-x) 
  
for (i in 1:m){ 
 
for (j in 1:k) 
{ 
 
if (x[i,j]==0)  
{ 
l_cl_exact[i,j]<-0 
u_cl_exact[i,j]<-u_cl_exact[i,j] 
} 
else if (x[i,j]==n)  
{ 
l_cl_exact[i,j]<-l_cl_exact[i,j] 
u_cl_exact[i,j]<-1 
} 
else 
l_cl_exact[i,j]<-l_cl_exact[i,j] 
u_cl_exact[i,j]<-u_cl_exact[i,j] 
 
#print(c(i,j)) 
 
} 
} 
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l_cl_exact_t<-t(l_cl_exact) 
u_cl_exact_t<-t(u_cl_exact) 
 
coverage<-matrix(data=0,nrow=k,ncol=m) 
 
for (i in 1:m){ 
 
for (j in 1:k) 
{ 
if (l_cl_exact_t[j,i]>.05) 
{ 
coverage[j,i]<-1 
} 
else{ 
coverage[j,i]<-0 
 
} 
} 
} 
 
avg_cov<-apply(coverage,1,mean) 
cov_prob<-mean(avg_cov) 
1-cov_prob  # Non-Coverage Probability 
 
 
Appendix 4D: R Code and Algorithm for Data Generation and Estimation 
for Multiple Outcome (Chapter 4) 
 
Sample R Code for data generation using correlated binomial copula method 
library(copula) 
for (i in 1:300) # i is number of datasets generated, equal to 300 here. Depending on # 
datasets to generate this can be changed 
{ 
tmp <- normalCopula( 0.50, dim=2 ) # desired correlation specified here 
x <- rcopula(tmp, 20) 
MVN <- cbind( qbinom(x[,1], 60, 0.3), qbinom(x[,2], 60, 0.11) ) 
 
Sample R Code for data generation using Bayesian method 
library(MASS) # library MASS used to generate multivariate normal data 
set.seed(1234) # setting seed helps regenerate the exact data 
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m<-300 # m is the number of datasets generated, equal to 300 here. Depending on # 
datasets to generate this can be changed 
 
y<-NULL 
k<-20 # number of sites, equal to 20 here 
Sigma1 <- matrix(c(.72,.57,.57,.46),2,2)  # covariance matrix for correlation=0.99 
#Sigma1 <- matrix(c(.72,.29,.29,.46),2,2)  # covariance matrix for correlation=0.50 
#Sigma1 <- matrix(c(.72,.10,.10,.46),2,2)  # covariance matrix for correlation=0.17 
Sigma1 
rho <- Sigma1[1,2]/sqrt(Sigma1[1,1]*Sigma1[2,2]) # correlation  
rho 
eta<-mvrnorm(k, mu=c(-0.85,-2.09), Sigma1) # mvrnorm function from MASS library is 
#used to generate the multivariate data. Mean in logit form 
 
p1<-exp(eta[,1])/(1+exp(eta[,1])) # transforming mean in proportional scale form 
p2<-exp(eta[,2])/(1+exp(eta[,2])) # transforming mean in proportional scale form 
 
n<-60 # number of subjects per site, equal to 60 here 
 
x1<-replicate(m,rbinom(k,n,p1)) # generating binomial counts given n and p 
x2<-replicate(m,rbinom(k,n,p2)) 
 
y<-cbind(x1[,1],x2[,1]) # dataset for counts  
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Sample R Code for estimation using maximum likelihood method 
#R 3.1.2 software is used to run the code 
# Set libraries to use the appropriate functions 
library(MASS) # library for function mvrnorm to generate normal data 
require(mixtools) # library for function ellipse to generate ellipse 
set.seed(1234) # setting seed to regenerate the multivariate normal data 
library(sp)# library for point.in.polygon function to find whether points lie within ellipse 
 
#Set working directory 
setwd("C://Tina/USB_Backup_042213/Paper II/MLN 
Automation/New_Sim_coverage/Bayes") 
 
 
# for rho=0.99 
#p1<- c(0.178868171,-1.107473009,-1.788963343,1.158493577,-1.245276111,-
1.344914042,-0.336776979,-0.433585937,-0.372432027,-0.138613355,-0.395337875,-
0.025787149,-0.224678572,-0.92750629,-1.737371995,1.798095737,-0.516576079,-
0.139183335,-0.154104977,-2.918209088) 
                                      
#p2<- c(-1.28192739,-2.249396457,-2.797655526,-0.531062252,-2.340289724,-
2.349083755,-1.734490646,-1.661971547,-1.7076698,-1.434915178,-1.83061792,-
1.388048924,-1.524780208,-2.10486324,-2.645166129,-1.948617282,-1.619838403,-
1.397426355,-1.507379825,-3.695976368) 
 
# for rho=0.50 
 
#p1<-c(0.15335786,-1.211025517,-1.842201291,1.156270705,-1.389920946,-
1.665413344,-0.22736333,-0.703143563,-0.402881862,-0.403636946,-0.155767032,-
0.186432479,-0.430397112,-1.0437041,-2.079342252,-1.092931777,-1.05957643,-
0.501585049,-0.26394581,-2.914150939) 
 
#p2<-c(-1.523567499,-2.01880505,-2.458720941,-1.076400051,-2.008458045,-
1.71790176,-2.044030099,-1.358620199,-1.791035315,-1.219175,-2.325569027,-
1.364656398,-1.377296171,-1.90387581,-1.873528375,-1.521564749,-0.870672259,-
1.030842411,-1.527544713,-3.137162585) 
 
# for rho=0.17 
 
p1<-c(0.170496177,-1.181197072,-1.834095309,1.174962239,-1.348575194,-
1.570386657,-0.256718438,-0.615757839,-0.389151822,-0.315014506,-0.226039506,-
0.129191149,-0.360950612,-1.008338382,-1.981169837,-1.004729623,-0.888075394,-
0.382747773,-0.223621079,-2.933947209) 
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p2<-c(-1.835346805,-1.864370325,-2.121000388,-1.718105194,-1.781328184,-
1.336632139,-2.284446442,-1.304624573,-1.922819118,-1.262800155,-2.637697338,-
1.516964971,-1.434578213,-1.798288867,-1.351644613,-1.337674492,-0.600038881,-
1.006601455,-1.674069689,-2.477608126) 
 
# for fixed effects data 
 
#p1<- c(-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-.85,-
.85,-.85,-.85) 
 
#p2<- c(-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-
2.09,-2.09,-2.09,-2.09,-2.09,-2.09,-2.09) 
 
for (k in 1:300){ 
  Y <- read.csv(file=paste0("MVNfreq",k,".csv")) 
 
Y<-as.matrix(Y) 
Y <- ifelse(Y==0,Y+.5,Y) 
 
 
Y1<-Y/60 # estimates of p 
 
#print(Y1) 
 
sigma2<- matrix(c(var(Y1[,1]),cov(Y1[,1],Y1[,2]),cov(Y1[,1],Y1[,2]),var(Y1[,2])),2,2) 
#print(sigma2) 
 
rho<-sigma2[1,2]/sqrt(sigma2[1,1]*sigma2[2,2]) 
#rho 
 
mean(Y1[,1]) 
mean(Y1[,2]) 
 
#within<-matrix(data=0,nrow=20,ncol=1) 
 
for (i in 1:20){ 
 
rate<-Y1[i,] 
#print(rate) 
rate1<-rate/(1-rate) 
rate2<-log(rate1) 
 
#Sigma11<-(1/(rate[1]*(1-rate[1]))^2)*sigma2[1,1] 
#Sigma22<-(1/(rate[2]*(1-rate[2]))^2)*sigma2[2,2] 
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#Sigma12<-(1/((rate[1]*(1-rate[1]))*(rate[2]*(1-rate[2]))))*sigma2[1,2] 
 
#Sigma2<-matrix(c(Sigma11,Sigma12,Sigma12,Sigma22),2,2) 
 
zigma11<-(rate[1]*(1-rate[1]))/60 
#zigma12<-((rate[1]*(1-rate[1]))*(rate[2]*(1-rate[2])))/60 
zigma22<-(rate[2]*(1-rate[2]))/60 
zigma12<-0.17*sqrt(zigma11*zigma22) 
 
zigma<-matrix(c(zigma11,zigma12,zigma12,zigma22),2,2) 
#print(zigma11) 
 
Sigma11<-(1/(rate[1]*(1-rate[1]))^2)*zigma[1,1] 
Sigma22<-(1/(rate[2]*(1-rate[2]))^2)*zigma[2,2] 
Sigma12<-(1/((rate[1]*(1-rate[1]))*(rate[2]*(1-rate[2]))))*zigma[1,2] 
 
Sigma2<-matrix(c(Sigma11,Sigma12,Sigma12,Sigma22),2,2) 
set.seed<-1234 
 
rate3<-mvrnorm(1000, mu=c(rate2[1],rate2[2]), Sigma2) 
 
#print(rate3) 
 
#x<-exp(rate3[,1])/(1+exp(rate3[,1])) 
#y<-exp(rate3[,2])/(1+exp(rate3[,2])) 
 
x<-rate3[,1] 
y<-rate3[,2] 
 
#print(mean(x)) 
#print(mean(y)) 
#print(var(x)) 
#print(var(y)) 
#print(cor(x,y)) 
 
dat<-structure(list(x,y),.Names = c("x", "y"), class = "data.frame", row.names = c(NA, -
1000L)) 
 
me <- apply(dat, 2, mean) 
v <- sigma2 
#print(v) 
rho_est<-v[1,2]/sqrt(v[1,1]*v[2,2]) 
#print(rho_est) 
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rad <- sqrt(2*qf(0.95, 2, nrow(dat)-1)) 
#z <- ellipse(me, v, alpha=.05) 
 
z<-dataEllipse(x,y,levels=0.95,xlab="(p1)", ylab="(p2)") 
 
dist2center <- sqrt(rowSums((t(z-me))^2)) 
 
est_area<-NULL 
est_area<-pi*(min(dist2center))*(max(dist2center)) 
#est_area<-as.data.frame(est_area) 
#print(est_area) 
 
within<-point.in.polygon(p1[i], p2[i], z[,1], z[,2]) 
print(within) 
#text(-0.85,-2.09,"x",col="red") 
 
} 
#stripchart(est_area ~ i, vertical = TRUE, pch=1, method="jitter") 
 
} 
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Sample R Code for estimation using Bayesian MCMC method 
library(MASS) 
set.seed(1234) 
require(mixtools) 
library(sp) 
 
 
# for rho=0.99 
p1<- 
c(0.54459820,0.24834230,0.14319987,0.76105888,0.22351894,0.20670311,0.41659260,0.39327037,0.407
95349,0.46540204,0.40243298,0.49355357,0.44406546,0.28343091,0.14964705,0.30791697,0.37365321,
0.46526023,0.46154982,0.05126073) 
 
p2<- 
c(0.21722232,0.09540154,0.05745100,0.37026917,0.08784070,0.08713863,0.15001408,0.15949752,0.153
46620,0.19233400,0.13816468,0.19971942,0.17875869,0.10862504,0.06628757,0.12470421,0.16522716,
0.19822483,0.18132743,0.02422194) 
 
# for rho=0.50 
 
#p1<-
c(0.53826450,0.22951965,0.13679116,0.76065442,0.19942038,0.15903666,0.44340277,0.33111563,0.400
62014,0.40043884,0.46113679,0.45352641,0.39403151,0.26043592,0.11112092,0.25106661,0.25739041,0
.37716825,0.43439399,0.05145845) 
 
#p2<-
c(0.17893679,0.11724261,0.07880314,0.25418788,0.11831774,0.15214163,0.11465700,0.20446465,0.142
94584,0.22808167,0.08902737,0.20348456,0.20144360,0.12967044,0.13313399,0.17923122,0.29511444,
0.26292082,0.17835321,0.04160010) 
 
# for rho=0.17 
 
#p1<-
c(0.54252109,0.23483703,0.13775113,0.76404079,0.20610341,0.17216128,0.43617056,0.35074688,0.403
92150,0.42189123,0.44372951,0.46774706,0.41072947,0.26730516,0.12119419,0.26801254,0.29150716,
0.40546434,0.44432654,0.05050072) 
 
#p2<-
c(0.13760255,0.13419447,0.10707239,0.15211539,0.14413921,0.20806445,0.09241932,0.21338774,0.127
54753,0.22049224,0.06675134,0.17990888,0.19238635,0.14205949,0.20560163,0.20789275,0.35433480,
0.26764548,0.15788234,0.07744292) 
 
# for fixed effects data 
 
#p1<- 
c(0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30,0.30) 
 
#p2<- c(0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11,0.11) 
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#Set working directory 
setwd("C://Tina/USB_Backup_042213/Paper II/MLN 
Automation/New_Sim_coverage/Bayes") 
 
bugs.output <- list() 
 
for (k in 1:300) 
{ 
    Y <- read.csv(file=paste0("MVNfreq",k,".csv")) 
 
Y<-as.matrix(Y) 
Y <- ifelse(Y==0,Y+.5,Y) 
 
library("R2WinBUGS") 
 
 
 
bugs.output[[1]] <-  bugs(data = list(Y=as.matrix(Y), Nf=20, n=60, mn=c(-1.59, -2.44),  
                          prec=matrix(c(.001,0,0,.001),nrow=2,ncol=2), 
                          R=matrix(c(1,0,0,1),nrow=2,ncol=2)), 
              inits = list(list(gamma=c(0,0), T=matrix(c(0.01,0,0,0.01),nrow=2,ncol=2))), 
              param = c("p","p1","T","sigma2","rho"),  
              model = "M-LN_model_ell.txt", 
              n.iter = 12000, n.burnin = 5000, n.sims=1000,n.chains = 1, 
bugs.directory="C://Tina/USB_Backup_042213/winbugs14/WinBUGS14", 
working.directory=NULL) 
#save mcmc 
    #write.csv(bugs.output[[i]]$sims.list$ell,paste0("mcmc",i,".csv"))} 
 
 
 
# Read CSV into R 
#MyData <- read.csv(file="c:/Tina/USB_Backup_042213/Paper II/MLN 
Automation/csvs_equal_20s/mcmc1.csv", header=TRUE) 
 
 
 
for (i in 1:20)                        # change for number of sites 
{ 
x1<-bugs.output[[1]]$sims.list$p1[,i,1] 
y1<-bugs.output[[1]]$sims.list$p1[,i,2] 
 
#v11<-bugs.output[[1]]$summary[85,1] 
#v12<-bugs.output[[1]]$summary[86,1] 
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#v22<-bugs.output[[1]]$summary[88,1] 
#v11<-mean(bugs.output[[1]]$sims.list$sigma2[,1,1]) 
#v12<-mean(bugs.output[[1]]$sims.list$sigma2[,1,2]) 
#v22<-mean(bugs.output[[1]]$sims.list$sigma2[,2,2]) 
 
 
dat<-structure(list(x1,y1),.Names = c("x1", "y1"), class = "data.frame", row.names = 
c(NA, -1000L)) 
 
m1<-mean(x1) 
m2<-mean(y1) 
me<-c(m1,m2) 
v11<-var(x1) 
v12<-cov(x1,y1) 
v22<-var(y1) 
 
v<-matrix(c(v11,v12,v12,v22),nrow=2,ncol=2) 
 
z1<-mvrnorm(1000, mu=c(m1,m2), v) 
 
#rad <- sqrt(2*qf(0.95, 2, nrow(dat)-1)) 
#plot(x1, y1, xlim=c(-5,0), ylim=c(-5,0), xlab="logit(p1)", ylab="logit(p2)") 
#z <- ellipse(me, v, alpha=.05) 
 
z<-dataEllipse(z1[,1],z1[,2],levels=0.95,xlab="logit(p1)", ylab="logit(p2)") 
 
 
dist2center <- sqrt(rowSums((t(z-me))^2)) 
 
#est_area<-NULL 
 
#est_area<-pi*min(dist2center)*max(dist2center) 
 
#print(est_area) 
 
within<-point.in.polygon(p1[i], p2[i], z[,1], z[,2]) 
print(within) 
text(-0.85,-2.09,"x",col="red") 
#text(0.30,0.11,"x",col="red") 
 
} 
} 
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Appendix 4E: R Code and Algorithm for Outlier Detection for Multiple 
Outcomes (Chapter 4) 
 
Data Generation 
 
Sample R code for data generation for outliers using correlated binomials (copula 
method) 
library(copula) 
for (i in 1:300) # i is number of datasets generated, equal to 300 here. Depending on # 
datasets to generate this can be changed 
{ 
tmp <- normalCopula( 0.0, dim=2 ) 
x <- rcopula(tmp, 15) 
MVN1 <- cbind( qbinom(x[,1], 60, 0.3), qbinom(x[,2], 60, 0.3) ) 
#write.csv(MVN, paste("C://Tina/USB_Backup_042213/Paper II/MLN 
Automation/copula/high/MVNfreq", i, ".csv", sep=""),row.names=F) 
#print(var(MVN[,1]/60)) 
#print(var(MVN[,2]/60)) 
#print(cor((MVN[,1]/60),(MVN[,2]/60))) 
y <- rcopula(tmp, 5) 
MVN2 <- cbind( qbinom(y[,1], 60, 0.45), qbinom(y[,2], 60, 0.45) ) 
xz<-rbind(MVN1,MVN2) 
xz<-round(xz) 
MVNfreq<-cbind(xz[,1],xz[,2]) 
write.csv(xz, paste("C://Tina/USB_Backup_042213/Paper II/MLN 
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Automation/csvs_equal_20s/outlier/MVNfreq", i, ".csv", sep=""),row.names=F) 
Estimation  
 
I. ML Method of Estimation to identify outlier sites 
 
1. Use the data generated to calculate Mahalanobis’ Distance Square using 
moutlier function from chemometrics library 
2. We use the robust Mahalanobis’ distance square 
3. To identify sites as outliers, we use the 90th quantile as the cutoff  
4. Sites with Mahalanobis’ Distance square greater than the cutoff are 
classified as outliers 
 
Sample R Code for estimation using maximum likelihood method   
x1<-MVNfreq[,1] # Data 
x2<-MVNfreq[,2] 
 
x1_t<-t(x1) 
x2_t<-t(x2) 
 
me1 <- apply(x1_t, 2, mean)  
me2 <- apply(x2_t, 2, mean) 
 
#print(me1) 
#print(me2) 
 
df.1<-data.frame(me1,me2) 
summary(df.1) 
 
# Calculate Mahalanobis' Distance Square here 
 
library(chemometrics) # library to call the chemometrics function 
md.1 <- Moutlier(df.1, quantile = 0.90, plot = FALSE) # use 90th quantile as the 
threshold 
 
#90% was suggested as a Threshold by committee because that is a standard used 
for #profiling sites in quality of care 
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md.1$cutoff 
summary(md.1$rd) 
 
qqplot(md.1$rd, df.1$me2, plot.it = TRUE, xlab = "Mahalanobis' distance", 
       ylab = "me2", main = "DF.1") 
 
hist(md.1$rd, main = "DF.1")#plot histogram of the robust Mahalanobis’ distance 
 
head(sort(md.1$rd, decreasing = TRUE)) 
 
# To identify those cases; simply use a which command with the 'cutoff' 
# value provided by the 
 
z<-which(md.1$rd > md.1$cutoff) 
 
#print(md.1) 
#print(md.1$cutoff) 
print(z) 
} 
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II. Bayesian Method of Estimation (MCMC) 
1. For counts equal to zeros from the data, we add a correction factor of 0.5. 
2. We first fit the Bayesian Multivariate Normal Binomial model to the data 
3. 1000 MCMC posterior samples are retained 
4. We then use the posterior means of p’s and posterior variance-covariance 
to calculate Mahalanobis’ distance square using moutlier function from 
library chemometrics 
5. We use the robust Mahalanobis’ distance square 
6. To identify sites as outliers, we use the 90th quantile as the cutoff 
7. Sites with Mahalanobis’ Distance square greater than the cutoff are 
classified as outliers 
 
 
Sample R Code for estimation using Bayesian MCMC method 
library(MASS) 
library(car) 
library(chemometrics) 
set.seed(1234) 
require(mixtools) 
 
#Set working directory 
setwd("C://Tina/USB_Backup_042213/Paper II/MLN Automation/csvs_equal_20s") 
 
bugs.output <- list() 
for (k in 1:300) 
{ 
    Y <- read.csv(file=paste0("MVNfreq",k,".csv")) 
 
Y<-as.matrix(Y) 
Y <- ifelse(Y==0,Y+.5,Y) 
 
library("R2WinBUGS") 
bugs.output[[1]] <-  bugs(data = list(Y=as.matrix(Y), Nf=20, n=60, mn=c(-1.59, -2.44),  
                          prec=matrix(c(.001,0,0,.001),nrow=2,ncol=2), 
                          R=matrix(c(1,0,0,1),nrow=2,ncol=2)), 
              inits = list(list(gamma=c(0,0), T=matrix(c(0.01,0,0,0.01),nrow=2,ncol=2))), 
              param = c("p","p1","T","sigma2","rho"),  
              model = "M-LN_model_ell.txt", 
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              n.iter = 12000, n.burnin = 5000, n.chains = 1, 
bugs.directory="C://Tina/USB_Backup_042213/winbugs14/WinBUGS14", 
working.directory=NULL) 
#save mcmc 
    #write.csv(bugs.output[[i]]$sims.list$ell,paste0("mcmc",i,".csv"))} 
x1<-bugs.output[[1]]$sims.list$p[,,1] 
y1<-bugs.output[[1]]$sims.list$p[,,2] 
 
me1 <- apply(x1, 2, mean) 
me2 <- apply(y1, 2, mean) 
 
df.1<-data.frame(me1,me2) 
summary(df.1) 
# Calculate Mahalanobis' Distance Square here 
library(chemometrics) 
md.1 <- Moutlier(df.1, quantile = 0.90, plot = FALSE) 
md.1$cutoff 
summary(md.1$rd) 
qqplot(md.1$rd, df.1$me2, plot.it = TRUE, xlab = "Mahalanobis' distance", 
       ylab = "me2", main = "DF.1") 
hist(md.1$rd, main = "DF.1") 
head(sort(md.1$rd, decreasing = TRUE)) 
 
# To identify those cases; simply use a which command with the 'cutoff' 
# value provided by the 
z<-which(md.1$rd > md.1$cutoff) 
 
print(z) 
} 
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